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Le diagnostic prénatal résulte encore aujourd’hui de procédures invasives, qui présentent des risques 
pour la grossesse. Le développement du diagnostic prénatal non-invasif (DPNI) changerait le rapport 
risque : bénéfice, rendant le diagnostic prénatal plus intéressant pour les femmes enceintes. Plusieurs 
chercheurs ont montré la présence de cellules fœtales dans le sang maternel et des travaux ont été entrepris 
afin de les cibler et de les utiliser éventuellement en DPNI. Toutefois, la faible concentration des cellules 
fœtales dans le sang maternel réduit les possibilités d’isolement ainsi que celles de leur utilisation en 
clinique. Un autre aspect technique du DPNI, le balayage manuel, est très laborieux, surtout en terme de 
temps technique. Il y a donc un besoin certain pour des études approfondies afin d’évaluer et d’améliorer la 
faisabilité du DPNI. 
La détection d’évènements rares dans une grande population cellulaire offre un potentiel pour le 
diagnostic en oncologie mais aussi en diagnostic prénatal. Dans cette thèse, la première étude était dédiée à 
l’optimisation d’une stratégie pour détecter les cellules rares. Nous avons développé une méthode 
d’étalement sur lame d’un nombre précis de cellules cibles parmi des centaines de milliers de cellules. 
Cette stratégie a permis d’évaluer le taux de détection d’évènements rares et de comparer l’efficacité des 
techniques d’enrichissement en connaissant le nombre exact et la localisation de cellules cibles sur les 
lames. De plus, il a été possible d’évaluer les problèmes d’hybridation des évènements manqués. Nous 
avons, par la suite, développé un algorithme robuste pour la détection de cellules rares en utilisant la 
plateforme de microscopie automatisée MetaSystems et utilisé cette approche dans la validation des 
balayages manuel et automatique d’un nombre précis de cellules mâles parmi une large population de 
cellules femelles marquées avec la technique FISH. Nous avons testé ce classificateur avec des échantillons 
de sang de femmes enceintes de grossesses normales et aneuploïdes et évalué la fréquence de cellules 
fœtales isolées par différentes méthodes d’enrichissement au cours des premier et second trimestres de 
grossesse. Les données accumulées ont confirmé la présence de cellules fœtales chez toutes les grossesses 
et leur fréquence plus élevée dans les grossesses aneuploïdes. Le nombre de cellules fœtales est dynamique 
tout au long de la grossesse. De plus, un nombre plus élevé de cellules fœtales peut être obtenu en 
optimisant le moment du prélèvement et les méthodes d’enrichissement. De plus, le balayage automatique 
s’est avéré plus sensible et constant que le balayage manuel, ce qui permet de balayer un grand nombre de 
cellules et devient plus approprié pour une application clinique. Nous avons aussi montré la faisabilité 
d’utiliser des cellules fœtales dans le cadre du DPNI. Cinq cellules amniotiques microdisséquées, 
provenant de grossesses normales et aneuploïdes, ont suffi pour poser un diagnostic prénatal par une 
combinaison de l’amplification du génome complet et de la technique QF-PCR (réaction quantitative en 
fluorescence d’amplification entraînée par une polymérase) permettant la détection d’anomalies 
chromosomiques. Nos résultats ouvrent la voie à l’utilisation de cellules fœtales dans le sang maternel pour 
le DPNI. 
Mots-clés: Cellules fœtales – Diagnostic prénatal – Hybridation in situ observée en fluorescence – 
Balayage automatique 
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Current prenatal diagnosis depends on invasive procedures and is thus offered only to high-risk 
pregnancies. Development of non-invasive prenatal diagnosis (NIPD) would change the risk-benefit 
ratio and make it likely that more women would benefit from prenatal testing. Scientists have 
documented the presence of rare fetal cells in maternal blood and envisioned targeting them with 
specific markers and their use in NIPD. Considering their extremely low frequency in maternal blood, 
fetal cells have been difficult to retrieve and use in clinical practice. Therefore, there is a pressing need 
for systematic sequential studies to evaluate their feasibility in NIPD. 
Generally, detection of rare cells within a large cell population carries great potentialities for the 
prospects of cancer management and NIPD. Manual scanning is very cumbersome and time-consuming 
Therefore; the first part of our project was, dedicated to the optimization of an effective strategy to 
evaluate retrieval of rare cells. We have developed a way of distributing a controlled number of target 
cells among hundreds of thousands of other cells on microscope slides. This strategy allows the precise 
evaluation of the retrieval of rare events and the comparizon of the efficacy of different techniques and 
enrichment approaches by knowing the definite number and locations of target cells on the slides. 
Furthermore, it allows the evaluation of hybridization of missed events. We have also developed a 
robust custom-made detection algorithm for rare cells using the MetaSystems automated platform and 
have used this strategy in the validation of manual and automatic scanning of 60 slides with a pre-
defined number of rare male cells among a pure population of female cells using XY-FISH. 
Consequently, we tested the developed classifier for the detection of real fetal cells from maternal blood 
in both normal and aneuploid pregnancies with Down syndrome. We further evaluated the number of 
fetal cells with different methods of enrichments in the first and second trimesters. The data collected 
confirmed the early presence of fetal cells in all of the pregnancies tested and their frequencies were 
higher in cases of aneuploidies. Fetal cells are in a state of dynamic change throughout the pregnancy. 
Higher numbers of these cells can be obtained by optimizing the harvest time and methods of 
enrichment. We found that automatic scanning is more sensitive and reliable than manual detection. 
Furthermore, it alleviates the burden of scanning large numbers of cells and thus is more suitable for 
clinical application. We also demonstrated the feasibility of using rare cells in NIPD. Five 
microdissected amniotic fetal cells from 26 cases of normal and aneuploid pregnancies were quite 
enough to provide accurate NIPD through using whole genome amplification coupled with QF-PCR. 
Our findings laid the ground for the use of rare fetal cells in maternal blood for NIPD. 
Keywords: Fetal cells – Prenatal diagnosis – Fluorescence in situ hybridization – Automatic 
microscopy  
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INTRODUCTION 
1. General Information  
The burden of genetic disorders is heavy in all parts of the world, particularly in 
under-resourced settings, which lack specialized health and social services to care for 
affected individuals. Large numbers of infants with genetic disorders are born each year 
from families in underserved populations as a result of the high birth rate, consanguinity and 
late procreation. As a result, most pregnant women would wish to be reassured that their 
unborn babies are healthy. Access to safe, accurate and affordable screening and diagnostic 
tests at a time that avails the mother an option of pregnancy termination is therefore 
essential.  
Prenatal diagnosis of aneuploidies is usually performed by collecting fetal samples 
through either amniocentesis or chorionic villous sampling (CVS). These procedures are 
invasive and are associated with a significant risk of miscarriage. Therefore, in recent 
years, considerable effort has been made to develop non-invasive prenatal diagnostic 
procedures (Finegan et al., 1990).  
One potential non-invasive approach is to utilize the fetal cells (FCs) within the 
maternal circulation. Cell’s trafficking between the fetus and its mother provides indirect 
clues as to the underlying pathophysiology during pregnancy. It also provides a source of 
fetal materials for non-invasive prenatal diagnosis. Many questions remain about the 
feasibility of using FCs from maternal blood (MB) for prenatal diagnosis.  
Although the retrieval of FCs from maternal blood (MB) is an attractive concept, 
many questions remain regarding the feasibility of using FCs from maternal blood (MB) 
for prenatal diagnosis. In fact, the very low abundance of FC in MB is a technical challenge 
(Bianchi et al., 2002; Ariga et al., 2001; Krabchi et al., 2001) and there is currently no 
application for these methods in clinical practice. Additional work is needed to isolate FC 
early in pregnancy in order to provide, if necessary, pregnancy termination options to the 
parents. 
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2. Historical background 
The presence of the FCs in maternal circulation during the pregnancy has been 
known for a long time. Indeed, the existence of FCs in MB was shown more than one 
century ago. Many authors in this field recognize the work of Georg Schmorl, a German 
pathologist, which was published in Leipzig in 1893,, to document the first description of 
feto-maternal cellular trafficking, as well as the first clues for the presence of retained FCs 
in maternal body organs (Schmorl, 1893). His elegant and pioneer work has been recently 
translated in English and critically re-evaluated from a 21st century perspective (Lapaire et 
al., 2007). Schmorl had noted for the first time the presence of multinucleated syncytial 
giant cells sequestered in the thin capillaries of the pulmonary parenchyma in the autopsies 
of 14 of 17 women who died of eclampsia. Schmorl assumed that the only source of the 
multinucleated cells could be the decidua or the placenta. Furthermore, he was the first 
physician to emphasize the importance of the placenta in the etiology of pregnancy 
complications such as eclampsia and preeclampsia (Schmorl, 1893). More than 60 years 
later, the placental origin of these trophoblastic cells was established. Other authors reported 
the presence of these cells in other tissues including the uterine veins and peripheral 
venous blood in both normal and complicated pregnancies (Wagner et al., 1964; Douglas et 
al., 1959).  
Many investigators, in late 1950s, began to demonstrate that fetal erythrocytes were 
also present in the maternal peripheral circulation. Kleihauer found FCs in the blood of 
pregnant women by using a specific stain for fetal haemoglobin (Kleihauer et al., 1957). 
Clayton et al. noted that the proportion of fetal red cells was higher in women with 
pregnancies complicated with preeclampsia or vaginal bleeding, and after abortion or 
amniocentesis (Clayton et al., 1964). 
The first cytogenetic study to identify FCs in maternal circulation was done in 1969 
by Walknowska et al (Walknowska et al., 1969). These authors treated MB with a 
lymphocyte mitogen and then examined the metaphase cells. They clearly showed the 
presence of XY metaphases in maternal peripheral blood of 19 out of 21 pregnancies with 
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male fetus. De Grouchy and Trebuchet (de Grouchy and Trebuchet, 1971) as well as other 
groups confirmed these results (Schindler and Martin-du-Pan, 1972; Takahara et al., 1972). 
Cell sorting techniques became available in late 1970s which allowed isolation and 
characterization of cells based on their antigenic characteristics. In 1979, Herzenberg et al 
added, to the step of analysis of Y chromatin of male FCs, a preliminary technique of 
enrichment using a flow cytometer (FACS: fluorescence-activated cell sorting) on the basis 
of cellular class I major histocompatibility antigens. They exploited the human leucocytes 
antigenic differences (HLA) between the mother and her fetus. Using blood from HLA-A2 
negative women whose partners were HLA-A2 positive, cells were sorted based on the 
presence of the HLA-A2 antigen. The sorted cells, most likely lymphocytes, were then 
analyzed for the presence of Y-chromatin fluorescence. Y-chromatin positive cells were 
found more frequently in women carrying male fetuses than in those carrying female 
fetuses. Five out of twelve pregnancies with male fetuses presented cells with Y 
chromosome (0.3 to 1.6% of the sorted cells). For  the other seven, the re  was  in  f ac t  
no cells with Y chromosome (Herzenberg et al., 1979). Iverson and co-workers (Iverson et 
al., 1981) used for the first time this technique to enrich FC in order to determine the sex of the 
foetus. The heterochromatin of the long arm of the Y chromosome was used as independent 
marker in pregnancies as early as 15 weeks of gestation. Y chromatin-containing cells were 
found among the sorted cells from prenatal MB specimens in eight pregnancies out of eight 
subsequently produced male infants. The presence of positive HLA-A2 with the 
heterochromatin of Y confirmed the fetal origin of the cells. 
Molecular techniques became available in late 1980s, which allowed reliable and 
significant analysis of genetic markers to confirm the presence of the FCs in MB circulation. 
In 1989, Lo and co-workers (Lo et al., 1989) proposed the use of polymerase chain reaction 
(PCR) to identify Y-specific DNA sequences in MB. Y-chromosome specific sequence 
could be detected in MB as early as six weeks of gestation. Four years later, the same group 
reported performing PCR on unsorted first trimester MB and were able to correctly identify 
six of seven pregnancies with male fetuses and five of six pregnancies with female fetuses. 
The detection rate was at least as good in the first trimester as in the second or third. Serial 
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dilutions of male DNA were also performed to calculate that this method has the sensitivity 
to detect one male cell d i spe r s ed  in 300,000 female cells (Liou et al., 1994; Lo et al., 
1993; Lo et al., 1990). These PCR results were also confirmed with the use of enrichment 
procedures of cellular sorting using either fluorescent monoclonal antibody by FACS 
(Bianchi et al., 1990; Mueller et al., 1990) or magnetic balls by Magnetic Activated Cell 
Sorting MACS (Wachtel et al., 1991). The recognition of FCs by specific antibodies and 
their isolation using cell sorter or magnetic beads were the subjects of intense search. It is 
however necessary to point out that the sensitivity and the specificity of these methods 
remain insufficient to allow a reliable prenatal diagnosis. 
Following these reports, the potential use of FCs, for a non-invasive prenatal 
diagnosis (NIPD), was strongly reconsidered. Many research teams studied the nature of 
these FCs. These studies raised much controversy, in particular, on the origin of these cells, 
their lifespan and antigenic specificities that could distinguish them from maternal cells. 
Other questions regarding their time of appearance and relative frequency throughout the 
gestational age were also the subject of intense studies.  
Several authors reported a quantification of the number of FCs (Krabchi et al., 2001; 
Bianchi, 1998). The frequency of FCs circulating in maternal peripheral blood in normal 
pregnancy is very low. In the pathological situations, such as for example in the 
preeclampsy or fetal aneuploidies, the fetomaternal cellular transfusion is apparently 
increased (Zhang et al., 2008; Krabchi et al., 2006b; Krabchi et al., 2006c).  
Various categories of FCs have been proposed. The possible cell types that can be 
isolated from MB and used for prenatal diagnosis include trophoblasts, lymphocytes, 
erythroblasts, granulocytes, and thrombocytes (Goldberg, 1997). All these cells are 
nucleated except for the blood platelets (thrombocytes) which loss their genomics DNA 
during the process of differentiation. The presence of rare lymphoid progenitor cells of fetal 
origin in MB from former pregnancies has been also reported (Bianchi et al., 1996). Given 
the extreme scarcity of these events and their antigenic specificities, they are not regarded as 
major handicap for the development of NIPD. Many attempts of isolation of the FCs, for the 
sake of NIPD, focus mainly on the erythroblasts and cytotrophoblasts. Indeed, these two 
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types of cells have the advantage of being highly differentiated and are known to have a 
short life span and thus unlikely to persist in MB postpartum. 
3. Aneuploidies and screening modalities 
Prenatal care has existed for over 100 years as an approach to improve maternal and 
newborn outcomes. Screening tests are usually non-invasive and may help delineate which 
patients are at high risk and should be offered invasive testing. Diagnostic tests on the other 
hand have the benefit of providing a definite answer about the presence of a genetic 
disorder. Since these tests carry varying risks of pregnancy loss, they are usually reserved 
for high-risk women with positive screening.  
3.1. Trisomy 21 and other aneuploidies 
Trisomy 21, also known as Down syndrome, is the leading cause of prenatal 
chromosome abnormalities, accounting for more than half of all reported chromosomal 
aneuploidies (Hook et al., 1983). The incidence of trisomy 21 in the general population is 
1.3 per 1000 live births (1/770). Incidence rate increases significantly with maternal age 
(Table1) (Huether et al., 1998).  
Table 1 Maternal age and risk of Down's syndrome 
 
Table 1 shows that risk of Down's syndrome increase with advancing maternal age. J Med 
Genet. Jun 1998; 35(6): 482–490 
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Down syndrome individuals have a distinct phenotype and show various degree of 
intellectual disability (Sherman et al., 2007). Patients with trisomy 21 have a slightly 
reduced life expectancy (Thorpe et al., 2012; Baird and Sadovnick, 1990). Indeed, they are 
often victims of medical complications and developmental disorders (Tenenbaum et al., 
2012; Hayes and Batshaw, 1993; Carey, 1992). They account for 20 to 30% of the subjects 
with moderate to severe mental retardation. More than 15% of the adult subjects will 
develop Alzheimer's disease around the age of forty (Strydom et al., 2013).  
In Canada, there are approximately 400,000 births with more than 600 new cases of 
trisomy 21 per year. A prenatal screening program has been created in Quebec in 1976 
(Okun et al., 2008; Forest et al., 1995; Baird and Sadovnick, 1990). The majority of mothers 
with affected fetuses, after being informed of the prognosis and postnatal therapeutic 
options, choose medical interruption of the pregnancy (Grant and Flint, 2007; Fletcher, 
1981).  
Other trisomies, such as trisomy 18 (Edward syndrome) and trisomy 13 (Patau 
syndrome), are associated with fatal congenital malformations. Survival is very poor with 
approximately 50% miscarriages prior to birth and, most liveborns die within the first month 
of life (Hutaff-Lee et al., 2013). 
3.2. Screening modalities  
Screening is conventionally described as the evaluation of asymptomatic people to 
detect unsuspected disease or risk in order to improve health outcome in a defined 
population (Henry and Bronson, 1996).  
Reproductive genetic screening is performed to assist reproductive decision-making 
and to give parents the opportunity to avoid the birth of an affected child. Because the 
decision to terminate a pregnancy is highly personal, prenatal screening is considered 
optional, in sharp contrast to the mandatory newborn screening after birth. In keeping with 
this difference, genetic professionals have developed a counselling approach to assist 
couples to determine their own preferred course of action (Mahowald et al., 1998).  
7 
 
  
3.2.1. Genetic counselling 
Genetic counselling begins with a thorough medical and family history of the patient 
and her partner to identify high-risk patients who may benefit from diagnostic or therapeutic 
procedures. Historically, the first and most important risk factor for trisomy 21 is advanced 
maternal age. Incidence increases gradually up to the age of 35 years then rises very sharply. 
The reason for this is not entirely known but may have to do with abnormal function of the 
meiotic spindle during female meiosis, resulting in nondisjunction (Zournatzi et al., 2008).  
Because, at the age of 35, the risk of having a newborn with chromosomal 
aneuploidy approximately equals the risk of pregnancy loss with invasive testing (0.5%, or 
1/200), it is standard of practice to offer invasive testing to women who will be 35 years or 
older at the time of delivery. However, this strategy is not very efficient because two third 
of the trisomic 21 children are born from women having less than 35 years old (Zournatzi et 
al., 2008). For this reason, different screening modalities were developed and implemented 
in order to re-evaluate the risk and precisely identify those that would benefit from invasive 
diagnostic tests.  
3.2.2. First trimester ultrasound 
Anatomical ultrasound has been used since the 1980s for detection of major 
structural abnormalities. With advances in technology, prenatal ultrasound has expanded to 
include detection of soft markers more commonly found in fetuses with chromosomal 
abnormalities (Getz and Kirkengen, 2003). During the first trimester, between 10 and 
14 weeks, thickening of an area behind the fetal neck (nuchal translucency) is associated 
with an increased risk of Down syndrome. This fluid-filled area of the posterior neck 
normally resolves by the second trimester (Snijders et al., 1998).  
Other soft markers linked to Down syndrome include echogenic bowel, renal pelvic 
dilation, absence of the nasal bone, ventriculomegaly, clinodactyly, and sandal gap toe 
(Cicero et al., 2001). The presence of one of these markers increases the risk by two-fold 
while three or more markers increases the risk by 100-fold (Benacerraf, 2010; Nyberg and 
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Souter, 2001). While these criteria help in determining relative risk, they remain limited by 
the quality of the ultrasound and the expertise of the sonographer. 
3.2.3. Maternal serum biomarkers 
Maternal serum biomarkers are substances secreted by the fetus or placenta during 
pregnancy and that can be measured in the MB. The level of these markers can be useful to 
predict congenital anomalies and chromosomal abnormalities, particularly trisomy 21. The 
expected amount of these substances found normally in the mother's bloodstream changes 
weekly during pregnancy, so it is important to to accurately determine the gestational age, 
usually using ultrasound at 10-12 weeks. 
The level of each marker is expressed as multiples of the median (MoM), obtained 
by dividing the serum concentration at a particular gestational age by the population median 
concentration at the same gestational age (Spector et al., 2005). Combined values of 
different markers provide a risk estimate rather than a definitive diagnosis. 
Alpha-fetoprotein (AFP) is produced by the fetal liver, but is transported to the MB 
across the placenta. High level of AFP is frequently associated with neural tube defects. 
Other possible causes of a high AFP include incorrect dates, multiple pregnancies, 
fetomaternal bleed, and other fetal malformations, such as defects of the abdominal wall. 
This may be due to leaky placental barrier or placental dysfunction associated with these 
pathologies. Low levels of AFP are associated with Down syndrome. Any abnormal AFP 
measurement should be followed by a detailed fetal ultrasound (Guibaud et al., 1998; Rose 
and Mennuti, 1993). 
Human chorionic gonadotropin (hCG) is also known as the ‘pregnancy hormone’. It 
is produced by the placenta very early in pregnancy. It is made of α and β chains. The rate 
of synthesis of the total hCG is dependent on the rate of synthesis of the free β -hCG 
fraction. This hormone peaks early in pregnancy at 8–10 weeks. After that peak, it 
progressively declines to reach a plateau at 18 to 20 weeks of gestation.  Levels are 
increased in Down syndrome, and decreased in trisomy 18. Elevated mid-trimester levels 
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have been associated with congenital abnormalities, placental dysfunction and adverse 
pregnancy outcome (Rose and Mennuti, 1993; Bogart et al., 1987). 
Unconjugated estriol (uE3) is the dominant form of estrogen during pregnancy. This 
hormone is derived from precursors from the fetal adrenal and liver that are processed in the 
placenta. Low estriol may be associated with Down syndrome and anencephaly, the most 
severe neural tube defect. Other syndromes associated with low estriol include congenital 
adrenal hypoplasia, and X-linked icthyosis (Guibaud et al., 1998; Canfield and O'Connor, 
1991). 
Inhibins are placental hormones that inhibit the secretion of follicle-stimulating 
hormone (FSH). There are two forms: inhibin-A and inhibin-B; however, only the former is 
found in pregnant women. Inhibin-A has been found to be increased in Down-syndrome 
pregnancies, and has most recently been added as a fourth serum marker for second 
trimester screening (Gagnon et al., 2008; Lockwood et al., 1997).  
Pregnancy associated plasma protein A (PAPP-A) is produced by the placenta and 
thought to have several functions, including prevention of recognition of the fetus by the 
maternal immune system. A PAPP-A level was found to be low in pregnancies with Down 
syndrome and other chromosomal defects. Recent studies support an association between 
low PAPP-A levels in first trimester and risk for adverse pregnancy outcomes as 
prematurity and growth retardation (Smith et al., 2002). 
3.3. Routine prenatal screening  
3.3.1. Second trimester screening 
Several studies showed that measurements of biochemical markers in the maternal 
serum between 15 and 17 weeks of gestation could be useful to identify complicated 
pregnancies. The possibility of prenatal screening, using maternal serum markers, was 
reported for the first time in 1984 by Merkatz et al. (Merkatz et al., 1984). AFP was the 
earliest serum marker used to detect open neural tube defects and abdominal wall defects 
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and with time it was extended to screen for Down syndrome (Cuckle et al., 1984; Wald et 
al., 1977).  
In 1987, Bogart and co-workers (Bogart et al., 1987) showed that serum 
concentrations of hCG are higher than normal in the pregnancies affected by trisomy 21. 
Continued advancements in research resulted in the introduction of a multiple markers 
screening panel, or the” triple test”, in 1991 (MacDonald et al., 1991). In addition to AFP, 
the panel included uE3 and total hCG. The triple screen was widely employed in obstetrical 
practice to detect neural tube defects and chromosomal aneuploidies. The detection rate for 
Down syndrome varies from 30% to approximately 69%.  
The quadruple test was introduced in 2000, when inhibin-A was added to the triple 
test panel (Hackshaw and Wald, 2001; Haddow et al., 1998b; Aitken et al., 1996). The 
introduction of the quadruple test has significantly increased the detection rate. By 
combining maternal age with the quad screen, the detection rate is roughly 75% for Down 
syndrome in women younger than 35 years and 80% in women 35 years and older with an 
approximately 5% false positive rate (Benn et al., 2001). 
3.3.2. First trimester screening 
It was not until the late 1990s that first trimester screening was introduced as an 
earlier screening option for the detection of Down syndrome. First trimester screening 
incorporates maternal age, nuchal translucency, and measurement of specific serum 
markers. A Collection of blood for biochemical analysis and ultrasound assessment is 
typically performed between 11 and 14 weeks. The most effective first-trimester 
biochemical markers are PAPP-A and free hCG in maternal serum (Biagiotti et al., 1998; 
Haddow et al., 1998a).  
However, there is no single marker can detect all the pathological pregnancies. The 
echographic signs and the serum markers together can increase the detection rate. First 
trimester biochemical markers alone have only 60% sensitivity (Cuckle and van Lith, 1999). 
Combined with nuchal translucency, the detection rate is around 80%, with a 5% false–
positive rate (Krantz et al., 2000).  
11 
 
  
Large collaborative, prospective studies have validated the clinical application of 
first-trimester screening, and showed that it could be superior to second-trimester screening 
(Nicolaides et al., 2005). In addition, it reduces both physical and psychological trauma 
related to late interruption of pregnancy as well as therapeutic costs.  
3.3.3. Combined first and second trimester screening 
Several investigators studied different ways of incorporating the results of first and 
second trimester serum screening to obtain the most accurate estimation of Down syndrome 
risk. Many modalities have been created to help maximize the sensitivity, while maintaining 
a low false-positive rate. 
Integrated screening in which a patient’s first trimester screening results are not 
disclosed until second trimester screening is performed and a combined risk can be 
calculated, has been ethically debated. This option precludes patients who are at high risk 
based on first-trimester screening from being offered early CVS or other available options 
(Knight et al., 2005). 
Independent sequential first and second-trimester screenings, with separate 
individualized risk assessments increases the detection rate from 80% to 90% but it also 
increases the false-positive rate from 5% to 11%. In contrast, stepwise sequential screening 
in which only patients who screen negative in the first trimester are offered second-trimester 
screening, increases the detection rate to more than 90% while still maintaining a low false-
positive rate of 6% (Aagaard-Tillery et al., 2009; Platt et al., 2004). 
Contingent screening method is similar to stepwise sequential screening. However, 
the contingent screening uses the first-trimester results to classify patients into three groups, 
i.e., screen-positive, screen-negative, and borderline. Second-trimester screening is only 
offered to patients who fall into either the screen-negative or the borderline group. The 
detection rate for this method is 95%, with a 5% false-positive rate (Palomaki et al., 2006; 
Wright et al., 2004). 
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4. Prenatal Diagnosis  
In most developed countries the option of having prenatal diagnosis is discussed as 
part of routine antenatal care. Testing strategies, guidelines, and diagnostic options have 
expanded from their conception in the 1970s. At that time, any woman aged 35 years or 
older was considered to be of advanced maternal age, and this was the sole criterion used by 
the American Congress of Obstetricians and Gynecologists (ACOG) to define pregnancies 
that should be offered amniocentesis or CVS. 
As of 2007, the ACOG has extended the definition of a “high-risk” pregnancy that 
justifies prenatal cytogenetic diagnosis to include advanced maternal age, parental 
chromosome rearrangements, previous pregnancy with autosomal anomaly, abnormal fetal 
ultrasound findings during the current pregnancy and increased risk calculated from non-
invasive screening (ACOG, 2007b).  
However, current ACOG guidelines stated unequivocally that neither age 35 years 
nor any specific age should be used as a threshold for invasive testing: ‘All women, 
regardless of age, should have the option of invasive testing’. The guidelines specifically 
elaborate that ‘patients informed of the risks, especially those at increased risk of having an 
aneuploid fetus, may elect to have diagnostic testing without first having screening’ 
(ACOG, 2007a). Younger women may elect an invasive procedure because they wish to 
achieve the near 100% detection, possible only with an invasive procedure; detection by an 
invasive procedure exceeds by 10–15% that of any non-invasive screening protocol.  
4.1. Routine prenatal diagnosis   
4.1.1. Invasive diagnostic procedures   
The Prenatal diagnosis of the chromosomal anomalies generally requires collection 
of fetal tissue and chromosomal analysis of FCs. Fetal tissues can be obtained by either 
CVS, amniocentesis or less commonly cordocentesis through puncture of the umbilical 
cord. Valenti and co-workers, in1969, (Valenti et al., 1969) reported the first prenatal 
diagnosis of Down's syndrome three years after the achievement of amniotic cell growth by 
13 
 
  
Steele and Berg (1966) (Steele and Breg, 1966). Amniocentesis is usually performed 
through puncture of amniotic sac to obtain amniotic fluid for karyotyping and other 
biochemical tests at 16-18 weeks of gestation. Amniocentesis performed before 15 weeks is 
referred to as ‘early amniocentesis’. Early amniocentesis is not a safe alternative to second-
trimester amniocentesis because of increased pregnancy loss, limb reduction defects and 
clubfoot (CEMAT, 1998). 
The development of CVS in the early 1980's has allowed anticipation of diagnosis in 
the first trimester (Brambati and Simoni, 1983). CVS is usually performed between 9 and 13 
weeks of gestation and involves aspiration or biopsy of placental villi. CVS can be 
performed using either a transabdominal or a transcervical approach. Several randomised 
trials show almost identical miscarriage rates after transcervical CVS compared with the 
transabdominal approach (Jackson et al., 1992; Brambati et al., 1991). Only one trial 
demonstrated the transabdominal approach to be significantly safer (Jackson et al., 1992).  
Hundreds of thousands of amniocentesis and CVS after 10 weeks of gestation have 
been done without causing any complications or an increase in fetal malformations. 
However, both procedures are sometimes difficult and associated with some risks mainly to 
the pregnancy, but in certain circumstances to both the mother and the fetus. They also 
require the expertise of a specialized medical team and present a risk of iatrogenic fetal loss 
estimated between 0.5 and 2% (Tabor et al., 1986). The clear advantage of an early 
procedure like CVS over amniocentesis is the avoidance of a prolonged period of 
uncertainty and the availability of less stressful options in cases in which termination of 
pregnancy is desired after an abnormal result (Bindra et al., 2002). However, the 
disadvantage is the increased risk of miscarriage after first trimester CVS. Some authors 
even reported higher rates of limb reduction abnormalities and subsequent development of 
preeclampsia with CVS carried out at 9 weeks or earlier (Grobman et al., 2009; Philip et al., 
2004). Other fetal risks include intrauterine fetal death and premature birth (Vigliani, 2009). 
Severe sepsis, including maternal death, has been reported following invasive prenatal 
procedures. The level of risk cannot be quantified as case report literature does not provide 
denominator information but the risk of severe sepsis is likely to be less than 1/1000 
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procedure (Bodner et al., 2011). Infection can be caused by inadvertent puncture of the 
bowel, skin contaminants or organisms present on the ultrasound probe or gel. The 
procedures also increase the risk of maternal isoimmunization provoked by fetomaternal 
hemorrhage. Therefore, maternal RhD status should be obtained and prophylaxis with anti-
D immunoglobulin must be offered following each procedure to RhD negative women in 
line with international recommendations (ACOG, 2006).  
Currently, these invasive procedures are offered only to small group of women who 
are in a higher risk of having an offspring with a chromosomal defect in comparison to the 
general population. This high-risk group constituted less than 5% of the pregnant 
population. In addition, only one out of 20 procedures performed will reveal aneuploidy 
(Crossley et al., 2002). Development of non-invasive methods would obviate this risk and 
change the risk-benefit ratio of prenatal diagnosis. Such a change would make it likely that 
more women presently eligible for prenatal diagnosis would choose to undergo testing. In 
addition, genetic testing could even be offered to women who are not considered at high 
risk. One of the most promising non-invasive sources of fetal genetic materials is the 
peripheral MB. In this view, analysis of FC represents a major objective of many researches. 
4.1.2. Routine fetal karyotype 
With invasive tests such as amniocentesis or CVS, FCs are obtained for culture. For 
routine fetal karyotype, culture of FCs is essential prior to analysis as chromosomes are 
only visible in dividing cells. The application of strategies for improving cell culture and 
chromosome banding has expanded the number of laboratories that may perform 
successfully fetal chromosome analysis (Cheung et al., 1987; Brackertz et al., 1983; Porreco 
et al., 1980). The standard analysis implies the study of the number and structure of the 23 
chromosome pairs. The most common chromosome anomalies, are related to non-
disjunctional errors, result in an extra copy or loss of one chromosome. Trisomy 21 is by far 
the single most common cause of aneuploidies. Other identified abnormalities involve 
trisomies of chromosomes 13, 18, or sex chromosomes.  
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Although high resolution banding could allow diagnosis of small structural 
anomalies, these anomalies are relatively uncommon, accounting for less than 1% of all 
chromosomal abnormalities. Furthermore, balanced translocations and inversions, which are 
the commonest identified structural anomalies, are clinically irrelevant for the current 
pregnancies (Warburton, 1984; Jensen et al., 1982). However, there is a general consensus 
among cytogeneticists and physicians that the extra knowledge provided by a full karyotype 
is beneficial and thus, a full fetal karyotype is the gold standard of prenatal diagnosis. 
4.1.3. Rapid diagnostic techniques of fetal chromosomal anomalies 
The time needed to culture FCs and complete the analysis ranges from 10 to 21 days, 
which is generally considered to be a psychological burden and results in late terminations 
following a pathological diagnosis. In the early 1990s, FISH (Fluorescence In Situ 
Hybridization) (Kuo et al., 1991) and, more recently, QF-PCR (quantitative fluorescence 
polymerase chain reaction) (von Eggeling et al., 1993) entered the field of prenatal 
diagnosis to overcome the need to culture FCs, and hence allowed a rapid diagnosis of some 
selected chromosomal anomalies. FISH and QF-PCR provide a rapid diagnosis of 
aneuploidies within 24–48  hours. Although both techniques could be applied to identify all 
chromosomes, only chromosomes 13, 18 and 21, as well as the sex chromosomes, are 
routinely tested (Divane et al., 1994). The result was, and still is, sufficient to take action if 
a chromosome anomaly is thus identified, but is usually considered only a preliminary step 
while awaiting the result of full karyotype. 
Array comparative genomic hybridization (CGH) has been proposed as a genome-
wide assessment approach for prenatal diagnosis of chromosomal abnormalities. Array 
CGH is a molecular cytogenetic method for analysing copy number variations relative to 
ploidy level in the DNA of a test sample compared to a reference sample, without the need 
for culturing cells. Many reports have demonstrated the sensitivity, specificity and accuracy 
of this methodology detecting large and small-size imbalances (Pickering et al., 2008; 
Shaffer et al., 2008; Shaffer et al., 2007). Although different types of chromosomal 
abnormalities have been successfully identified by array CGH, the CGH traditionally is 
costly and requires advanced equipment (Lao et al., 2008). Another disadvantage of an 
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array CGH system is the time required for analysis and interpretation of the results, 
especially with the many incidental findings of unknown clinical significance, which creates 
an ethical dilemma and raises the maternal anxiety (Keren et al., 2010). However, array 
CGH has particular importance in investigating cases with strong history of intellectual 
disability or congenital abnormalities despite a normal conventional karyotype. 
Although these techniques hasten the process of prenatal diagnosis, they did not 
overcome the risk associated with invasive sampling of fetal tissues, which, therefore, limits 
offering prenatal diagnosis only to women with high risk pregnancies, as estimated by 
increased maternal age, abnormal biochemical markers and ultrasonographic findings. 
4.2. Non-invasive prenatal diagnosis  
The long-term goal of modern prenatal genetics is the development of definitive 
NIPD. That is, an analysis of MB that can detects fetal aneuploidy and other disorders 
without the need for an invasive procedure. Currently, prenatal diagnosis safety is limited by 
the need of invasive means to obtain fetal tissues. This limits its application to only small 
group of high-risk patients, which constitute less than 5% of all pregnancies. However a 
fairly good non-invasive method to obtain fetal tissues would obviate this risk and extend 
prenatal testing to include wider portion of pregnant population. It is currently agreed that 
genetic fetal material including both cells and cell-free fetal DNA (cffDNA) pass into 
maternal circulation during pregnancy. Non-invasive fetal diagnosis could therefore be 
possible from their isolation and analysis from peripheral MB. Although the cffDNA is 
increasingly used with massively parallel sequencing (Jensen et al., 2013; Liang et al., 2013; 
Liao et al., 2012; Ashworth, 1869) or targeted deep sequencing (Nicolaides et al., 2013; 
Zimmermann et al., 2012) to test for aneuploidy and single-gene disorders, it is still consider 
as a screening test and its application in clinical practice is very cumbersome and expensive. 
Although, cffDNA is currently a topic of great interest, this review will focus on the 
discussion of intact FCs in MB.  
Intact FCs have considerable advantage over cffDNA as the whole fetal genomic 
DNA can be purely recovered without maternal contamination and consequently simplify 
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the analysis and enables more women to undergo prenatal diagnosis without a significant 
increase in health expenditure. Analysis of pure fetal DNA from intact FCs would allow not 
only readily diagnosis of aneuploidy but also other small structural genetic defects 
concurrently. Even if one or few FCs were recovered, the approach would merely be 
analogous to that already routinely carried out on blastomeres or polar bodies in pre-
implantation genetic diagnosis. Analysis of intact FCs rather than cffDNA should facilitate 
provision of information about Mendelian disorder, and other chromosomal abnormalities. 
 An array allows comparative genomic hybridization (CGH) detection of aneuploidy 
for all chromosomes on a single cell is already available. This approach is proposed for 
analysis of a polar body or blastomere. The same approach could be applied for analysis of 
FCs. Furthermore; genetic diseases where the mother does not have the genetic alteration 
can be diagnosed by analyzing cffDNA in the maternal plasma. However, plasma analysis 
cannot be used for prenatal diagnosis of maternally inherited genetic diseases. 
However, even if several diagnostic perspectives could theoretically be realized, the 
use of these FCs for non-invasive prenatal diagnosis is currently far from being achievable 
in routine. Many interrogations persist on the types of FCs, physiology of trans-placental 
passage to the maternal circulation and the feasibility of their use in NIPD. Original efforts 
involved recovering intact FCs from MB. Various types of FCs in MB were recovered, 
primarily trophoblastic, erythroblastic and leucocytic cells. Each cell type has its own 
unique cellular characteristics and antigenic specificity. Consequently, various types of 
enrichments and cellular sorting have been tried. Given the fragility and rarity of these cells 
in MB (1 fetal cell for 106 to 108 maternal cells), translation into clinical utility remained 
elusive. Adapted techniques and new technologies are required to enable cellular recovery 
and accurate single cell analysis.  
Clearly, these newly developed techniques that could retrieve FCs from MB MB 
need additional improvements and clinical validation before being proposed in clinic for 
aneuploidy detection. Admittedly, though the harmlessness of these techniques seems 
attractive, but this does not mean they should necessary lead to NIPD. 
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5. Types of fetal cells in maternal blood 
The possible cell types that can be isolated from MB and used for prenatal diagnosis 
include erythroblasts, trophoblasts and lymphocytes. 
5.1. Erythroblasts  
Fetal erythroblasts or nucleated red blood (NRBC) appear to be the ideal candidates 
for detection and enrichment of FCs in MB. For multiple reasons, they are the cellular 
category most commonly studied and, probably, well characterized in MB.  Fetal 
erythroblasts are abundant in fetal blood especially in early gestation, comprising 
approximately 10% of the red blood cells in the 11-week fetus. This proportion declines as 
pregnancy progresses reaching approximately 0.5% at the 19 weeks of gestation.  
The trafficking of fetal red blood cells into the maternal circulation is clinically 
evident by cases of ‘silent’ rhesus isoimmunisation in rhesus negative women (MacKenzie 
et al., 1999). They have a nucleus with full complement of genetic information and a limited 
lifespan of approximately 90 days. In contrast to lymphocytes, they are unlikely to persist 
more than few days’ post-partum and are rare in the peripheral blood of a normal adult 
(except in clinical circumstances of increased haematopoiesis such as pregnancy). Fetal 
NRBC can be recognised in a number of different ways and many groups have convincingly 
sorted this fetal cell type using a variety of strategies. These cells were identified by their 
morphological characteristics and positive coloration for fetal hemoglobin (Clayton et al., 
1964).  
Nucleated erythrocytes express several unique antigens, such as the transferrin 
receptor, which is recognize by the AntiCD71 antibody, which recognizes the transferrin 
receptor (Ganshirt-Ahlert et al., 1992). Unfortunately, NRBC in the maternal circulation are 
not exclusively fetal, as was previously thought. AntiCD71 antibody recognizes also other 
nucleated fetal and maternal cells. Slunga-Tallberg has demonstrated that a definite 
population of maternal NRBC can be found during pregnancy and others have shown that 
only half of the erythroblasts in MB are of fetal origin (Troeger et al., 1999a; Slunga-
Tallberg et al., 1995). 
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Enrichment of erythroblasts can be improved with the use of several specific 
markers at the same time (e.g., CD71, size of the cells, granularity and positivity of the 
glycophorine A). The glycophorine A is a major glycoprotein of the erythroid membrane, 
which appears later than the CD71 and is not present in monocytes or lymphocytes. In a 
study carried out by Wachtel and co-workers (Wachtel et al., 1991), PCR technique could 
identify a sequence of the Y chromosome in 12/12 samples of enriched MB from male 
fetuses. In addition, researchers of the same team combined two markers, glycophorine A 
and CD71, with FISH technique and could successfully detect fetal chromosomal anomalies 
by analysis of MB. Using this technique, they were able to detect both trisomy 18 (Price et 
al., 1991) and trisomy 21 (Elias et al., 1992). 
Other approaches of enrichment encountered more difficulties. The detection of the 
fetal erythroblasts using antibodies directed against the gamma (γ) globin chain was not 
conclusive because of the presence of this same globin in maternal erythroblasts. However, 
other antibodies directed against the chains of embryonic zeta and epsilon (ζ or ε) globins 
were shown to be more specific. The expression of these globins is limited to early stages of 
pregnancy. The expression of the gene, which codes for the globin ζ decreases in a drastic 
way after six to seven weeks of pregnancy. It is present in only less than half of the 
erythroblasts at 11-12 weeks and becomes practically undetectable after the 15th week of 
gestation (Choolani et al., 2001). 
Many studies suggest that most nucleated erythrocytes that are present in first 
trimester MB samples are maternal in origin (Slunga-Tallberg et al., 1995; Slunga-Tallberg 
et al., 1994). Enrichment of nucleated erythrocytes in general will enhance the concentration 
of maternal cells as well as fetal. Therefore, a unique marker for fetal nucleated erythrocytes 
continues to be sought. 
5.2. Trophoblastic cells 
Trophoblastic cells represent the key element of the human placenta and are 
essential for its development and function. It has long been recognized that trophoblasts 
circulate in MB in pregnancies complicated by pre-eclampsia (Attwood HD, 1958). 
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Trophoblasts would seem ideal targets for fetal cell sorting efforts because of their 
abundance at the feto-maternal interface. Evidences suggest their early passage into the 
maternal circulation. They have also a particular morphology and apparently are present 
only during the period of pregnancy. Indeed, one highly specialized group of trophoblastic 
cells, the extravillous trophoblast, actually migrate into the walls of the spiral arteries which 
supply the maternal stroma and epithelium to bring about a process of remodelling of these 
blood vessels. It is these mononuclear cells that van Wijk and colleagues believe to be the 
trophoblasts that are most frequently found in MB (Van Wijk et al., 1996).  
Initial concerns that trophoblasts could only be found in MB in pregnancies affected 
by pre-eclampsia (Chua et al., 1991) have been dismissed in the light of results achieved 
subsequently by a number of groups (Vona et al., 2002; Lim et al., 2001; Van Wijk et al., 
1996). Nonetheless, targeting trophoblasts is not a straightforward process. While a 
considerable number of trophoblastic cells escape into the MB, very little stay in the 
peripheral circulation. In fact, the majority of the multinucleated syncitio-trophoblasts are 
filtered and sequestered by maternal lungs. In addition, their multinucleated nature may 
also limit subsequent genetic analysis (Benirschke, 1994). 
Furthermore, enrichment of trophoblastic cells is difficult. The membrane markers 
specific to the trophoblastic cells are rare. Several erroneous observations of trophoblasts 
were published from mixing up with maternal leucocytes containing either trophoblastic or 
erthroblastic antigens. In 1984, Covone and co-workers were the first to successfully isolate 
trophoblastic cells from maternal peripheral blood at various stages of the pregnancy 
(Covone et al., 1984). They used a monoclonal antibody, anti-H315, directed against a 
placenta’s isoform of alkaline phosphatase of placental type. In fact, it has been found that 
the isolated cells were maternal cells on which the H315 antigen had been adsorbed. These 
observations did not prevent the study of this cellular category from ensuing with much 
enthusiasm in order to develop a NIPD (Bertero et al., 1988; Covone et al., 1988). 
One of the major characteristics, which differentiate the trophoblastic cells, is their 
expression of the cytokeratins. Whereas all hematopoietic as well as endothelial cells are 
keratin negative, the trophoblasts are keratin positive. This difference in the expression and 
21 
 
  
the development of the specific monoclonal antibodies provided a base for their isolation 
and enrichment. The most sensitive and specific method of recognising trophoblasts has 
been developed by Vona who sorted trophoblasts purely on the basis of size and then used 
either staining with haematoxylin and eosin or immunohistochemical localisation with KL1 
antibody (recognises a cytokeratin found in cytotrophoblasts) or anti-placental alkaline 
phosphatase antibody (recognises syncytiotrophoblasts) (Vona et al., 2002). 
Other trophoblastic markers such as HLA-G (Moreau et al., 1994), human placental 
lactogen (HPL) (Van Wijk et al., 1996) and Human Achaete-Scute Homologue 2 (HASH-2) 
(Alders et al., 1997) have been tested. The major disadvantage of the use of cytokeratins and 
other antigens for separation by FACS or MACS remains the permeabilization of the 
cellular membranes. The latter is, indeed, necessary to make it possible for the antibodies to 
penetrate and reach their antigens inside the cells. Also the antibodies directed against the 
epithelial cytokeratins, in particular CK 7 and CK 17, and other antigens are not ultimately 
specific. Bruch used trophoblast specific antibodies to detect sequences of the Y 
chromosome from newly enriched samples (Bruch et al., 1991). However, the cells 
resembled leucocytes more than trophoblasts.   
Other concerns remain over the possibility of confined placental mosaicism and 
variability along the fetal-placental karyotypic axis. Confined placental mosaicism 
represents a discrepancy between the chromosomal makeup of the cells in the placenta and 
the cells in the baby. The extra-embryonic placental tissue does not always reflect the fetal 
genotype and 1-2% of placental cells differ in their karyotype from that of the fetus due to 
placental mosaicism (Farra et al., 2000; Kalousek and Vekemans, 1996). This also limited 
the use of trophoblasts in MB and led many investigators to conclude that trophoblasts are 
not the ideal cells to use for prenatal diagnosis (Bianchi, 1999).  
However, despite these biological and technical problems, some diagnostic success 
has been achieved. Several groups have successfully isolated trophoblastic cells from 
maternal peripheral blood and could carry out some morphological and genetic confirmation 
(Vona et al., 2002; Lim et al., 2001; Van Wijk et al., 1996).  
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5.3. Lymphocytes 
Fetal lymphocytes are a potential source of cells for prenatal diagnosis. Walkowska 
and co-workers showed the presence of the Y chromosome in metaphases of lymphocytic 
cells of fetal origin in maternal peripheral blood stimulated with phytohemaglutinine 
(Walknowska et al., 1969). This was also confirmed by quinacrine, which highlights the 
heterochromatin of the long arm of Y chromosome (Iverson et al., 1981). 
The analysis of the fetal lymphocytes is limited by several factors, in particular the 
lack of monoclonal antibodies specific to this cellular type. The antigens of surface of the 
fetal lymphocytes are not very different from those of the maternal ones. The technique used 
to isolate the fetal lymphocytes consists of identifying the specific paternal HLA, so that if 
the mother and the father have distinct HLA, cells may be sorted by flow cytometry and 
enriched for paternal antigen expressing cells. However, this approach requires paternal 
HLA typing, and is impossible when paternal and maternal HLA antigens are shared 
(Herzenberg et al., 1979). This approach is further limited because fetal production of 
lymphocytes does not begin until the 20th weeks of gestation after the development of fetal 
bone marrow. 
Another important limitation is the misinterpretations of the subsequent pregnancies 
as the fetal lymphocytes can persist in the maternal circulation for many years after a 
pregnancy. Bianchi et al., flow sorted cells based on hematopoietic stem cell markers and 
found Y-chromosome-specific sequences in six of eight non-pregnant women who were not 
pregnant who had previously had a male child and were 6 months to 27 years post-partum 
(Bianchi et al., 1996). This confirmed findings by Schroder et al and Ciaranfi et al, who, two 
decades earlier, had demonstrated male lymphocytes in MB in the first year after the birth of 
a male child (Ciaranfi et al., 1977; Schroder et al., 1974). 
5.4. Granulocytes 
They were studied in a limited number of cases and their presence in MB is 
uncertain. Only one group claimed of having successfully isolated these cells from MB and 
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raised the possibility of using fetal granulocytes as target cells for NIPD (Wessman et al., 
1992). 
 This group used a Ficoll gradient followed by a cellular sorting by FACS and 
suggested early presence of these cells in the maternal compartment. Using FISH technique, 
they detect a Y signal among eight women of which one did not give birth to a male child. 
The reported explanation for this case was either a technical error or the presence of fetal 
male cells from a previous pregnancy (Bianchi, 1995). The granulocytes account for 0.02 to 
0.04% of the mononucleated cells. But, these cells are unlikely to be potential candidates 
(Geifman-Holtzman et al., 1994; Simpson and Elias, 1993). 
5.5. Haemopoietic progenitor cells  
The presence of fetal haematopoietic progenitor cells in maternal peripheral blood 
was shown by the use of surface antigen CD34 (Little et al., 1997). The application of FISH 
followed by immunohistochemistry using anticytokeratin antibody AE1/AE2 (markers of 
the epithelial cells), anti-CD45 antibody (leucocytic markers) and heppar-1 (hepatocytic 
marker), made it possible to confirm the presence of these totipotent FCs (Khosrotehrani et 
al., 2004).  
Under appropriate conditions, these cells can be cultured and would provide enough 
material for the genetic analysis of the fetal genome (Jansen et al., 2000). However, the 
inherent problem of maternal cellular contamination makes this analysis difficult. Tutschek 
et al., found that only 0.8% of colonies were purely fetal in origin (Tutschek et al., 2000).  
Furthermore, there is evidence that these cells can persist in the MB from previous 
pregnancies (Guetta et al., 2003). This was shown by the presence of male cells in 
pregnancies with female fetuses (Bianchi et al., 1996). Therefore, it appears that these cells 
are not ideal candidates for prenatal diagnosis. 
5.6. Thrombocytes (platelets) 
The blood platelets do not have a nuclei or DNA material to facilitate their detection 
by molecular cytogenetics. Consequently, they were excluded from fetal cell researches. 
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6. Biological Parameters of feto-maternal cell trafficking 
The detection and characterization of FCs in the maternal circulation is a rapidly 
expanding field with important implications for both prenatal diagnosis and for a better 
understanding of the physiology of feto-maternal interactions. Relatively little is known 
about the biological parameters governing the passage of FCs into maternal circulation. For 
example, it is still not known, for sure, whether the existence of FCs in maternal circulation 
represents a normal physiological phenomenon present in all pregnant women or whether it 
is merely a consequence of spontaneous feto-maternal hemorrhage. This key issue has a 
direct consequence on the general applicability of prenatal diagnosis using FCs in MB. 
Further research is still required before any clinical application can be made. 
6.1 Anatomy of the placenta 
The placenta is a gestational organ of very complex structure and function. It is 
made up of both fetal and maternal components. During the pregnancy, the stromal cells of 
the uterine endometrium are differentiated into bulky decidual cells, known as decidua 
basalis, which forms the maternal component of the placenta. The fetal component is 
derived from a tissue that arises from the conceptus, called the chorion. The chorion 
comprises a chorionic plate and finger-like projections of chorionic villi. The intervillous 
space lies between the fetal and maternal parts of the placenta and is filled with MB. The 
two portions are held together by anchored chorionic villi, which are attached to the decidua 
basalis at the site of implantation. Chorionic villi are separated from MB by a double layer 
of trophoblastic cells: the cytotrophoblasts, which form the internal layer and the 
multinucleated syncytiotrophoblasts, which form the external layer (Huppertz, 2008).  
Maternal blood flows into the intervillous space through spiral endometrial arteries 
and leaves through endometrial veins on the surface of the decidua basalis. The fetal blood 
is separated from the MB by a thin membrane, so fetal blood and MB are in close proximity 
but do not intermix. This allows bidirectional exchange of gases, nutrients, metabolites and 
endocrine secretions (Figure 1) (Lightner et al., 2008). During the pregnancy, the bulky 
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decidual cells play an important role in the control of the invasive potential of the 
trophoblast and provide immunomodulatory function (Lisman et al., 2007). 
 
Fig. 1 shows a diagrammatic presentation of the human maternal-fetal interface 
Fetal blood enters and exits the placenta via the umbilical cord. Fetal vessels lie at the core of 
each placental villae and all villae are lined externally by trophoblast cells. The cells of the 
inner layer are called villous cytotrophoblast cells. Those of the outer layer develop from the 
villous cytotrophoblast through syncytialization and are called syncytiotrophoblast. Floating 
villae are completely bathed in maternal blood; anchoring villae traverse the intervening blood-
filled space to attach to the maternal decidua. Some extravillous cytotrophoblast cells will 
invade the maternal uterine arteries and become endovascular trophoblast cells Clin Dev 
Immunol. 2008;2008:631920. 
 
Immunologically, the relationship between the uterus and the placenta is comparable 
to that between a recipient and a clinically transplanted graft, which is partially foreign for 
it. Immunologists have never found it easy to explain why the semi-allogeneic fetus is not 
attacked by the maternal immune system. Most researchers agree that local effects at the 
maternal–placental interface are important to tolerate paternal antigens. The geneticists 
consider it as special organ of embryonic origin, which presents unique characteristics, in 
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particular, the inactivation of paternal X chromosome, and is sometimes the seat of confined 
placenta mosaicism, which is frequently associated with intra-uterine growth restriction 
(Lestou and Kalousek, 1998). Lastly, the placenta represents for the cellular biologist a 
single model of limited and controlled pseudo-tumor invasion, and which in addition 
constitutes one of the rare models in human biology of cellular fusion leading to the 
formation of a syncytium (Cox et al., 2009). 
6.2 Factors affecting passage of fetal cells to maternal blood 
Bi-directional trafficking of cells between the mother and the fetus is a component of 
maternal-fetal tolerance. Thus, alterations in trafficking may be related to the breakdown of 
tolerance between the mother and the fetus (Starzl, 2004). The mechanism by which cells 
are exchanged across the placental barrier is unclear. Possible explanations include 
deportation of trophoblasts, micro-traumatic rupture of the placental blood channels or that 
specific cell types are capable of adhesion to the trophoblasts of the walls of the fetal blood 
channels and migration through the placental barrier created by the trophoblasts. Intervillous 
thrombi containing mixed maternal and FCs occur in the fetal placenta (Batcup et al., 1983). 
Histological defects in the continuity of the trophoblasts lining the vasculature of the 
placenta are also reported (Jauniaux and Hustin, 1992). Together these observations suggest 
the possibility that fetomaternal hemorrhage may allow exchange of cells between the fetal 
and maternal circulation (Figure 2) (Dawe et al., 2007). 
The factors, which can influence the frequency of the FCs in MB, are numerous. 
One can mention among others, the type of placentation, multiple pregnancies (Al-Mufti et 
al., 2003), feto-maternal incompatibility (Batcup et al., 1983), gestational age (Hamada et 
al., 1993), bimanual pelvic examination (Simpson and Elias, 1993), invasive prenatal 
diagnostic procedures (Adinolfi, 1995), and abortions. The trafficking of FCs has been 
demonstrated to be greater in fetuses with abnormal karyotypes (Krabchi et al., 2006b; 
Krabchi et al., 2006c; Ganshirt-Ahlert et al., 1993; Elias et al., 1992; Bosso and Al-Mulla). 
Mechanisms for this increase in fetal cell trafficking remain speculative. Trisomic placentae 
demonstrate immaturity and hydropic change and it is suggested that the passage of 
trophoblastic FCs across such placentae are made easier as a result of these changes. It is 
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possible also that the compromised fetus has more NRBC secondary to the chronic 
stimulation of hypoxic bone marrow. Alternatively, placental damage may result in greater 
fetal cell trafficking (Holzgreve et al., 1998). 
Increased amounts of FCs and cell-free fetal DNA have been also seen in maternal 
serum after fetal intervention (Wataganara et al., 2005), certain maternal complications such 
as diabetes (Al-Mufti et al., 2004), and may be a marker in prenatal complications as 
preeclampsia and preterm labor (Farina et al., 2005). However, the most important potential 
application remains to be the NIPD of fetal chromosomal abnormalities. 
 
Fig. 2 Simplified diagram of the hypothesized mechanisms of fetomaternal cell traffic 
Fetal blood enters the placenta via the umbilical cord passing through the intervillous space bathing 
the branches of the villous trees to exit through the maternal veins. Hypothesized mechanisms of 
fetomaternal cell traffic include (i) deportation of trophoblasts lining the maternal vessels and 
intervillous space; (ii) microtraumatic hemorrhage; and (iii) cell adhesion and transmigration across 
the placental barrier. Cell Adh Migr. 2007 Jan-Mar;1(1):19-27. 
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6.3 Microchimerism 
Microchimerism is the presence of a small population of genetically distinct and 
separately derived cells within an individual. This usually occurs following transfusion or 
transplantation (Reed et al., 2007; Adams and Nelson, 2004). Microchimerism can also 
occur between a mother and her fetus. Recent studies showed the presence of male cells, 
proposed to be of fetal origin, in up to 50% of normal healthy women after delivery of male 
infant (Lambert et al., 2002). Microchimeric FCs are found in various maternal tissues and 
organs. Some of these cells can persist for decades in MB (Bianchi et al., 1996). Their 
presence creates a cellular state of microchimerism considered as an epiphenomenon of 
pregnancy with potential pathological consequences. 
The FCs are semi-allogenic for the maternal immune system. Thus, microchimerism may 
have some implications regarding the immune status of women such as influencing 
autoimmunity and tolerance to transplantation. Bianchi reported an association between the 
persistence of this kind of FCs and the later development of autoimmune diseases like 
Sjogren syndrome. Greater numbers of cells were found in women suffering from 
autoimmune diseases like scleroderma (Nelson et al., 1998) and thyroiditis (Srivatsa et al., 
2001) as well as non-autoimmune pathologies, such as hepatitis C (Johnson et al., 2002) and 
cancer (Cha et al., 2003). Increased maternal microchimerism has been also described in 
patients with type 1 diabetes mellitus (Nelson et al., 2007), neonatal lupus syndrome-
congenital heart block (Stevens et al., 2003), and biliary atresia (Muraji et al., 2008). Little 
information is available on the phenotype of the FCs present in non-hematopoietic maternal 
tissues. The long-term consequences of the cellular microchimerism hardly start to be 
considered and its biological significance remains unclear. 
It is recognized that the cellular exchange through the placental barrier is 
bidirectional (Lo et al., 1996). Trafficking of cells between the mother and the fetus is 
mostly considered from the feto-maternal side. Researchers focus on the implications of FCs 
on maternal health. However, trafficking in the other direction (maternal into fetal) is less 
well understood. The passage of the maternal cells to fetal tissues occurs in all species with 
hemochorial placentation, like mouse and humans (Piotrowski and Croy, 1996). Recent 
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studies re-examined the assumption that persistent maternal cells in offspring may play a 
key role in the pathogenesis of certain diseases like severe combined immunodeficiency 
(Pollack et al., 1982) and juvenile myopathies (Artlett et al., 2001). More detailed 
understanding of the biology of microchimerism is required (Klonisch and Drouin, 2009). 
6.4. Problems linked to persistence of fetal cells from former pregnancies 
One of the main criticisms for using FCs in MB for NIPD is a concern about the 
presence of remanent FCs from a former pregnancy or miscarriage. Hamada and co-workers 
followed up the FCs from day one to 24 months postpartum of 25 primiparous women. Fetal 
cells were detected shortly after childbirth at a rate of an average one fetal cell for 17500 
maternal cells. This frequency decreased with time reaching an undetectable level three 
months after childbirth (Hamada et al., 1994).  
The FCs present in maternal circulation are mainly of hematopoietic origin. Studies 
report diversities of the expressed hematopoietic markers. Several publications have shown 
the persistence of CD34+ cells several years after the childbirth (Adams et al., 2003; Guetta 
et al., 2003). These progenitor cells have the ability of self-activation by fusion or trans-
differentiation in maternal tissues. FCs were also identified among the mononuclear subsets 
of B and T lymphocytes, natural killer cells and T-cells which express the antigens 
CD4/CD8 (Artlett et al., 2002; Evans et al., 1999). This indicates that these cells are able to 
be grafted and to be differentiated in hematopoietic cell lines. Thus, certain hematopoietic 
FCs (lymphoid progenitors; B and T lymphocytes) can be found for a long time after 
pregnancy, and thus preclude their use in NIPD.  
Contrary to the fetal lymphocytes, fetal trophoblasts and erythroblasts are unlikely to 
persist more than few days post-partum and are rare in the peripheral blood of a normal 
adult. They have a full complement of genetic material yet have a limited lifespan and 
therefore seem ideal targets for the screening of fetal aneuploidies. Furthermore, they appear 
at an earlier stage of gestation in contrast to fetal lymphocytes. In summary, the duration of 
persistence of FCs seems to depend on the cellular type and the long-lived FCs cannot, 
consequently, be used for possible systematic screening of fetal aneuploidies. 
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7. Frequency of fetal cells   
The analysis of several publications has made it possible to know the percentage of 
FCs at various stages of the pregnancy. The FCs circulating in MB can be detected as early 
as the 4-5th week after implantation (corresponding to 6-7th weeks of amenorrhea) in nearly 
30% of the pregnancies. The rate of detection clearly increases between 8th and the 13th 
week, to reach 80% of pregnancies. More optimistic results were also published. Thomas 
and co-workers using PCR technique of Y chromosome (Thomas et al., 1994) detected male 
FCs in 18 pregnancies out of 18 at the 6th week of gestation. Liou et al., (Liou et al., 1994; 
Liou et al., 1993) found specific sequences of male fetuses in 19 out of 19 pregnancies 
analyzed at 10th to 11th weeks. It is necessary however to consider these figures with great 
caution because they depend on a limited number of cases. 
The frequency of FCs varies with the gestational age, which may influence fetal cell 
trafficking. Ganshirt et al., (Ganshirt-Ahlert et al., 1993) showed an increasing trend in the 
frequency of NRBC with advancing gestation from 10th to 40th weeks. De Alba et al 
(Rodriguez de Alba et al., 2001) found a slight, but nevertheless significant, increase in fetal 
NRBC between the first and second trimesters. Sohda et al., (Sohda et al., 1997), however, 
demonstrated a non-significant reduction in the number of presumed fetal NRBC after 19th 
weeks gestation. Neither Lim et al., (Lim et al., 2001) nor Shulman et al., (Shulman et al., 
1998) saw a change in the number of fetal NRBC as gestation advanced. Lim et al., (Lim et 
al., 2001) found a decreasing trend for the mean number of trophoblasts and Taniguchi et 
al., (Taniguchi R, 2001) found the optimal time for trophoblast RNA isolation to be from 
9th to 13th weeks of gestation.  
Estimates of absolute fetal cell numbers circulating in MB have varied significantly. 
The rate varies widely from less than 1 to more than 150 FCs per 1 ml of MB. Studies, 
which count specific types of FCs based on staining or morphological criteria probably, 
overestimated the total number of cells because no fetal cell recognition system is 
completely specific. The majority of the studies of fetal NRBC have found between 1 and 
10 FCs per ml of MB (Kitagawa et al., 2002; Rodriguez de Alba et al., 2001; Campagnoli et 
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al., 2000; de Graaf et al., 1999; Rodriguez De Alba et al., 1999; Bischoff et al., 1998; 
Simpson et al., 1995; Ganshirt-Ahlert et al., 1993). Nevertheless, Lim apparently sorted 30–
40/ml (Lim et al., 2001), Troeger 40–50/ml (Troeger et al., 1999b), Sohda 60–70/ml (Sohda 
et al., 1997) and Wachtel 150 NRBC per ml of MB (Wachtel et al., 1998). The later 
concludes that more than 30% of the erythroblasts circulating in MB were of fetal origin 
using a technique of cellular separation based on physical differences between fetal and 
maternal cells. It is however extremely probable that most of these cells are not fetal in 
origin.  Lesser numbers of trophoblast sorting reports have produced similar yields (Vona et 
al., 2002; Lim et al., 2001; Van Wijk et al., 1996). 
On the other hand, less generous predictions are usually given by studies, which use 
universal marker that recognise cells as fetal only by the presence of a Y chromosome FISH 
signal in male pregnancies. Bianchi et al., (Bianchi et al., 1997) found a mean of 19 male 
fetal cell DNA equivalents per 20 ml sample of MB using quantitative PCR suggesting that 
each millilitre of MB contains one fetal cell. More recently, Ariga et al., (Ariga et al., 2001) 
found between 2 and 40 genomic equivalents of male cells in the cellular fraction of 1 ml of 
MB using real-time PCR. Quantitative PCR work carried out by Bianchi did not support a 
gestational effect unlike that of Ariga, which suggested increased trafficking as pregnancy 
progresses. All these data did not take into account a well-known risk of PCR technique, 
which is that the wrong amplification of parasitic sequences may give falsely positive 
results. It should however be noted that the recent improvements in this technique have 
made it possible to reduce this risk to great extent,.  
Other studies have used a laborious but far more accurate approach. Small samples 
of unsorted MB have been fixed onto slides and all mononuclear cells examined for their 
FISH signals. Hamada et al., (Hamada et al., 1993) used specific sequences of Y 
chromosome (DYZ1) on samples collected directly without enrichment. They observed two 
slides of approximately 150,000 cells, representing the equivalent of 0.01 to 0.03 ml of MB 
per patient. The frequency of the FCs observed was estimated as 0.27/105 cells during the 
1st and 2nd trimesters and 8.5/105 cells during the 3rd trimester. In our laboratory, Krabchi 
et al., used FISH and PRINS techniques to investigate a larger volume of MB (1 ml) in 
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twelve cases of male pregnancies (Krabchi et al., 2001). An average of 2 to 6 FCs was 
found per ml of MB during the 2nd trimester. Our results are in agreement with those of 
Ariga et al., (Ariga et al., 2001) and that of Kolvraa et al., (Kolvraa et al., 2005). 
Although the number of FCs in MB is variable and no consensus has been reached, 
all are agreed that number is very low. The rate probably ranges from 1 per 500,000 
maternal cells to 1 per 1.5 million maternal cells. In the light of the many false results 
reported by certain investigators, it becomes essential that accurate and specific techniques 
with suitable controls be used to enrich the samples for FCs and to confirm their nature. 
Unfortunately, these conditions were not always respected in the literature (Wachtel et al., 
1998; Adinolfi, 1995; Tharapel et al., 1993). 
8. Techniques for isolation and analysis of fetal cells  
The original motivation for developing NIPD for chromosomal abnormalities was 
the low sensitivity and positive predictive values of existing screening tests and the 
subsequent need for invasive procedures for confirming the diagnosis. Although enrichment 
and isolation of FCs from MB has dominated the work in the field of NIPD, improvements 
in the detection and analysis of the FCs may overcome the problems of impurity and high 
contamination with maternal cells. 
8.1 Techniques for enrichment and isolation of specific cell type 
The strategy generally adopted for enrichment was not to obtain a pure sample of 
FCs, but to generate a sample with which one will be more likely to find FCs. Fetal cells can 
be harvested from the maternal circulation in a variety of ways. Negative enrichment 
techniques deplete unwanted maternal cells whereas positive enrichments actively select for 
FCs. 
It is well recognized that even after enrichment, the majority of the cells are of 
maternal origin. Reaching a concentration of 1 fetal cell to 50,000 maternal cells, would 
allow more comfortable detection and analysis by FISH technique. The problem of 
enrichment is that there is no unique marker of different types of presumed FCs and, 
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consequently, one cannot enrich all FCs at a time and should target a specific type of FCs.  
Furthermore, many of these fragile cells could be lost or destroyed in the process of 
enrichment itself decreasing the chance of prenatal diagnosis. 
8.1.1. Density gradients enrichments 
The principle of this method consists of a centrifugation of the MB across a 
continuous or discontinuous gradient to isolate the mononuclear cells and to separate cells 
according to their densities. The gradients are specific solutions of different densities, which 
superimpose according to its individual densities. The cellular suspension is deposited on 
the surface of the gradient and then the cells migrate during centrifugation according to their 
own density. The solutions used can be of Ficoll, Percoll or Histopaque. These solutions are 
made up of polysucrose and a radiopaque medium (sodium diatrizoate). One can use a 
simple gradient of only one layer or a multiple gradients containing two or more layers 
(Samura et al., 2000; Troeger et al., 1999b; Johansen et al., 1995; Ganshirt-Ahlert et al., 
1993). 
The yield of FCs tends to be inversely related to the purity of the final sample and, 
inevitably, a compromise must be reached between target cell losses and contamination with 
maternal cells. The optimum gradient, which minimises target cell losses but also limits 
contamination by non-target cells is unclear for both trophoblasts and NRBC although some 
comparative work has been carried out. The cytoplasmic-to-nuclear ratio of fetal NRBC 
varies as gestation progresses and the embryonic Hb drops from 90% to 10% to be 
superseded by gamma globin (HbF). The cells progressively become smaller and have a 
lower cytoplasmic-to-nuclear ratio (Choolani et al., 2003). This variability in size and 
density causes them to sediment over a wider density range with more than 80% 
overlapping with that of maternal red blood cells at a given density. 
Ganshirt-Ahlert et al., used a triple gradient of 1.077 g/ml, 1.110 and 1.119 Ficoll-
Histopaque. Most NRBC settled between 1.077 and 1.110 (Ganshirt-Ahlert et al., 1993). 
Subsequently, a gradient of 1.090 g/ml was found to deliver a superior cell yield than 1.083 
g/ml (Sekizawa et al., 1999). Later, the yield of heavier gradient, 1.119 g/ml, was found to 
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be even higher (Samura et al., 2000; Troeger et al., 1999b). The trophoblasts are said to 
sediment between 1.051 and 1.064 g/ml (Johansen et al., 1995). However, narrowing the 
‘density window’ from 1.053 to 1.060 g/ml was found to reduce the final yield but increase 
the cell purity (Van Wijk et al., 1996). 
 Overall, the separation by density gradient was often used as preliminary stage in 
the isolation of FCs. Few groups argued that prenatal diagnosis is possible after simple 
enrichment by one gradient (Oosterwijk et al., 1998) whereas the majority believe that a 
more thorough enrichment is required. 
8.1.2. Cellular sorting 
Further improvement in FC enrichment can be achieved using antibody-based 
methods. Two principal methods have been used to exploit distinct cell antigens for the 
purposes of cell separation. Fluorescence activated cell sorting (FACS) and magnetic 
activated cell sorting (MACS) are cell separation techniques, which are significantly more 
selective than density gradients.  
8.1.2.1. Cellular sorting by fluorescence flowcytometry or FACS 
The technique takes advantage of the differences between maternal and FCs, in 
particular, regarding the expressed intracellular and surface antigens. FACS selects cells 
using fluorescent antibodies. If a monoclonal antibody which recognises the fetal-specific 
antigen is fluorescently labelled and then incubated with the cells, only those bearing the 
particular antigen will bind antibody, fluoresce and be recognised during flow cytometry. 
The isolated cells are put in contact with monoclonal antibodies to these antigens. The cell 
suspension is then passed through a vibrating jet, which changes continuous liquid flow into 
droplets that contain individual cells. After generation of droplets, the liquid intercepts a 
laser beam. The laser excites the fluorescent molecules that are present on the surface of 
target cells, which consequently acquire an electrical charge. The positive droplets are then 
deviated into a collecting tubule. This method allows simultaneous evaluation of several 
parameters including cell size, nuclear shape and surface antigenicity (Lewis et al., 1996; 
Herzenberg et al., 1979).  
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A number of different antigens have been exploited, depending on the target fetal 
cell type. Fetal NRBC have been sorted by recognizing CD71, the transferrin receptor 
(Ganshirt-Ahlert et al., 1992), glycophorin-A (Elias et al., 1992; Price et al., 1991), CD36, 
the thrombospondin receptor (Zhao et al., 2002; Sohda et al., 1997), gamma-globin 
(DeMaria et al., 1996) and epsilon-globin (Choolani et al., 2001). Finding trophoblastic 
specific antigens has been more difficult. The majority of work on trophoblasts has either 
used negative depletion (van Wijk, 1998; Van Wijk et al., 1996) or has sorted cells 
according to size (Vona et al., 2002). 
Apart from its complexity, the flow cytometry is time consuming and expensive. 
FACS is also difficult to carry out, requires specialised equipment and considerable 
expertise. Furthermore, cell sorting may reduce target cell numbers if cell losses are 
significant or cell recognition is inadequate.  
8.1.2.2 Cellular sorting by immunomagnetic beads or MACS 
MACS technique is the most widely used technique in fetal cell sorting. Tiny 
magnetic beads are labelled with the monoclonal antibody, which recognise specific fetal 
antigen. They are incubated with the cell mix and then extracted using a magnet. The beads 
fixed at the FCs will retain them at the time of their passage through a distillation column 
attached to a magnetic field creating positive selection of FCs. The cells, which do not 
present specific antigen, will not attach to the beads and will pass freely through the 
magnetic field (Miltenyi et al., 1990). After release of the magnetic field, the cells attached 
to the beads remain hung along the column. An elution will then detach them from the 
column so they can be collected and analysed (Simpson and Elias, 1995). Unfortunately, 
none of the antigens are unique to FCs and this inevitably results in a lot of contamination 
from maternal cells (Zhao et al., 2002; Ganshirt-Ahlert et al., 1993). 
The question of which fetal enrichment technique is best is an extremely complex 
one as very few comparisons have been made. Evidence suggests that MACS is favoured 
over FACS as it is simpler and cheaper. Furthermore, the cellular yield with MACS is 
usually greater than that from FACS although at the expense of purity. These conclusions 
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were reached by Johansen and colleagues (Johansen et al., 1995) and have been supported 
by the findings of the National Institutes of Health Fetal Cell Study (NIFTY), trial. The 
NIFTY trial represents the largest assessment of fetal cell sorting made to date. The results 
were published in 2002 (Bianchi et al., 2002) and have been discussed in depth 
subsequently at the National Institute of Child Health and Human Development conference 
on FCs entitled ‘Sharpening the Tools’. Jackson reported a general feeling that new ideas 
and technologies will be necessary if significant improvements are to be made (Jackson, 
2003). Unless specific fetal cell identifiers become available the sorting techniques will 
remain too laborious and inconsistent for clinical practice. 
There is no doubt that FCs are present in MB but it remains unclear as to whether 
they will ever be sorted and analysed with sufficient efficacy and accuracy for the 
techniques to be applied for screening and diagnosis of common chromosomal 
abnormalities in the general population. 
8.2 Techniques for detection and analysis of fetal cells 
Isolating FCs from MB is only of value if these cells can be meaningfully analyzed. 
In view of the difficulties in finding a truly fetal-specific antigen, which detects all FCs and 
persists throughout the pregnancy, alternative approaches to enhance detection and analysis 
of FCs in samples highly contaminated with maternal cells have been pursued. It is hoped 
that further new concepts and technological advances will hasten the development of this 
field and lead to the introduction of NIPD into routine clinical practice. The major 
techniques used to detect and analyse FCs are: 
- Cytogenetic analysis of the FCs: FISH or PRINS 
- Molecular evaluation of fetal genotype: PCR technique 
 
Unfortunately, these tests have limitations, which add further to the challenges of 
fetal cell sorting. Their usage is critic when cell numbers and purity are low, as is the case 
with FCs sorted from MB. 
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8.2.1 Fluorescence In Situ Hybridization (FISH) technique 
Refinements in cytogenetic techniques over the past 30 years have allowed an 
increasingly sensitive detection of chromosome abnormalities. Banding techniques, though 
historically pivotal in cytogenetics, are limited to mitotically active cells. The introduction 
of FISH in the late 1980s, has revolutionized cytogenetic analysis at the molecular level 
(Pinkel et al., 1988). FISH technique is used to detect numerical and structural anomalies, 
for which there is an appropriate probe, either in the metaphase spread of dividing cells or in 
the interphases nuclei of non-dividing cells. The high sensitivity and specificity of FISH and 
the speed with which the assays can be performed have made FISH a powerful technique 
with numerous applications, and it has gained general acceptance as a clinical laboratory 
tool (Gozzetti and Le Beau, 2000). The use of interphase FISH in the study of FCs in 
maternal circulation allowed detection and even quantification of these cells. The presence 
of a Y chromosome hybridization signal (in a pregnancy with a male fetus) or of three 
chromosome 21 hybridization signals within one nucleus (in a pregnancy affected by Down 
syndrome) was taken as reliable evidence of fetal cell sorting. 
8.2.1.1 Principle 
FISH is essentially based upon the same principle as a Southern blot analysis, a 
cytogenetic equivalent that exploits the ability of single-stranded DNA (probe) to anneal to 
its complementary DNA (target). In the case of FISH, the target is the nuclear DNA of 
either interphase cells or metaphase chromosomes fixed to a microscope slide. The nucleic 
acid probes are a small sequence of DNA (or RNA) whose normal site is known in the 
genome and is chemically marked in order to be located thereafter (Figure 3) (Speicher and 
Carter, 2005). This anneals to its complementary sequence in the specimen DNA and is 
detected either directly or indirectly through a reporter molecule (Kearney, 2001).  
For direct detection, an attached fluorochrome of FITC, Rhodamine, Texas Red, 
Cy2, Cy3, or Cy5 is used as reporter molecule. This enables direct visualization of the probe 
as coloured fluorescent signal at the hybridization site by fluorescence microscopy. In the 
indirect detection method, hapten molecules such as biotin, digoxigenin and dinitrophenol 
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are used as reporter molecules. This enables indirect visualization of the probe after an 
additional step in the process in which there is binding with an antibody coupled to a 
fluorochrome (Ramos-Vara, 2005).  
 
Fig. 3 shows a diagrammatic presentation of the principles of the FISH technique 
The principles of fluorescence in situ hybridization; (A) The basic elements are a DNA probe and a 
target sequence. (B) Before hybridization, the DNA probe is labelled indirectly with a hapten (left 
panel) or directly labelled via the incorporation of a fluorophore (right panel). (C) The labelled probe 
and the target DNA are denatured to yield single-stranded DNA. (D) They are then combined, which 
allows the annealing of complementary DNA sequences. (E) If the probe has been labelled 
indirectly, an extra step is required for visualization of the non-fluorescent hapten that uses an 
enzymatic or immunological detection system. Finally, the signals are evaluated detected by 
fluorescence microscopy. Nat Rev Genet 6: 782–792, 2005. 
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8.2.1.2 Types of probes  
One of the most important considerations in FISH analysis is the choice of probe. A 
wide range of probes can be used, from whole genomes to small cloned probes. There are 
broadly three types of probes, each with a different range of applications:  
- Chromosome painting probe (WCP: Whole Chromosome Painting): The probe 
consists of a set of small probes, which cover the whole chromosome. These probes are 
obtained after isolation and labelling of the DNA of an entire chromosome without 
necessarily knowing the sequence of this DNA. They provide intense and specific 
fluorescent staining of entire human chromosomes, allowing the distinctive identification of 
chromosomes involved in complex rearrangements. There are also specific painting probes 
for chromosomal arms or even certain bands. This type of probe is most useful for clarifying 
cytogenetically visible structural or numerical chromosome rearrangements in metaphase 
and to determine precisely the origin of an unidentified fragment. Painting probes are not 
otherwise helpful in the analysis of interphase cells because the signal domains are too large 
and diffuse (Ried et al., 1998). 
 Whole chromosome painting is technically available for every human chromosome. 
Application of all WCP probes together allows the simultaneous painting of the entire 
human genetic complement in 24 colours. This promptly led to the developments of two 
independent FISH techniques, spectral karyotyping (SKY) (Veldman et al., 1997) and 
multicolour FISH (M-FISH) (Azofeifa et al., 2000) that have both been invaluable for 
diagnostic and research applications.  
- Centromeric probes (CEP: Chromosome Enumeration Probe): This approach 
targets the α and β satellite repetitive sequences which are present as thousands of copies 
localized in the centromeric area of human chromosomes. The signal obtained is thus very 
intense making CEPs particularly suitable for the detection of monosomy, trisomy and other 
aneuploidies. In most cases, these sequences are distinct, such that an α -satellite probe 
derived from one chromosome will hybridize only to that chromosome, however pan-
centromeric probes, which target all human centromeres, are also available. 
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Other type of probes which target the repetitive sequences is the pan-telomeric probe 
targeting the tandemly repeated (TTAGGG) sequences present on all human chromosomal 
ends (Kearney, 2001). 
- Locus-specific probes (LSI: locus specific identification), are usually clones of 
small sized and highly specific sequence, make it possible to identify a very precise area of 
the genome. These probes obtained by marking of the DNA cloned in various vectors and 
their size vary depending on the nature of the cloning vector, from plasmids (1–10 kb) to the 
larger PAC, YAC and BAC vectors (80 kb to 1 Mb). Probes of this classification are 
particularly useful for detecting precise structural rearrangements such as specific 
chromosomal translocations, inversions or deletions in both metaphase and interphase. They 
can be used alone or in combination to allow multicolour deciphering of complex 
chromosomal rearrangements.  These unique sequence probes also allow specific 
recognition of chromosomes whose centromeric sequences have a strong homology like the 
one between CEP13 and CEP 21 (Gozzetti and Le Beau, 2000). 
8.2.1.3 Applications and limitation of FISH 
The potential of almost all applications of in situ hybridization is greatly enhanced 
by multicolour detection of simultaneously hybridized probes. This is particularly useful 
when structural chromosome aberrations involving different chromosomal regions are to be 
diagnosed, or when several numerical aberrations should be detected in parallel. A 
particular advantage of FISH techniques is the possibility of also studying chromosomal 
aberrations in non-dividing cells, which is useful for the direct visualization of chromosomal 
aberrations in cytological preparations and tissue sections. However, FISH techniques have 
a major downfall because it can only target pre-suspected genetic aberrations, providing that 
specific probes are available. In other words, a probe for a known genetic aberration has to 
be hybridized to the specimen in order for the FISH technique to indicate the presence or 
absence of that specific genetic aberration alone. Therefore, FISH cannot serve as a 
screening test for all chromosomal rearrangements (Kearney, 2001). 
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Technically, non-specific binding of the probe, or failure of the probe to bind, may 
result in extra signals or missing signals and false results. Furthermore, a lone signal may 
split and appear as two distinct signals, or two separate signals may overlap and appear as 
one. G2 nuclei can also give rise to four signals for each chromosome. The possibility for 
diagnostic error is clear when so few target cells are available for analysis. Because of these 
potential problems, careful quality control has been introduced to avoid false signals. 
Therefore, the quality control must ensure scoring a minimum number of cells (often 50) to 
ensure that aberrant binding becomes inconsequential (Gozzetti and Le Beau, 2000). 
8.2.2. Primed In Situ Labelling (PRINS) Technique 
8.2.2.1 Principal 
The PRINS technique of human chromosomes uses primers for repeated DNA 
sequences from centromeric alpha-satellite motif. The length of the primers ranges from 18 
to 35 nucleotides, which greatly facilitates their accessibility to genomic target sequences. 
Based on the use of chromosome-specific primers, the PRINS reaction combines the high 
sensitivity of the PCR with the cytological localization of DNA sequences as in FISH 
technique (Lebo et al., 1992). The chromosomal identification is performed by in situ 
annealing of specific and unlabeled oligonucleotide primers to complementary sites of target 
sequence on interphase and metaphase spreads. The annealed primers provide initiation sites 
for chain elongation catalysed by Taq DNA polymerase in the presence of free nucleotides, 
of which at least one is labeled with fluorochrome. The in situ visualization of generated 
fragments results from the incorporation of the labeled nucleotides. The complementation 
process between the primer and its centromeric target will be so specific that a simple 
mismatch between the 3’-end of the primer and the genomic sequence will prevent initiation 
of the in situ elongation by the Taq DNA polymerase. Thus it has been possible to define 
specific alpha-satellite primers for some chromosomes indistinguishable by FISH with 
centromeric probes, such as chromosomes 13 and 21, which share 99.7% homology in their 
alpha-satellite DNA sequences (Pellestor et al., 1994).  
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The use of automatic thermocyclers allows for optimization of both annealing and 
extension conditions. An additional improvement was the direct use of fluorochromes in 
sequential PRINS reactions (Hindkjaer et al., 1994). Recently, our group has developed a 
new multicolour PRINS protocol, allowing the performance of ultra-rapid detection on 
several chromosomes by only mixing different fluorochromes during the chain elongation 
reaction (Yan et al., 2001). Each PRINS reaction consists of a unique four minutes step for 
annealing and elongation of each chromosome-specific primer. This new sequential 
procedure simplifies the PRINS technique and provides an easy way to carry out multi-site 
labelling. 
8.2.2.2 Applications 
PRINS has successfully been tested for the assessment of aneuploidy in 
lymphocytes, amniocytes (Pellestor et al., 1995) and pre-implantation embryos (Findlay et 
al., 1998). The use of PRINS has also been reported for analysis of structural aberrations 
such as translocations, marker and ring chromosomes (Hindkjaer et al., 1995). More 
recently, the PRINS protocol has been tested to detect fetal cells from MB (Krabchi et al., 
2006a; Orsetti et al., 1998a; Orsetti et al., 1998b). It is also worth mentioning here that 
PRINS technique can be used in combination with or as an alternative to FISH technique for 
detection of FCs. The PRINS technique allows for detection of FCs and appears to have 
comparable sensitivity and specificity to that of FISH technique at a much lower cost 
(Krabchi et al., 2006b; Krabchi et al., 2006c; Krabchi et al., 2001). 
8.2.3. Polymerase Chain Reaction (PCR) Technique 
PCR consists of an exponential amplification of DNA sequences through repeated 
cycles of DNA replication. Each cycle involves DNA denaturation, primer annealing and 
primer extension. All cells, maternal and fetal, obtained by enrichments or through sorting 
procedures are lysed to release their DNA and analysed by PCR (Durrant et al., 1996; Van 
Wijk et al., 1996). PCR technique was employed to amplify particular sequences of DNA of 
the fetal genome for recognition by a labelled DNA probe. Theoretically, PCR technique 
can diagnose chromosomal abnormalities and even detect polymorphisms of certain genes 
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related to genetic disorders providing a pure population of FCs are available and the genes 
are clearly identified (Saiki et al., 1988). Despite the sorting process, the majority of the 
DNA obtained was maternal in origin because of the many maternal cells that escape 
through the sorting process. This technique, therefore, is mainly useful for the detection of 
fetal DNA sequences not shared with the mother and this seriously limits its clinical 
application for the detection of aneuploidies and maternally inherited mutations. The 
development and the improvement of the sensitivity and the specificity of this technique 
will allow its use in a more reliable way. 
Within the framework of research on FCs, the sequences most frequently used are 
those specific for the Y chromosome when the fetus is male to indicate the presence of some 
cells of fetal origin in the MB. Successful amplification of fetal cell specific DNA 
sequences, such as those found on the Y chromosome was also used to assign fetal gender 
and taken as evidence of successful fetal cell sorting (Durrant et al., 1996; Van Wijk et al., 
1996). They were also used for rough estimation of the frequency of FCs throughout the 
pregnancy (Ariga et al., 2001; Bianchi et al., 1997). Specific sequences of the Rhesus gene 
and HLA of paternal origin were also used. The amplification of rhesus-D DNA sequences 
from rhesus-D negative woman can be taken as a sign that the fetus is rhesus-D positive 
while failure of amplification would indicate a rhesus negative fetus with no threats from 
maternal antibodies (Hahn et al., 2000).  
8.3. Advanced technologies and clinical applications: automatic detection and 
microdissection  
Although QF-PCR and other techniques can be used to test for karyotypic 
abnormalities, a pure population of FCs would be needed. The very low number of FCs after 
enrichment or sorting techniques limits these clinical applications. Prenatal diagnosis of 
most single gene or chromosomal disorders in this way would, however, require a pure 
sample of FCs, otherwise, DNA simultaneously released from maternal cells would 
confound the results (Mansfield, 1993). Fluorescence in situ hybridization circumvents this 
problem because cells are fixed onto a slide and each cell provides its own result. 
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Manual detection of FCs requires laborious examination of the nucleus of each and 
every cell in the final mix to determine if any FCs had been sorted. The use of automated 
image cytometry may help to overcome this problem of low purity and non-specific cell 
identifiers. This technology can acquire data from hundreds of cells in a short period of time 
and has already been applied to amniocentesis samples with great success (Hennerbichler et 
al., 2003; Merchant and Castleman, 2002).  
If a fetal cell can be reliably identified and detected under the microscope, it can 
then be removed and placed in isolation, making a ‘pure’ fetal cell sample. Laser-capture 
microdissection instruments are able to lift individual cells off the slide in this way. It is 
then possible to use the technique of single cell PCR, which has been developed for whole 
genome amplification, to test for karyotypic abnormalities and also for single gene 
mutations. Provided the fetal origin of the cell can be guaranteed, maternally inherited 
mutations and aneuploidies can be tested by simple techniques like QF-PCR. Furthermore, 
it opens the way to genome-wide screening using techniques like comparative genomic 
hybridization (CGH) array. One of the main advantages of CGH is as its use as a discovery 
tool, in that it requires no prior knowledge of the target chromosome imbalance that is 
sought. Such techniques require significant time and skills; however, the effort may be 
justified for the sake of NIPD especially for precious pregnancies where the risks of genetic 
diseases are high such as those occur after in-vitro fertilization. This technique is 
particularly important in investigating cases with strong family history of hereditary genetic 
disorders of unexplained etiology. In such cases, a thorough look throughout the genome 
without prior knowledge of expected chromosomal abnormalities is required. Array CGH in 
postnatal diagnosis allows accurate diagnosis, characterization of syndromes, phenotype and 
genotype correlation, prevention, prognosis and better clinical management. The detection 
rate of array CGH in postnatal diagnosis was estimated between 7-11% in patients with 
intellectual disability or multiple congenital abnormalities despite normal conventional 
karyotype (Pickering et al., 2008; Shaffer et al., 2008; Shaffer et al., 2007). 
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9. Objectives of research 
9.1 General Objectives 
Currently, prenatal diagnosis of fetal genetic traits relies on invasive procedures 
associated with increased risk of pregnancy loss. A long sought goal of prenatal diagnosis 
has been the replacement of current invasive procedures by non-invasive methods. Data 
generated in different laboratories led to the conclusion that few intact FCs are present in 
MB (Liou et al., 1994; Simpson and Elias, 1993). NIPD through using FCs would permit 
accurate prenatal diagnosis for aneuploidies and single gene disorders without attendant 
risks associated with invasive procedures. 
Fetal cells could be identified by targeting specific genetic marker exclusive for the 
FCs by immunologic or molecular techniques such as FISH or PRINS. Manual scanning 
was commonly used for retrieval of these rare FCs from MB (Krabchi et al., 2006b; Krabchi 
et al., 2006c; Krabchi et al., 2006a; Feldman et al., 2002; Krabchi et al., 2001; Orsetti et al., 
1998b). Although there is general agreement about the presence of FCs in the MB, their 
routine use in clinical practice is not yet feasible due to their extreme low frequency in the 
maternal circulation. Most workers agree that the presence of FCs in MB is a rare event, 
only one FC per 105-109 of maternal cells, which makes their isolation difficult but not 
impossible (Hamada et al., 1993; Price et al., 1991; Ganshirt-Ahlert et al., 1990). 
In quest for the development of NIPD using FCs, two strategies have emerged; the 
enrichment of rare circulatory FCs from MB and the analysis of fetal DNA from single 
cells.  
Considering their extreme low frequency in MB and relative abundance of 
contaminating maternal cells, various purification and enrichment procedures have been 
proposed over the last two decades (Kitagawa et al., 2002; de Graaf et al., 1999; Wachtel et 
al., 1998; Ganshirt-Ahlert et al., 1992; Wachtel et al., 1991). Efforts were made to improve 
the development and evaluation of enrichment protocols. Despite all these efforts, a simple 
and efficient procedure is not yet available in clinical practice for routine testing using FCs.  
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Array-based comparative genomic hybridization has been proposed as a genome-
wide assessment after whole genome amplification from single cells. However, traditionally 
comparative genomic hybridization requires DNA from large number of cells in addition to 
the high cost and complicated equipment (Fiegler et al., 2007; Hu et al., 2007).  
In summary, through the last several decades, considerable effort has been done but 
no conclusive progress has been made in the field of FCs. Many controversies persist about 
the type and frequency of target cells as well as the best recovery time and enrichment 
protocol. A thorough assessment of the available protocols and innovative technologies are 
required before implementation of using these rare FCs in NIPD. Therefore, we assigned 
and committed ourselves in this work to the following general objective:  
 
“Development and assessment of strategies for non-invasive prenatal diagnosis using 
fetal cells in maternal blood” 
9.2. Specific objectives 
The specific objectives of my thesis projects were carried out in terms and appear in 
the various chapters of this thesis. 
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9.2.1. Chapter 1: Development of a protocol that allows accurate evaluation of 
detection of rare cellular events through controlled spreading of a pre-determined 
number of target cells on slides within different cellular populations and using this 
strategy in measuring of the efficacy of manual scanning used in retrieval of fetal cells 
from maternal peripheral blood. 
The number of FCs in MB is very low compared to that of maternal cells. Therefore, 
an accurate identification of circulating FCs is essential for their reliable use in prenatal 
diagnosis. Many groups identified FCs by molecular and cytogenetic techniques and used 
manual scanning for retrieval of FCs from MB (Krabchi et al., 2006b; Krabchi et al., 2006c; 
Krabchi et al., 2006a; Krabchi et al., 2001; Orsetti et al., 1998b; Hamada et al., 1993). 
Although these studies yielded important information concerning the number of circulating 
FCs in MB, the results were possibly skewed by the fact that the methodology of detection 
of these rare cellular events by manual scanning has never been evaluated. Assessing the 
efficacy of detection of extremely rare cellular events, although required for different 
applications, remained problematic. Artificial sample mixtures (spiked samples) could be 
acceptable up to certain limits but were not suitable for extreme rare events like FCs 
(Ntouroupi et al., 2008; Johnson et al., 2007). An accurate establishment of the frequency of 
FCs in the MB remains a prerequisite to determine the feasibility of using FCs in NIPD and 
is critical before optimizing any enrichment procedures. Therefore, we assigned the 
following objectives for this study: 
1.  Development of a procedure of sequential spreading of two different groups of 
cells and allowing identification of shape and coordinates of the rare target (true 
positive) cells on the slides by Giemsa staining after the initial spread.  
2.   Using the previously mentioned strategy to spread a determined number of XY 
cells ranging from 0-10 cells in pre-defined areas on slides among a pure 
population of XX cells to evaluate the efficacy of detection of rare XY cells. 
3. Optimization of FISH protocol for the detection of rare cellular events. 
4. Measuring the efficacy of manual scanning for the detection of rare cellular 
events. 
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9.2.2. Chapter 2: Development of a robust custom-made detection algorithm for the 
detection of rare cellular events using an automated platform and validation of its 
efficacy on slides with a pre-defined number of rare events. We compared manual with 
automatic scanning as well as FISH with PRINS techniques. We have also tested this 
classifier for detection of fetal cells in maternal blood samples from normal and 
aneuploid pregnancies.  
Detection of rare cellular events is required for different applications in cancer and 
NIPD (Maheswaran and Haber, 2010; Wei et al., 2007; Thornhill and Snow, 2002). When 
target cells are present in very low frequency, manual scanning is very cumbersome, time-
consuming and unsuitable for clinical applications (Krabchi et al., 2006b; Krabchi et al., 
2001). Innovative technologies have been invented to allow detection of cellular events. 
Although they proved efficient for routine clinical tasks, their validation for rare cellular 
events remained questionable. Therefore, we used the aforementioned strategy for the 
optimization of automatic scanning using MetaSystems automated platform. We developed 
a robust custom-made detection algorithm and validated its efficacy on the retrieval of rare 
XY cells among a nearly pure population of XX cells. Slides were scanned for presence of 
predefined XY cells after FISH and PRINS techniques. After optimization of the classifier, 
it has been used for retrieval of FCs from MB of normal and aneuploid pregnancies. We 
assigned the following objectives for this study: 
1.  Development of a robust custom-made algorithm for the detection of rare 
cellular events using an automated platform. 
2. Optimization of FISH and PRINS protocols and evaluation of their efficiencies 
for detection of rare cellular events. 
3. Comparison between the efficacy of FISH and PRINS techniques for the 
detection of rare cellular events. 
4. Comparison between the efficacy of manual and automatic scanning for the 
detection of rare cellular events. 
5. Evaluation of the frequency of FCs in both normal and aneuploid pregnancies. 
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9.2.3. Chapter 3: Evaluation of the impact of enrichment of fetal cells from maternal 
blood by density gradient centrifugation which is used as an initial step of FC 
enrichment in the vast majority of enrichment protocols published to date and the 
development of an alternative version of the procedure that reduces fetal cell loss. 
Over the past two decades, investigators have devised and pursued different 
strategies that depend on the combination of two or more successive steps of enrichments to 
provide efficient isolation of FCs from MB (Zhao et al., 2002; de Graaf et al., 1999; 
Simpson and Elias, 1995). The physical separation by density gradient centrifugation is by 
far the most common initial step of enrichment protocols published to date (Al-Mufti et al., 
2003; Kitagawa et al., 2002; Vona et al., 2002; Rodriguez de Alba et al., 2001). Many 
protocols were designed but no single approach was efficient enough to provide NIPD using 
FCs. Procedures and methods were difficult to compare due to non-uniformity of protocols 
among different groups and a comparative analysis has been limited by the fact that the 
samples were being processed across the entire protocol rather than determining the efficacy 
and impact of each single step. Recovery of FCs is jeopardized by their loss during the 
process of enrichment. It would have been more appropriate to evaluate each step to devise 
the most efficient protocol for enrichment of FCs from MB. Therefore, we assigned the 
following objectives for this study: 
1.  The main task of this study was to evaluate the impact of the density gradient 
centrifugation step on fetal cell loss during enrichment. 
2. We analyzed the FC frequency before and after enrichment by density gradient 
centrifugation in samples of MB from both normal and aneuploid pregnancy. 
3. We also optimized an alternative version of the procedure that reduce fetal cell 
loss to be used in subsequent studies. 
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9.2.4. Chapter 4: The purpose of this study was to assess the feasibility of using a few 
fetal cells to determine the fetal sex and major chromosomal abnormalities by 
quantitative fluorescence-polymerase chain reaction (QF-PCR) as a proof of concept 
of the feasibility of using fetal cells in non-invasive prenatal diagnosis. 
The detection and molecular characterization of rare cellular events was first 
proposed more than one century ago, but has only been recently realized and used in 
different applications. It is now clear that these cells can provide novel approaches for 
cancer management, pre-implantation genetic and non-invasive prenatal diagnosis 
(Maheswaran and Haber, 2010; Wei et al., 2007; Thornhill and Snow, 2002). Scarcity of 
DNA in rare cells, such as FCs in MB, is a major limiting factor for their routine use in 
clinical diagnosis. Array-CGH has been proposed as a genome-wide assessment and was 
successfully used for the detection of chromosomal abnormalities from single cells 
following whole genome amplification. However, the current protocol is costly, time-
consuming and does not seem to fit into clinical schedule (Fiegler et al., 2007; Hu et al., 
2007). Looking for an alternative approach that is clinically practical and has the potential to 
detect chromosomal abnormalities and single gene disorders, this study focuses on 
evaluating the fidelity of DNA from few cellular events in terms of detection of fetal sex 
and major chromosomal aneuploidies using rapid and cost-effective multiplex QF-PCR. 
Therefore, we outlined the following specific objectives: 
1.  Optimization of the protocol of whole genome amplification from a few 
microdissected FCs and evaluation of their efficacy to determine fetal sex and 
major chromosomal abnormalities by quantitative fluorescence-polymerase 
chain reaction. 
2. Determination of the required number of FCs that can be quite enough to 
provide accurate and reliable non-invasive prenatal diagnosis.  
This application must demonstrate that the detection and utilization of as few as 5 FCs can 
be quite enough to provide accurate and reliable non-invasive prenatal diagnosis.  
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RESULTS 
Chapter I:  
Development of protocol that allows accurate evaluation of extreme rare 
cellular events detection within different populations of cells on slides and using 
this strategy in measuring of the efficiency of manual scanning used in retrieval 
of fetal cells from maternal peripheral blood. 
Article 1: 
Efficiency of manual scanning in recovering rare cellular events 
identified by fluorescence in situ hybridization (FISH): simulation of 
the detection of fetal cells in maternal blood. 
Ahmed EMAD1, Seemi AYUB1, Oumar SAMASSEKOU1, Marie-Chantal GRÉGOIRE1, 
Macoura GADJI1, Aimé NTWARI1, Josée LAMOUREUX1, Francis HEMMINGS1, 
Triantafyllos TAFAS2, Michael W. KILPATRICK2, Kada KRABCHI1, Régen DROUIN1. 
1: Division of Genetics, Department of Paediatrics, Faculty of Medicine and Health 
Sciences, Université de Sherbrooke, Sherbrooke, QC, Canada 
2:  Ikonisys, 5 Science Park, Suite 1000, New Haven, Connecticut, 06511 USA. 
 
This article has been published in the J Biomed Biotechnol. 2012; 2012:610856 (Emad et 
al., 2012). 
 
My contribution in work: 
I made the experimental design and developed sequential spreading approach, carried out 
70% of the experiments, and wrote the first full version of the article. 
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Résumé 
L’hybridation in situ observée en fluorescence (FISH) et le balayage manuel en 
microscopie font partie d’une stratégie couramment utilisée dans la détection de cellules 
rares comme les cellules fœtales circulant dans le sang maternel. Afin de déterminer 
l’efficacité de ces techniques, des lames ont été préparées avec un nombre connu (0-10) de 
cellules XY dans une population de cellules XX. Après l’hybridation FISH, les lames ont 
été balayées par différents observateurs à l’aveugle pour la détection des cellules XY. 
L’efficacité moyenne de détection était de 84% (125/148). L’évaluation de la qualité 
d’hybridation de la sonde en ce qui concerne les évènements non détectées a montré que 9% 
(2/23) des évènements n’ont pas été hybridés, 17% (4/23) sont mal hybridés tandis que 
l’hybridation n’était pas en cause pour les autres évènements manqués (74%; 17/23). En 
conclusion, le balayage manuel est une méthode relativement efficace dans la détection 
d’évènements cellulaires rares mais environ 16% des évènements ont été ratés. Ainsi, le 
nombre de cellules fœtales par unité de volume de sang maternel a probablement été sous-
estimé par l’utilisation du balayage manuel. 
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Abstract 
Fluorescence in situ hybridization (FISH) and manual scanning is a widely used 
strategy for retrieving rare cellular events such as fetal cells in maternal blood. In order to 
determine the efficiency of these techniques in detection of rare cells, slides of XX cells 
with predefined numbers (1-10) of XY cells were prepared. Following FISH hybridization, 
the slides were scanned blindly for the presence of XY cells by different observers. The 
average detection efficiency was 84% (125/148). Evaluation of probe hybridization in the 
missed events showed that 9% (2/23) were not hybridized, 17% (4/23) were poorly 
hybridized, while the hybridization was adequate for the remaining 74% (17/23). In 
conclusion, manual scanning is a relatively efficient method to recover rare cellular events, 
but about 16% of the events are missed, therefore, the number of fetal cells per unit volume 
of maternal blood has probably been underestimated when using manual scanning. 
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1. Introduction 
Detection of rare cellular events has enormous potential in both cancer [1-3] and 
prenatal diagnosis [4-7]. The presence of fetal cells in maternal circulation generates a great 
amount of interest as a source of genetic material for non-invasive and risk-free diagnosis of 
aneuploidies and single gene disorders [8]. Instead of cell-free fetal DNA (cffDNA) in 
maternal plasma, fetal cells in the maternal blood can be an alternative approach for the 
development of a non-invasive method for prenatal diagnosis that accurately detects 
chromosome anomalies for two major reasons: 1) to work with pure fetal DNA material, 
which will allow specific characterization of fetal genome, and 2) to have the whole genome 
of the fetus and not just part of it.  
The number of fetal cells is extremely low in maternal blood [9,10], therefore, 
enrichment, accurate identification and optimal timing of recovery are essential for their 
reliable use in prenatal diagnosis [11-15]. Fetal cells could be identified by targeting 
specific genetic marker exclusive for the fetal cells by molecular cytogenetic techniques 
such as fluorescence in situ hybridization (FISH) and primed in situ labelling (PRINS). 
Manual scanning is a commonly used strategy for retrieving these rare fetal cells from 
maternal blood.  
Recent studies have indicated that fetal cells can be detected directly from the 
maternal blood without prior enrichment, to avoid losing fragile fetal cells, using techniques 
such as FISH and PRINS. Low frequency predictions were given by these studies that 
recognized fetal cells only by the presence of a Y chromosome signal in male pregnancy 
[4,5,9,16]. Although these studies yielded important information concerning the number of 
circulating fetal cells in maternal blood, the results are possibly skewed by the detection 
efficiency of these rare events by cumbersome and time consuming manual scanning. 
Therefore, automation will be required for widespread clinical use of fetal cells in prenatal 
diagnosis. Precision of manual scanning is crucial to validate adequately any automatic 
scanning device. However, the accuracy and reliability of locating these rare cells by 
manual scanning has never been evaluated.  
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The purpose of this study was to develop a robust protocol to assess the detection 
efficiency of rare events such as fetal cells in the maternal blood. We developed a strategy 
to spread a known number of XY cells in pre-defined areas on the slide and to detect these 
XY cells amongst thousands of XX cells. This strategy allows for evaluation of the 
detection efficiency of the manual scanning by knowing the exact number of XY cells and 
their exact location on the slides. In addition, the efficiency of the FISH technique in 
recovering rare cells can be evaluated by verification of the missed events and evaluation of 
the hybridization signals after scanning. Furthermore, this strategy has various potential 
applications as it could be used in the validation of automatic scanning and comparisons 
between different detection techniques. 
2. Materials and Methods 
2.1. Sampling 
Three millilitres (3mL) of heparinised peripheral blood were obtained from both 
male and female donors and rendered anonymous. Donors were healthy, non-pregnant 
adults between 20 and 35 years of age. Immediately after sampling, whole blood samples 
were dispensed into 250µL aliquots, washed with Hank's balanced salt solution, and 
harvested by standard cytogenetic techniques. For both XX and XY cells, small aliquots of 
fixed cell suspensions were prepared and stored at −20°C until needed. 
2.2. Spreading and Counting 
Spreading of 2µL of diluted fixed XY nucleus suspension at one, two, or three 
predefined spots onto cleaned slides was performed in a modified Thermotron 
environmental control unit (CDS-5, Thermotron, Amsterdam, Netherlands) at 25°C and 
36% humidity. All slides were encoded and stained with 4% Giemsa solution (Harleco; 
EMB, Gibbstown, NJ) containing 4% of Sorensen's phosphate buffer [17]. 
Two different observers scored the number of XY cells on each slide, blindly. Slides 
with more than 11 cells or with no concordance of cell counts between observers were 
excluded. Each Giemsa-stained target cell was located, imaged using the 100x objective on 
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an Olympus BX-61 microscope and coordinates were registered. The selected slides were 
then subjected to secondary spreading with XX nuclei suspension of 1.5 × 105 nuclei on top 
of XY spreading areas. In addition, 100% XX and XY cell slides were spread as controls. A 
total of 148 XY cells were distributed on 60 slides. For statistical analysis, the slides were 
divided in two categories: 30 slides with a range of 2 to 11 XY cells on each slide and 30 
slides with either 0 or 1 XY cell per slide. 
2.3. FISH Procedure 
Slides were first aged overnight at 37°C, then, immersed in 2xSSC at 37°C for 30 
minutes. Slides were dehydrated through a series of ethanol baths (70%, 80%, 100%). 
Conventional dual-color FISH was performed, using probes specific for chromosomes X 
and Y (CEP X: spectrum orange alpha-satellite and CEP Y: spectrum green satellite-III; 
Vysis/ABBOTT Diagnostics, Downers Grove, IL) diluted 1:100 and 1:300, respectively, in 
cDenHyb-1 (Insitus Biotechnologies, Albuquerque, NM). The slides and the probes were 
co-denatured at 75°C for 5 minutes before being sealed with rubber cement and placed in a 
humid chamber for hybridization at 37°C for 16 hours. Coverslips were then carefully 
removed and the slides were washed with a solution of 0.4xSSC/0.3% NP-40 at 72°C for 2 
minutes. A second wash was performed in a solution of 2xSSC/0.1% NP-40 at room 
temperature for 3 minutes. After a final wash with distilled water, the slides were mounted 
in DAPI II (0.1M Tris pH 8.0, 90% glycerol, 1mg/mL p-phenylenediamine, 0.01% 4,6-
diamidino-2-phenylindole). 
2.4. Microscopic Observation 
Microscopy equipped with appropriate filter sets. Fluorescence nucleus pictures 
were taken using a CCD camera and ISIS-2 software (Metasystems, Altlussheim, 
Germany). All slides were analyzed using the appropriate single band pass filter. Primary 
search was performed for Y-signal using spectrum green band filter (FITC). Suspected 
events were subsequently verified for the presence of single X chromosome-specific signal 
on a DAPI-stained nucleus under the appropriate spectrum red (TRITC) and blue (DAPI) 
filters. The number of detected XY cells per slide, cellular location, and imaging were 
57 
 
  
recorded, along with time required for the scoring of each slide Manual scoring was 
performed blindly on an Olympus BX-61 fluorescent microscope. All manual microscopy 
was performed at 1000X magnification. We also scored the hybridization status of the Y 
signals in 5000 cellular events distributed in the 5 control slides of 100% XY cells. The 
slides were stored in dark at −20°C after the scanning process to avoid bleaching of signals. 
In all cases, cells were considered to be positive if the following criteria were met: 
nuclei had two different fluorescent signal colours representing both the X and Y 
chromosomes, an intact nuclear border as indicated by DAPI staining, and presence of 
fluorescent signals only through appropriate filters. Cells in direct contact with each other 
were excluded. The hybridization signals were usually bigger and brighter than the 
background signals such as debris, fluorescent materials, or air bubbles that are not blocked 
by the filter. Most of these background signals could be excluded by bleed through signals 
that is, signals which appears in all filters. 
2.5. Rehybridization Procedure (Re-FISH) 
A reverse color FISH was done for all recovered cells to confirm the identity of the 
cells. Evaluation of its reliability in confirming positive events was also recorded. For the 
re-FISH procedure, coverslips were removed by dipping the slides in a prewarmed 2xSSC 
bath, at 37°C for 10 minutes. The existing FISH probes were then removed by denaturing 
the slides with 70% formamide/2xSSC at 73°C for 2 minutes 30 seconds. Slides were then 
dehydrated in successive ice-cold ethanol baths (70%, 80%, 100%) and air-dried. Finally, 
slides were processed through a second round of FISH procedure using the opposite 
fluorochrome labelling (X probe in green and Y probe in orange) to produce the reverse 
color FISH pattern. 
2.6. Analysis of Cellular Scanning 
The slides were scanned blindly (without knowing the number of XY cells or their 
location on the slide) by one investigator, then the analysis was performed within 48 hours 
after scanning by another investigator. Following the scanning, the location (coordinates) 
and the shape of captured events were compared with that of the previously recorded 
58 
 
  
Giemsa-stained photos. Depending on the results of the scanning, three different 
possibilities were observed (Section 3). 
2.7. Statistical Methods 
The statistical analysis was performed using “proc reg” and “proc mixed” 
procedures of the Statistical Analysis System (SAS) software, version 9.1.3 (SAS Institute 
Inc., Cary, NC). Spearman's correlation was used to assess the process of the manual 
scanning and regression analysis curve was plotted to demonstrate the detection efficiency 
of the target events. Kruskal-Wallis test was done for the analysis of variance of status 
versus different observers. The odds ratio was calculated for determining the effect of 
hybridization on the detection efficiency. Index of Youden was used for assessment of the 
methodology. 
3. Results 
As our manual scanning approach was based on the finding of the Y signal first, we 
first tested the hybridization efficiency of the Y chromosome centromere probe. We found 
that the hybridization efficiency of the Y probe in 5,000 pure XY cells, processed by 
conventional FISH, was 99.1% (4,955/5,000). The hybridization was adequate in 97.3% 
(4,865/5,000) of cells whereas the remaining 1.8% (90/5,000) showed poor hybridization 
signals.  
Next, we evaluated the retrieval of rare cellular events by a manual scanning based 
FISH method, using an approach, which is summarized in Figure 1 and Table 1. All slides 
were screened at 1000X for the Y-signal for primary detection, with subsequent 
confirmation of an X chromosome-specific signal on a DAPI stained nucleus, using the 
appropriate band pass filters. Comparison of the location (coordinates) and the shape of 
captured events with that of the previously recorded Giemsa stained photos resulted in three 
possible results (Figure 1 and Table 1).  
The first one is when a captured fluorescent image matched with a previously taken 
Giemsa photo, in which case the cell was scored as a recovered event (Figure 2). The 
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second possibility is when no corresponding fluorescent image was found for a previously 
recorded Giemsa one, in which case the cell was scored as a missed event. In these 
circumstances, retrieval of the cell, using the coordinates and shape of the recorded Giemsa 
image, and evaluation of its hybridization efficiency were performed. Cells were scored as 
either a missed event or a hybridization failure. In the third scenario, a captured fluorescent 
image had no corresponding Giemsa one. Re-FISH was then used to score the cell as either 
a true positive or false positive.  
Table 1 Interpretation of detected cellular events by manual scanning according to the 
concordance of FISH images with those previously taken with Giemsa. 
 
Comparison of location and shape of captured events with previously recorded Giemsa 
images brought up three possibilities. The first one is when a captured fluorescent image 
matched with a Giemsa photo, in which, the cell is scored as recovered event. The second 
possibility is when no corresponding fluorescent image found for a Giemsa one, in which, 
the cell scored as a missed event. In this case, retrieval of the cell, using the coordinates and 
shape of the Giemsa image, and evaluation of its hybridization efficiency were performed. 
For the third scenario, a captured fluorescent image had no corresponding Giemsa one. The 
re-FISH was used to score the cell as true positive or false positive  
 
 
Interpretation of Cellular event FISH photo Giemsa photo 
Retrieved XY target (true 
positive cell) 
Present Present 
Missed event Absent Present 
Extra-cell detected Present Absent 
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Figure 1 Schematic management of detected (A), missed (B), and extra cells (C).  
FP: false positive, TP: true positive, N/A: not acquired. Panel A: cells scored as detected 
when a captured fluorescent image matched with a previously taken Giemsa photo, in which 
re-FISH is done as confirmatory to evaluate its efficiency. Panel B: cells scored as missed 
when no corresponding fluorescent image was found for a previously recorded Giemsa one, 
in this case, the cell was retrieved and hybridization was evaluated. Panel C: cells scored as 
extra-cells when captured fluorescent image had no corresponding Giemsa one. Re-FISH 
was then used to score the cell as either a true positive or false positive. 
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Figure 2 Example of Giemsa, FISH and re-FISH images of three detected events. 
Figure demonstrates three examples of cells scored as retrieved when a captured fluorescent 
image matched with a previously taken Giemsa photo. FISH showed positive XY cells (Y 
probe in green and X probe in red) and cell identity confirmed by reverse color FISH (Y 
probe in red and X probe in green). 
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Table 2 summarizes the results obtained by manual scanning. Two observers A and 
B blindly scanned 18 and 42 slides, respectively, in order to retrieve 148 XY positive cells 
among around 90 x 105 XX cells, distributed on 60 slides, with an average of 1.5 x 105 XX 
cells per slide. The overall detection rate of the true positives was 84.5% (125 out of the 148 
XY cells). The remaining 23 missed cells were considered false negatives. Individually, 
observers A and B detected 100 out of the 113 XY (88.5%) and 25 out of the 35 XY cells 
(71.4%), respectively (Figure 3A). The variance analysis did show a statistical difference 
between the two observers (p=0.606). Therefore, the combined findings of these two 
observers were used to assess the sensitivity, specificity and efficiency of rare events 
detected by the manual scanning and FISH technique.  
Figure 3 Comparison between detected cells and real number of XY cells. (a) Analysis 
of detection efficiencies of the two observers by comparing detected cells to real 
number of XY cells. 
Bar charts represent the total number of target cells (white bars), detected (grey bars) and 
missed (black bars) cells reported for observer A and observer B. Although the overall 
detection efficiency of manual scanning is acceptable, analysis show marked inter-observer 
variability. 
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Table 2 Results obtained by manual scanning of rare cellular events hybridized by 
FISH technique. 
Slide ID Spread XY cells  Detected cells (TP) Missed cells (FN) 
AMP-9 1 1 0 
AMP-10 4 4 0 
AMP-11 2 0 2 
AMP-12 5 4 1 
AMP-13 5 2 3 
AMP-14 2 2 0 
AMP-18 3 3 0 
AMP-19 0 0 0 
AMP-20 1 1 0 
AMP-21 1 1 0 
AMP-22 3 + 2E* 4 1 
AMP-23 0 0 0 
AMP-24 1 1 0 
AMP-25 1 0 1 
AMP-26 3 1 2 
AMP-27 0 0 0 
AMP-28 1 1 0 
AMP-29 0 0 0 
SMP-10 4 3 1 
SMP-11 11 10 1 
SMP-12 2 2 0 
SMP-13 11 9 2 
SMP-24 5 5 0 
SMP-25 3 3 0 
SMP-26 2 2 0 
SMP-27 3 3 0 
SMP-28 1 1 0 
SMP-29 5 4 1 
SMP-30 6 6 0 
SMP-31 3 3 0 
SMP-32 6 5 1 
SMP-33 7 6 1 
SMP-34 6 5 1 
SMP-35 4 3 1 
SMP-36 2 2 0 
SMP-37 1 1 0 
SMP-38 3 3 0 
SMP-39 2 2 0 
SMP-40 5 5 0 
SMP-41 4 3 1 
SMP-42 0 0 0 
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SMP-43 3 3 0 
SMP-44 1 1 0 
SMP-45 0 0 0 
SMP-46 1 1 0 
SMP-47 0 0 0 
SMP-48 2 2 0 
SMP-49 0 0 0 
SMP-50 1 1 0 
SMP-51 1 + 1E* 2 0 
SMP-52 0 0 0 
SMP-53 0 0 0 
SMP-54 0 0 0 
SMP-55 3 3 0 
SMP-56 0 0 0 
SMP-57 1 1 0 
SMP-58 0 0 0 
SMP-59 1 0 1 
SMP-60 1 0 1 
SMP-61 1 0 1 
 
TP: true positive, FN: false negative, ID: identification code, E*, extra-true positive cells 
confirmed by Re-FISH. Spread XY cells represent the target rare cells on the slides within 
pure population of XX cells. Detected cells represent the true positive events detected by 
manual scanning with FISH technique and missed cells represent the false negative events 
missed by the process of scanning. 
 
We found that the specificity and sensitivity for detection of XY cells were 99.9% 
and 84.5%, respectively, with a positive predictive value of 97%. In the same vein, by using 
the Spearman’s correlation, we found high correlation between the detected cells and the 
number of predefined target cells per slide (C.C= 0.947, P < 0.001). Regression analysis 
was plotted to demonstrate the relation of the detected cells versus the true number of XY 
cells (Figure 3B). Furthermore, a high index of Youden at 0.85 confirmed the efficiency of 
our approach. In summary, the manual scanning is a reliable method to detect rare events 
hybridized using the FISH technique.  
To gain deeper insight into the causes of the occurrence of false negative events, we 
evaluated missed cells after scanning. Of the 23 missed cells, 2 cells (8.7%) were not 
hybridized for the Y chromosome, 4 cells (17.4%) were poorly hybridized and the 
hybridization was adequate in the remaining 17 cells (73.9%). Thus, manual scanning and 
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the related FISH procedure were responsible for the occurrence of 73.9% and 26.1% of the 
false negative events, respectively.  
 
 
Figure 3 Comparison between detected cells and real number of XY cells. (b) 
Regression analyses represent correlation between detected cells by manual  scanning 
and real number of XY cells on the slides. 
Regression analysis plotted to demonstrate relation between numbers of detected cells by 
FISH technique and real numbers of XY cells and Spearman’s correlation showed a high 
correlation coefficient (C.C= 0.947, P < 0.001). 
 
The major cause of false negative cells is the manual scanning and human fatigue. 
The long scanning time, which was estimated to be on average 150 minutes, might be one of 
the reasons for the occurrence of false negatives due to the manual scanning. The second 
cause of false negatives is defective hybridization, which could be attributed to insufficient 
hybridization at the target site or fading of the fluorescent signals (Figure 4). The later is 
highlighted by the higher prolonged automatically adjusted exposure time for the Y probe 
channel (> 0.72 second) in contrast to an average of (<0.32 seconds) for the detected cells. 
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Next, we investigated if the percentage of cells with inadequate hybridization could be due 
to a drawback of the double spreading and Giemsa staining procedure.  
We compared the hybridization efficiency of the Y probe on pure XY cells, without 
double spreading and Giemsa staining (see above), to that obtained from our FISH 
procedure on the pre-spread XY cells and we did not find any statistical significant 
difference of the percentage of non-hybridized (P=0.393) and poorly hybridized (P=0.179) 
cells of both groups. This led us to exclude the possibility of a procedure related effect on 
the hybridization efficiency.  
 
 
Figure 4 Giemsa and corresponding FISH photos of missed events due to inadequate 
hybridization (a) or non-hybridization (b). 
Evaluation of hybridization of 23 missed events show that, 4 out of 148 cells (2.7%) were 
poorly hybridized and 2 cells (1.4%) were not hybridized at all for the Y chromosome and 
the hybridization was adequate in the remaining 17 cells (11.5%). 
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To evaluate extra-cells and exclude false positive events, we performed re-FISH on 
all detected cells, including the predefined XY cells and six additional cells. Evaluation of 
its reliability was measured on the detected predefined XY cells. Re-FISH gave an 
unambiguous reverse color pattern in 90.4% (113/125) of detected XY cells. Detected extra-
cells did not show the expected reversed signal pattern after re-FISH hybridization except 
for three extra-cells (two in slide AMP-22 and one in slide SMP-51) as shown in table 2. 
Interestingly, these three cells were inside the pre-defined area of spreading, very close to 
other positive target cells in the corresponding slides. It appeared that they were missed in 
the original Giemsa stained target-counting step. These three events were included in the 
positive XY spread cells on the slides in the final tabulation for the sake of statistical 
analysis. Therefore, re-FISH is a highly reliable approach, which can help to exclude false 
positive events. 
4. Discussion 
In this study, we develop a robust protocol to validate the detection of rare events by 
a manual scanning and FISH technique. We found that manual scanning and FISH allows 
the detection of 1–10 targeted cells, among a total of 1.5 ×  105 cells, with 99.9% of 
specificity, 84.5% sensitivity, and a positive predictive value of 97%. In addition, we found 
that this method is highly reliable and efficient with high Youden index of 0.85. Moreover, 
we determined the rate of false-negative and false-positive events and the inherent causes of 
their occurrence. 
The experimental design, which involved the assessment of slides containing known 
numbers of predefined rare target cells, allowed, for the first time, the retrieval and 
evaluation of hybridization of false-negative or missed events. Our results indicated that the 
manual scanning process is responsible for 73.9% of false-negative events while the 
remaining 26.1% was due to the FISH technique. 
The fatigue generated by the long time of scanning, on average 150 minutes per 
slide, and the screening of low numbers of small dots among thousands, might be some 
reasons of the occurrence of false negatives. These factors can be overcome by the 
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development and validation of automatic scanning to search for these kinds of rare events. 
The second cause of false-negative events was the FISH technique, responsible for missing 
4% of the target cells and this percentage was not statistically different from the efficiency 
of the Y centromere probe. The diffuse and weak Y signal was mostly responsible for the 
FISH drawback. Diffused signals can be explained by chromatin extension forming 
chromatin fibres, which links two or more condensed domains of chromatin. These fibres 
usually show a very weak signal, which fades faster than a normal one [18]. The nature of 
defective signals resulting from over-decondensed chromatin points to the importance of 
pre-hybridization steps in the FISH technique. However, more effort should be oriented 
toward the reduction of false-negative events due to manual scanning, which can be 
overcome by the development of an automatic scanning system. 
Interestingly, data collected in this study confirmed the reliability and accuracy of 
our previous methodology using manual scanning for the determination of the frequency of 
fetal cells in maternal blood. Using this methodology, we previously located a median of 2 
to 6 fetal cells per milliliter of maternal blood in the second trimester of normal pregnancy 
between 18 and 22 weeks [9]. This number is increased by 3 to 5 times in cases of Down's 
syndrome. Similar increases were also detected in different types of aneuploidies [4,5].  
According to our study, the number of detected fetal cells seemed to be 
underestimated by an average of 16% due to the occurrence of false-negative cells. Thus, 
these missing cells can be likely recovered by a robust automatic scanning, increasing the 
likelihood of the development of non-invasive prenatal diagnosis in future. 
Our findings lay the groundwork for the validation of automatic scanning for the 
detection of fetal cells in maternal peripheral blood. Many innovative technologies have 
been developed to alleviate the burden of scanning large numbers of cells and allow rapid 
and precise detection of rare events using an automated slide-scanning device and image-
analysis software [19,20].  
A robust system allowing detection of one male fetal cell or one trisomic 21 cell 
among 10,000 to 100,000 maternal cells would be extremely useful. Such system would 
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obviate the need or at least significantly reduce the required level of enrichment of fetal 
cells and facilitate screening large number of slides, making prenatal diagnosis more easily 
achievable [18]. Evaluation of the efficiency of these automatic slide-scanning devices is 
mandatory before clinical implementation.  
Different investigators have already tried to validate automatic scanning devices for 
the detection of fluorescent signals of rare cellular events [1,6,21,22]. When detection of 
extremely rare cellular events is required, an accurate evaluation is difficult to obtain. Some 
groups worked on real clinical samples and compared the results of automatic and manual 
scanning [19,21]. However, the accuracy of the manual scanning, which is considered the 
gold standard, in the detection of rare cellular events had never been validated. Other studies 
measured the detection efficiency by using prediluted artificial sample mixtures (spiked 
samples) [1,18,19,21-23]. Dilutions of target cells within a whole cell population are 
reliable within certain limits of dilution.  
Nevertheless, in case of fetal cells, an average of 2 to 6cells/mL have been located 
by manual scanning of 20 to 30 slides with an average of 100,000 cells per slide [9]. In such 
situations, where the target cells represent an extremely low proportion with an average 
required dilution of more than 1:105, the predilution strategy seems imprecise and could be 
considered as an approximation of the real situation. In summary, our protocol can be an 
accurate tool for the comparison of manual and automatic scanning and the development 
and validation of the latter for the detection or rare events such as fetal cells in the maternal 
circulation. 
5. Conclusion 
Our current investigation indicates that a small amount of circulating male fetal cells 
dispersed in thousands of female cells can be detected with high specificity and sensitivity 
using FISH and manual scanning. However, the FISH technique was responsible for 
missing of 4% of cells due to non-hybridization or inadequate signalling while 11.5% were 
missed as a drawback of the process of manual scanning. Even if the accuracy of manual 
scanning for signal counting is good, speed and reliability of manual scanning is dependent 
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on technical expertise. This methodology allowed us to determine the efficiency of detection 
of rare cell events by manual scanning. It establishes a standard for testing new detection 
strategies of rare event such as fetal cells in the maternal circulation using automatic 
scanning. 
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 Chapter II:  
Development of a robust custom-made detection algorithm for detection of rare 
cellular events using an automated platform and validated its efficiency on slides with 
pre-defined numbers of rare events. We compared between manual and automatic 
scanning as well as between FISH and PRINS technique. We also tested this classifier 
for detection of fetal cells from maternal blood samples from normal and abnormal 
pregnancies. 
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Résumé 
OBJECTIF 
La détection d’évènements cellulaires rares est requise pour différentes applications 
dans le diagnostic en oncologie et en diagnostic prénatal non invasif. Quand les cellules 
cibles sont présentes avec une très faible fréquence, comme les cellules fœtales circulant 
dans le sang maternel, le balayage manuel en microscopie (BMan) devient très lourd, en 
temps et en technique, et peu approprié pour des applications cliniques. Comme alternative, 
nous avons optimisé un classificateur spécialement adapté pour la détection automatique des 
évènements cellulaires rares. 
MÉTHODOLOGIE 
En utilisant la plateforme automatisée de microscopie MetaSystems, nous avons 
développé un algorithme de détection et validé son efficacité de détection des cellules XY 
rares parmi une population de cellules XX. Les lames ont été préparées avec un nombre 
connu de cellules XY, hybridées suivant la technique d’hybridation in situ observée en 
fluorescence (FISH) ou en hybridation par synthèse in situ amorcée (PRINS). Le nombre de 
cellules fœtales a été évalué sur des échantillons de sang maternel hybridés par FISH. 
RÉSULTATS 
L’efficacité de détection de la technique FISH était de 88% (117/133) 
comparativement à 78% (53/68) avec la technique PRINS. Le balayage automatique a été 
plus efficace et constant que le balayage manuel même s’il requiert plus de temps pour le 
balayage. Les cellules fœtales ont été détectées dans des échantillons provenant de femmes 
enceintes de fœtus normaux et aneuploïdes. 
CONCLUSION 
Le balayage automatique semble plus efficace que le balayage manuel dans la 
détection des évènements cellulaires rares. Le balayage automatique combiné à la technique 
FISH est plus sensible que lorsque combiné à la technique PRINS. Cette étude valide la 
fiabilité du balayage automatique dans la détection des cellules fœtales hybridées en FISH à 
partir du sang maternel. 
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Abstract: 
OBJECTIVE 
Detection of rare fetal cells (FCs) in the maternal circulation could be used for non-
invasive prenatal diagnosis. Considering that FCs in maternal blood are present in extremely 
low frequency, manual scanning is cumbersome, time-consuming and unsuitable for clinical 
applications. As an alternative, we optimized a custom-made classifier for automatic 
detection of FCs. 
METHOD 
Using MetaSystems’ automated platform, we developed a robust detection algorithm 
and validated its efficiency on retrieval of rare XY cells in a pure population of XX cells. 
Slides were scanned for presence of predefined XY cells after fluorescence in situ 
hybridization (FISH) and primed in situ labeling (PRINS). Retrieval of FCs was also 
performed on samples from maternal blood. 
RESULTS 
The efficiency of detection of rare XY cells was 88% using FISH (117/133) in 
comparison to 78% (53/68) with PRINS. FC frequencies per 1 ml of maternal blood ranged 
from 3 to 6 FCs in normal pregnancies versus 13 to 21 FCs in Down syndrome pregnancies. 
CONCLUSION 
Automatic scanning was more efficient and consistent than manual scanning for 
detection of rare FCs and required considerably less operator time. Automatic scanning 
using FISH is more sensitive than that using PRINS. The study validates automatic scanning 
retrieval of FCs from maternal blood. 
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1. Introduction 
Detection of rare cellular events within a large cell population carries great potential 
for the prospect of cancer management and non-invasive prenatal diagnosis (NIPD).1-4 
Routine prenatal diagnosis currently depends on collecting fetal samples through invasive 
procedures, which are associated with significant risk of pregnancy loss. Prenatal testing is, 
therefore, generally considered when the perceived risk for an abnormal pregnancy 
outweighs the procedure-related risk.5 Development of a non-invasive diagnostic method 
can eliminate this risk and change the risk-benefit ratio, making it more likely for women to 
benefit from prenatal testing. 
The presence of fetal cells (FCs) in maternal blood was first described more than a 
century ago and has since been confirmed by many investigators.6-10 The use of these cells 
as an alternative source of fetal genetic material can provide a non-invasive, risk-free 
opportunity for detection of fetal chromosomal abnormalities. Although there is general 
agreement about the presence of FCs, their routine use is not yet feasible. Most researchers 
agree that the presence of FCs in maternal blood is a rare event with only one FC per 105-
109 of maternal cells.8,10,12 This makes their isolation difficult but not impossible. Manual 
screening was used for the retrieval of FCs from maternal blood after targeting a specific 
genetic marker exclusive to the FCs.4,11,12 Considering their extremely low frequency in 
maternal blood, manual screening was cumbersome, time-consuming and unsuitable for 
clinical applications. Various purification procedures have been tried, but it has been 
difficult to use data obtained by these methods to generalize about absolute numbers of FCs 
in maternal blood. There is, therefore, a pressing need for systematic studies designed to 
evaluate enrichment procedures, time of entry of FCs into maternal blood, and their absolute 
concentrations at different periods of gestation. Our group and others applied a direct 
detection strategy, without prior enrichment to avoid losing fragile FCs during 
purification.4,8,11,13 In this way, we were able to locate a median of four FCs per milliliter of 
maternal blood in euploid pregnancies by manual screening approach.8 The accuracy and 
reliability of manual screening have been validated, but was dependent on operator 
expertise.14 Therefore, automation will be required before widespread application in clinical 
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practice. A robust system allowing detection of rare FCs among thousands of maternal cells 
would be extremely useful. Such a system would remove the need or significantly reduce 
the required level of FC enrichment needed and facilitate screening large number of slides, 
making NIPD more easily achievable.15  
In a previous study, we developed a strategy for spreading a predefined number of 
rare XY cells in a pure population of XX cells on slides and validated the efficiency of 
manual screening.14 In the present study, we developed a robust custom-made detection 
algorithm for detection of rare cellular events using MetaSystems’ automated platform and 
validated its efficiency on 90 slides with a pre-defined number of XY cells detected by 
fluorescence in situ hybridization (FISH) or by primed in situ labeling (PRINS) in 
comparison with manual screening. We have also tested this algorithm for detection of FCs 
from maternal blood samples from euploid and aneuploid pregnancies. 
2. Materials and Methods 
2.1 Sampling 
Heparinized blood samples (20 mL) were obtained from eight healthy donors 
including two men and six non-pregnant women as well as from 12 cases of male 
pregnancies including six cases with normal fetal karyotype and six with trisomy 21 
according to the protocol approved by our institutional research ethical committee after 
informed consent. Maternal blood was collected from women receiving prenatal care at our 
Centre 4 weeks after the amniocentesis and before any medications were given for 
termination of pregnancy. Blood was harvested, and small aliquots of donor XX and XY 
cells were prepared. For maternal blood, 3 mL of maternal blood was harvested and pooled 
in three microtubes (each represented 1 mL of maternal blood) as described in Krabchi et 
al.8 Cells were fixed and stored in Carnoy solution (3:1, methanol:glacial acetic acid) at 
−20°C. 
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2.2 Preparation of slides with defined number of XY cells 
Slides with defined numbers of XY cells, ranging from 0 to 8 cells per slide, were 
prepared from XX and XY cells as previously described.14 Briefly, spreading of diluted 
fixed XY cells at one, two or three spots on each slide was carried out. Slides were encoded 
and stained with Giemsa, and XY cells were located, imaged, and scored. Slides were then 
subjected to subsequent spreading with XX cell suspension on top of XY spots. A total of 
201 XY cells were distributed on 90 slides using sequential spreading technique. Slides with 
100% XX cells were prepared as controls.  
2.3 Spreading of maternal blood samples 
Slides were prepared from one of the stored microtubes in a modified Thermotron 
environmental (CDS-5, Thermotron, Amsterdam, The Netherlands) at 25°C and 36% 
humidity. The number of slides ranged from 16 to 22 with an average of 1.5–2x105 cells per 
slide as previously described.14  
2.4 Molecular detection: FISH and PRINS techniques 
Dual-color FISH was performed using probes specific for chromosomes X and Y 
(CEP X: spectrum orange alpha-satellite; CEP Y: spectrum green satellite-III; 
Vysis/ABBOTT Diagnostics, Downers Grove, IL, USA) diluted in cDenHyb-1 (Insitus 
Biotechnologies, Albuquerque, NM, USA) as described before.14 PRINS labeling reactions 
were performed as previously described.16,17 The sequence of oligonucleotide primers used 
was as follows: Xc: GTTCAGCTCTGTGAGTGAAA18 and YD599: 
TGGGCTGGAATGGAAAGGAATCGAAAC and YD600: 
TCCATTCGATTCCATTTTTTTCGAGAA.19 
2.5 Automated microscopy 
Automatic scoring was performed using Metafer, MetaSystems’ automated imaging 
platform (Altlussheim, Germany). The system consists of a motorized Zeiss Axioplan2 
microscope equipped with an appropriate filter set, a motorized slide stage, and a CCD 
camera. The Metafer software can detect multiple hybridization spots using specific color 
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channels. A binary image was obtained by thresholding the digitized images in a user-
defined channel. Target cell size and shape are identified by the number of pixels to discard 
clusters and debris. The stage and image coordinates of retrieved cells are stored along with 
each cell's morphological features (area, shape, and dot count). The detected cells can be 
automatically relocated using the stored coordinates.  
2.6 Target cells detection 
A simple detection algorithm simulating manual detection of FCs in hematologic 
samples was used. The primary search was performed for Y signals using a spectrum green 
filter at 20x magnification. Suspected events were verified at 40x magnification for the 
presence of an X chromosome signal on a 4,6-diamidino-2-phenylindole (DAPI)-stained 
nucleus. Selected events were automatically imaged and recorded. The gallery was 
manually reviewed to reject obvious false events. Subsequently, the remaining cells were 
assessed under the microscope using the relocation option for final selection of potentially 
positive cells. Cells were considered if all the following criteria were met: (1) nuclei had 
two different fluorescent colored signals representing both X and Y chromosomes, (2) an 
intact nuclear border as indicated by DAPI staining (cells in direct contact were excluded), 
and (3) presence of fluorescent signals only through appropriate filters. Slides with pure XX 
cells and others spiked with a defined number of XY cells served as controls for 
optimization of the classifier. Knowing beforehand the numbers and locations of positive 
cells allowed for better characterization and fine-tuning of selection criteria and required 
magnification for optimum detection. After optimization, slides with defined numbers of 
target cells and maternal blood samples were scored.  
2.7 Rehybridization and analysis of Re-FISH  
A reverse-color FISH using opposite fluorochrome (X probe in green and Y probe in 
red) was carried out for recovered cells to exclude false positive cells. Detailed protocol for 
stripping and rehybridization for re-FISH can be found in Krabchi et al.8 Slides with 
predefined XY cells were decoded, and both coordinates and shapes of captured events were 
compared with previously scored Giemsa-stained cells. Extra-detected cells were relocated 
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and examined for reverse hybridization pattern as previously described.14 For maternal 
samples, all detected cells were relocated and examined for reverse hybridization pattern. 
Each target cell was imaged and compared with its corresponding FISH image for 
identification of true positive cells.  
2.8 Statistical methods  
The statistical analysis was performed using “proc reg” and “proc mixed” 
procedures of the Statistical Analysis System (SAS) software, version 9.1.3 (SAS Institute 
Inc., Cary, NC, USA). Spearman’s correlation was used to assess the process of the 
automatic scanning, and regression analysis curve was plotted to demonstrate detection 
efficiency of target cells. Index of Youden combines both the sensitivity and the specificity 
and is employed to capture the performance of diagnostic tests. It was used for assessment 
of methodology. 
3. Results 
We evaluated automatic retrieval of rare XY cells by interphase spot analysis using 
custom-made detection algorithm (Figure 1). Sixty slides of XX cells spiked with 
predefined numbers and locations of XY cells were hybridized by XY FISH probes and 
scanned blindly using our custom-made classifier. On the 60 slides, there were 133 XY cells 
among 90x105 XX cells distributed with an average of 1.5x105 XX cells per slide. The 
gallery size, number of fields, detected XY cells per slide, cellular locations, and images 
along with the time required for automatic scanning and operator revision were recorded. 
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Figure 1 Schematic presentation of the custom-made detection algorithm used for 
detection of rare XY cells from pure population of XX cells.  
Cells are located first in DAPI channel (blue) to determine the focus plane. Primary search 
is performed for Y-signal using spectrum green filter on 20X. Suspected events are verified 
at 40X for the presence of X chromosome signal on a DAPI-stained nucleus. If X 
chromosome signal (spectrum red) on DAPI stained background is found, picture is taken 
and image is stored. Otherwise, repeat the whole process in the next field and so on. After 
finishing the automatic scanning process the observer revise the gallery to exclude obvious 
false positive events (90%)t then the observer proceed to visual revision under the 
microscope using relocation option to verify the rest of the events (10%). 
 
No significant correlation between scanning time (190–280 min; average of 239) and 
number of fields (1628–2320; average of 1987) has been found. Slide quality and level of 
noise were more important in reducing scanning time and size of generated galleries, which 
varied widely from 43 to 467 images with an average of 166 per slide. Most generated 
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images were false positives that can be easily rejected by reviewing the gallery; the operator 
only needed microscopic verification in less than 10% of the images. Most of background 
signals were excluded by bleed through signals that appeared in all filters.  
The total operator scoring time ranged from 5 to 29 min, with an average of 15 min 
per slide. The slides were then decoded, and selected events were compared with Giemsa 
images. Comparison of locations and shapes brought up three possibilities as we have 
previously discussed14 (Table 1). 
Table 1 Interpretation of detected cellular events by automatic scanning according to 
the concordance of FISH or PRINS images with those previously taken with Giemsa. 
Interpretation of Cellular event FISH photo Giemsa photo 
Retrieved XY target (true 
positive cell) 
Present Present 
Missed event Absent Present 
Extra-cell detected Present Absent 
 
Comparison of location and shape of captured events with previously recorded Giemsa 
images brought up three possibilities. The first one is when a captured fluorescent image 
matched with a Giemsa photo, in which, the cell is scored as recovered event. The second 
possibility is when no corresponding fluorescent image found for a Giemsa one, in which, 
the cell scored as a missed event. In this case, retrieval of the cell, using the coordinates and 
shape of the Giemsa image, and evaluation of its hybridization efficiency were performed. 
For the third scenario, a captured fluorescent image had no corresponding Giemsa one. The 
re-FISH was used to score the cell as true positive or false positive  
 
The detection rate of true positive events was 117 out of 133 XY cells with an 
overall hybridization efficiency of 98.5% (Table 2). The sensitivity and specificity for 
detection of XY cells by FISH were 87.9% and 99.9% respectively, with a positive 
predictive value of 95.1%. Regression analysis showed a close concordance between 
numbers of detected cells and real numbers of XY cells (Figure 2) with a high Spearman’s 
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correlation coefficient (C.C=0.963, p<0.001). The index of Youden of 0.88 confirmed the 
efficiency of automatic detection of rare cellular events hybridized by FISH. 
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Figure 2 Regression analyses represent correlation between detected cells by FISH 
with automatic scanning and real number of XY cells on the slides. 
Regression analysis plotted to demonstrate relation between numbers of detected cells by 
FISH technique and real numbers of XY cells and Spearman’s correlation showed a high 
correlation coefficient (C.C= 0.963, P < 0.001). 
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Table 2 Results obtained by FISH technique. 
Slide ID Spread XY cells Detected cells TP Missed cells FN 
AuSc-F01 2 2 0 
AuSc-F02 3 3 0 
AuSc-F03 1 1 0 
AuSc-F04 8 7 1 
AuSc-F05 5 5 0 
AuSc-F06 1 1 0 
AuSc-F07 2 2 0 
AuSc-F08 1 1 0 
AuSc-F09 3 3 0 
AuSc-F10 3 2 1 
AuSc-F11 4 2 2 
AuSc-F12 4 3 1 
AuSc-F13 5 4 1 
AuSc-F14 6 5 1 
AuSc-F15 7 7 0 
AuSc-F16 1 1 0 
AuSc-F17 2 2 0 
AuSc-F18 1 1 0 
AuSc-F19 3 3 0 
AuSc-F20 4 4 0 
AuSc-F21 1 1 0 
AuSc-F22 3 3 0 
AuSc-F23 1 1 0 
AuSc-F24 2 2 0 
AuSc-F25 2 2 0 
AuSc-F26 3 3 0 
AuSc-F27 2 1 1 
AuSc-F28 0 0 0 
AuSc-F29 4 4 0 
AuSc-F30 0 0 0 
AuSc-F31 2 2 0 
AuSc-F32 0 0 0 
AuSc-F33 2 2 0 
AuSc-F34 1 1 0 
AuSc-F35 0 0 0 
AuSc-F36 5 3 2 
AuSc-F37 3 3 0 
AuSc-F38 1 1 0 
AuSc-F39 0 0 0 
AuSc-F40 1 0 1 
AuSc-F41 0 0 0 
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AuSc-F42 2 2 0 
AuSc-F43 0 0 0 
AuSc-F44 1 1 0 
AuSc-F45 1 1 0 
AuSc-F46 0 0 0 
AuSc-F47 3 2 1 
AuSc-F48 0 0 0 
AuSc-F49 1 1 0 
AuSc-F50 4 3 1 
AuSc-F51 2 2 0 
AuSc-F52 4 3 1 
AuSc-F53 3 3 0 
AuSc-F54 0 0 0 
AuSc-F55 1 1 0 
AuSc-F56 1 1 0 
AuSc-F57 4 4 0 
AuSc-F58 0 0 0 
AuSc-F59 3 2 1 
AuSc-F60 4 3 1 
Sum 133 117 16 
 
TP: true positive, FN: false negative, ID: identification code. Spread XY cells represent the 
target rare cells on the slides within pure population of XX cells. Detected cells represent 
the true positive events detected by automatic scanning with FISH technique and missed 
cells represent the false negative events missed by the process of scanning. 
 
Of the 16 missed events, two cells (1.5%) were not hybridized at all for Y 
chromosome, four cells (3%) were poorly hybridized (Figure 3), and the hybridization was 
adequate in the remaining 10 cells (7.6%). Statistically, this hybridization efficiency was not 
significantly different from the one obtained on pure XY cells after ordinary spreading. Of 
the 10 well-hybridized cells, three cells were detected by the scanning platform but rejected 
during manual revision of the gallery. Thus, automatic scanning was responsible for 43.7% 
of missed events (7/16), whereas the process of manual revision was responsible for 18.7% 
(3/16). FISH and technical procedures were responsible for 37.5% (6/16). Stripping and 
rehybridization were carried out on the slides with extra-detected events to exclude the 
remote possibility of being true positive missed by observer using Giemsa stain during slide 
preparation as previously described.14 All additional detected cells failed to give the reverse 
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hybridization color pattern after rehybridization with opposite probe color (Supplementary 
Table S1). 
 
Figure 3 FISH and corresponding Giemsa images of missed events both due to non-
hybridization (Panel A) or inadequate hybridization (Panel B). 
Evaluation of hybridization of the 16 missed events show that, 4 out of 133 cells (3%) were 
poorly hybridized and 2 cells (1.5%) were not hybridized at all for the Y chromosome and 
the hybridization was adequate in the remaining 10 cells (7.5%). 
  
As an alternative to FISH, 30 slides with an average of 1.5x105 XX cells per slide 
were evaluated by PRINS in order to retrieve 68 XY cells. The detection rate of true 
positive events was 53 out of 68 XY cells with an overall hybridization efficiency of 96.5% 
(Table 3). Although having comparable specificity with FISH, PRINS has a lower 
sensitivity at 77.9%. Spearman’s correlation showed a lower correlation coefficient of 0.882 
between detected cells and real numbers of XY cells on the slides (Figure 4).
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Figure 4 Regression analyses represent correlation between detected cells by PRINS 
with automatic scanning and real number of XY cells on the slides. 
Regression analysis plotted to demonstrate relation between numbers of detected cells by 
PRINS technique and real numbers of XY cells and Spearman’s correlation showed a lower 
correlation coefficient in comparison to FISH   (C.C=0.882, P < 0.001). 
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Table 3 Results obtained by PRINS technique.  
Slide ID Spread XY cells Detected cells TP Missed cells FN 
AuSc-P01 1 1 0 
AuSc-P02 2 2 0 
AuSc-P03 2 1 1 
AuSc-P04 5 4 1 
AuSc-P05 2 1 1 
AuSc-P06 1 1 0 
AuSc-P07 2 2 0 
AuSc-P08 4 2 2 
AuSc-P09 1 1 0 
AuSc-P10 1 1 0 
AuSc-P11 5 4 1 
AuSc-P12 3 3 0 
AuSc-P13 2 2 0 
AuSc-P14 3 2 1 
AuSc-P15 0 0 0 
AuSc-P16 2 2 0 
AuSc-P17 1 0 1 
AuSc-P18 3 3 0 
AuSc-P19 2 1 1 
AuSc-P20 5 4 1 
AuSc-P21 3 3 0 
AuSc-P22 1 1 0 
AuSc-P23 1 1 0 
AuSc-P24 2 2 0 
AuSc-P25 4 3 1 
AuSc-P26 1 1 0 
AuSc-P27 2 1 1 
AuSc-P28 1 0 1 
AuSc-P29 3 3 0 
AuSc-P30 3 1 2 
Sum 68 53 15 
 
TP: true positive, FN: false negative, ID: identification code. Spread XY cells represent the 
target rare cells on the slides within pure population of XX cells. Detected cells represent 
the true positive events detected by automatic scanning with PRINS hybridization and 
missed cells represent the false negative events missed by the process of scanning. 
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After evaluating the classifier on artificial samples, 12 maternal blood samples from 
male pregnancy were processed: six cases with a normal fetal karyotype and six with 
trisomy 21. For normal pregnancies, four cases were sampled at the end of the first trimester 
between 11th and 13th weeks, whereas the other two were taken between the 18th and 20th 
weeks of gestation. All cases of trisomy 21 were sampled between the 16th and 20th weeks, 
and before interruption of pregnancy. The slides were processed by XY-FISH and 
automatically scanned. Generated events were revised, and selected events were evaluated 
by re-FISH to exclude false positive cells. True FCs were confirmed by re-FISH, and extra 
cells that failed to give a reverse signal pattern were excluded (Figure 5). Table 4 
summarizes the results obtained from the analysis of maternal blood using the FISH 
technique. 
Table 4 Results obtained from counting of Fetal cells in maternal blood by FISH. 
Case number  1 2 3 4 5 6 
Fetal karyotype 46,XY (Normal male pregnancy) 
Gestational age (weeks) 11w 12w 11w 13w 20w 19w 
Number of FISH slides 20 18 17 16 19 16 
FCs confirmed (1 ml) 4 3 6 5 4 5 
Ratio of FCs per slide (1 ml)  0.20   0.17   0.35   0.31   0.21   0.31  
Case number  7 8 9 10 11 12 
Fetal karyotype 47,XY, +21 (Down syndrome male pregnancy) 
Gestational age (weeks) 17w 20w 18w 19w 18w 17w 
Number of FISH slides 18 22 17 18 20 18 
FCs confirmed (1 ml) 19 14 13 15 17 21 
Ratio of FCs per slide (1 ml)  1.06   0.64   0.76   0.83   0.85   1.17  
 
Table shows the Gestational age by weeks, Number of prepared FISH slides from one 
milliliter of maternal blood, number of fetal cells detected by automatic scanning and 
average number of fetal cell per slide of twelve cases of male pregnancies, six cases with 
normal fetal karyotype and six with trisomy 21.  
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Figure 5 Assessment of selected events by re-FISH  
Panel A: shows true fetal cells detected by FISH (Y probe in green and X probe in red) and 
confirmed by reverse color FISH (Y probe in red and X probe in green). Panel B: shows 
suspicious cells by FISH that failed to give reverse pattern (false positive). 
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The analysis of the number of FCs showed a significant difference between normal 
and aneuploid pregnancies (p<0.001), although we did not find a difference in the frequency 
of FCs between 1st and 2nd trimesters of normal pregnancies (Figure 6). 
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Figure 6 Comparison of average number of detected fetal cells in the first versus 
second trimester and in normal versus aneuploid pregnancies. 
Analysis of number of fetal cells showed statistically significant difference between normal 
and aneuploid pregnancies (P< 0.001) while no difference was observed in the frequency of 
fetal cells between 1st and 2nd trimester. 
 
4. Discussion 
Researchers have documented the presence of FCs in maternal blood and have 
envisioned their use in NIPD.1,8,20 FCs can be identified by molecular or immunological 
approaches. However, the key-limiting factor is their extremely low frequency in maternal 
blood, which makes manual detection labor-intensive and unsuitable for routine clinical 
application. This creates the need for automated systems that allow for reliable unbiased 
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detection of FCs from maternal blood. Automation will be able to enhance current research 
in NIPD and help in the evaluation of enrichment procedures in terms of both yield and 
purity. 
Flow and imaging cytometry can be used for automatic detection, but only imaging 
cytometry can offer the ability to relocate detected cells using previously determined spatial 
locations on slides. This allows for the re-examination and further micromanipulation of 
such cells.21,22 The automatic detection of fluorescent signals in interphase nuclei was first 
reported in 1997 using one-color FISH.23 Subsequently, fully automated hybridization dot 
analyzers were developed for multi-color FISH specimens in both two and three 
dimensions.24-26 
Although they proved to be efficient for routine clinical diagnostic tasks, their 
validation for rare cellular event detection has remained questionable. Evaluations using 
pre-diluted artificial sample mixtures15,27-31 are reliable within certain limits of dilution. In 
the case of FCs, when target cells represent extremely low proportions, the pre-dilution 
strategy seems imprecise. Other strategies like comparing the efficiency of automatic 
scanning to manual detection28,29 have also been proposed. However, manual screening, 
which is considered as the gold standard, has never been validated for the detection of a rare 
cellular event. Furthermore, the efficiencies of the platforms’ built-in software for rare 
cellular event detection were usually unsatisfactory in terms of scanning time and 
sensitivity.  
Therefore, we have previously developed a strategy for spreading predefined number 
of rare XY cells in a pure population of XX cells on slides and validated the efficiency of 
manual screening.14 Here, we used the same strategy for the evaluation of automatic 
scanning using FISH and PRINS technique. Although Metafer/RC Detection built-in 
classifier can be used for automatic detection of rare cellular events, a semi-automated 
approach using a custom-made detection algorithm has been preferred for scoring FCs. The 
scanning platform was used as a tool to find potential target cells with final assessment 
being performed by experienced operator. An acceptable balance has been achieved 
between the required high sensitivity and the reduction of automatic scanning time. 
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Operator revision compensates for a possible lower specificity associated with this approach 
and highlights the importance of adapting the selection algorithm according to user’s 
purpose and needs. This explains the difference in automatic scanning efficiency among 
various groups.28,32,33  
Automatic scanning with FISH was 10% superior to automatic scanning with PRINS 
in the detection of FCs. The average scanning time was 239 minutes per slide, which is 
shorter than that which has been previously published by the same platform.28 Automatic 
scanning has a better sensitivity (87.9%) than manual detection (84.5%) using FISH. Both 
methods have a high specificity of 99.9% but automatic scanning has a slightly lower 
positive predictive value of 95.1% versus 97% in manual detection. The index of Youden 
was 0.88 in automatic scanning compared with 0.85 in manual detection. Thus, automatic 
scanning is more sensitive than manual detection of rare XY cells using FISH technique. 
Although automatic scanning required a longer scanning time, the operator time was 
significantly reduced when compared to manual detection. Increasing the throughput of 
automatic scanning and using it overnight would potentially overcome this limitation. 
The experimental design allowed for the retrieval and evaluation of missed events. 
Automatic scanning was responsible of 43.7% of missed events, whereas the process of 
manual revision was responsible for 18.7%. The FISH technique was responsible for the 
remaining 37.5%. The most common problem occurring during automatic scanning and 
leading to missing of true positive cells was the inadequacy in maintaining the plane of 
focus throughout the whole defined scanning area on the slide. The problem could arise 
from non-homogeneous mounting of the slides because applying a gentle homogenous 
pressure on the coverslips for 10 minutes or leaving the slides overnight at 4°C helped to 
reduce this problem.  
Defective hybridization, which could be attributed to insufficient hybridization in the 
target site or the fading of the fluorescent signals, was second most common cause for 
missing target cells. This problem was highlighted by the prolonged average exposure time 
for the Y probe color channel in the missed events in contrast to that of detected cells. 
Diffused weak Y signals can be explained by chromatin overextension forming chromatin 
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fibers, which fades faster than usual.15 This points to the importance of pre-hybridization 
steps in FISH preparations. Interestingly, a considerable proportion of cells were missed 
during manual revision of the generated gallery, although they were actually detected by 
automatic scanning. This emphasizes the operator expertise and importance of microscopic 
revision before excluding a suspect event.  
After evaluating our custom-made classifier on artificial samples, it was tested for 
the detection of FCs from 12 maternal blood samples. Automatic scanning retrieved FCs 
from all cases of normal and aneuploid pregnancies. Interestingly, we did not find a 
significant difference in the frequency of FCs between the first and second trimesters of 
normal pregnancies. Most workers found a slight, but significant, increase in fetal nucleated 
red blood cells (NRBCs) between the first and second trimesters,34-36 whereas there was a 
decreasing trend for the mean number of trophoblasts.37 The peak number of trophoblasts 
was found to be between the 9th to 13th weeks of gestation.38 As all first trimester samples 
were obtained between the 11th to 13th weeks, and we used a universal marker that detected 
both NRBCs and trophoblasts, the decreased number of NRBCs could have been 
compensated for by the increased number of trophoblasts. We think that this period at the 
end of the first trimester may present an opportunity for an early NIPD, although this should 
be verified on large series of samples. 
The current results also confirmed the increased frequency of the FCs in aneuploid 
pregnancies when compared with normal pregnancies (p<0.001). It is possible that fetuses 
compromised by genetic disorders have more fetal NRBCs secondary to the chronic 
stimulation of hypoxic bone marrow. Alternatively, a placental defect in an aneuploid 
pregnancy could have resulted in greater FC trafficking. Interestingly, our findings 
correspond with previous results of Krabchi et al., on the frequency of FCs in maternal 
blood using manual screening.8,11 However, the number of FCs seemed to be 
underestimated by at least 16% because of the inherent false negative rate associated with 
manual detection.14  
A robust automatic scanning can greatly increase the likelihood of development of 
NIPD. The combination of sex-independent immunohistochemical labeling of one type of 
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FCs, automation, and microdissection of the FCs would also be extremely valuable to 
overcome the rarity of FCs in maternal blood, because sample purity would not be of utmost 
importance and maternal contamination would not interfere with automatic scanning. 
Furthermore, amplification and analysis of a few recovered FCs using arrays or DNA 
sequencing could provide a genome-wide picture not only for the diagnosis of major fetal 
chromosomal aneuploidies but also for single gene disorders. 
Conclusion 
Our current investigation indicates that small amounts of circulating male FCs 
dispersed in thousands of female cells can be detected with high specificity and sensitivity 
using automatic scanning. Automatic scanning is more sensitive than manual screening in 
the detection of rare cellular events. The detection efficiency of automatic scanning with 
FISH technique was superior to PRINS. Data have confirmed the reliability and accuracy of 
automatic scanning in the detection of FCs in maternal blood. Automatic scanning with an 
interactive result review requires considerably less operator time than manual scanning. In 
this study, the throughput was limited to an average of six slides per day per automatic 
scanner, but current advances in scanning technology have the potential to increase the 
throughput by two to five times. In summary, automatic scanning alleviates the burden of 
scanning large numbers of slides and allows rapid and precise detection of rare cellular 
events.  
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Chapter III:  
Evaluation of the impact of enrichment of fetal cells from maternal blood 
by density gradient centrifugation which was used as an initial step of 
enrichment in the vast majority of enrichment protocols published to date 
and development of an alternative version of the procedure that reduce 
fetal cell loss. 
Article 1: 
Evaluation of the impact of density gradient centrifugation on 
fetal cell loss during enrichment from maternal peripheral blood 
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Résumé 
OBJECTIF 
La séparation par centrifugation sur gradient de densité est habituellement utilisée 
comme une étape initiale des protocoles d’enrichissement pour la purification des cellules 
fœtales provenant du sang maternel. Plusieurs protocoles ont été utilisés mais aucune 
approche n’a été assez efficace pour fournir un diagnostic prénatal non invasif (DPNI). Les 
procédures et méthodes sont difficiles à comparer à cause de la non-uniformité des 
protocoles entre les différents groupes. La récupération des cellules fœtales est mise en péril 
par leur perte durant le processus d’enrichissement. Toutes les pertes de cellules fœtales 
doivent être minimisées à cause de l’effet multiplicatif des processus d’enrichissement à 
plusieurs étapes. L’objectif principal de cette étude était d’évaluer la perte de cellules 
fœtales causée par la centrifugation sur gradient de densité. 
MÉTHODES 
Les cellules fœtales ont été quantifiées dans le sang périphérique de femmes 
enceintes de grossesses normales et aneuploïdes avant et après enrichissement par 
centrifugation sur gradient de densité utilisant l’Histopaque® 1,119 g/ml. 
RÉSULTATS 
La centrifugation sur gradient de densité cause une perte majeure de 60-80% des 
précieuses cellules fœtales, ce qui peut compliquer les étapes subséquentes du processus 
d’enrichissement. La perte de cellules fœtales peut être significativement minimisée par 
l’élimination des manipulations agressives comme la centrifugation. 
CONCLUSION 
Les données obtenues soulèvent des questions concernant le choix d’une étape de 
centrifugation sur gradient de densité dans l’enrichissement des cellules fœtales rares et 
appuient plutôt les versions non-agressives présentées ici ou la priorisation d’autres 
méthodes d’enrichissement. 
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Abstract 
OBJECTIVE 
Physical separation by density gradient centrifugation (DGC) is usually used as an 
initial step of multi-step enrichment protocols for purification of fetal cells (FCs) from 
maternal blood. Many protocols were designed but no single approach was efficient enough 
to provide non-invasive prenatal diagnosis (NIPD). Procedures and methods were difficult 
to compare due to the non-uniformity of protocols among different groups. Recovery of FCs 
is jeopardized by their loss during the process of enrichment. Any loss of FCs must be 
minimized because of the multiplicative effect of each step of the enrichment process. The 
main objective of this study was to evaluate FC loss caused by DGC. 
METHODS 
FCs were quantified in peripheral blood samples obtained from both euploid and 
aneuploid pregnancies before and after enrichment by buoyant DGC using Histopaque 
1.119 g/ml.  
RESULTS 
DGC results in major loss of 60-80% of rare FCs, which may further complicate 
subsequent enrichment procedures. Eliminating aggressive manipulations can significantly 
minimize FC loss. 
CONCLUSION 
Data obtained raise questions about the appropriateness of the DGC step for the 
enrichment of rare FCs and argues for the use of the alternative non-aggressive version of 
the procedure presented here or prioritizing other methods of enrichments. 
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1. Introduction 
A long sought goal of prenatal diagnosis has been the replacement of current 
invasive procedures of fetal sampling by non-invasive methods with virtually no risk to 
mother, fetus and pregnancy. Data generated in different laboratories led to the conclusion 
that fetal material (fetal cells and more recently cell-free fetal DNA) are, undeniably, 
present in maternal blood.1-5 Investigators envisaged that they could provide an alternative 
source of fetal genetic material for non-invasive prenatal diagnosis (NIPD). Although cell-
free fetal DNA was successfully used with expensive technologies like massive parallel and 
deep sequencing to diagnose fetal aneuploidies6-9 and has largely eclipsed the use of purified 
fetal cells (FCs) in NIPD. FCs can potentially provide pure fetal genetic material and their 
use can consequently be easier, affordable and clinically acceptable approach for NIPD. 
 Considering the extreme low frequency of FCs in maternal blood and relative 
abundance of contaminating maternal cells,10-12 various purification and enrichment 
procedures have been employed. By far the simplest was the buoyant density gradient 
centrifugation (DGC), which exploits the differing densities of nucleated FCs likely to be 
present and which separates and enriches a specific FC type from a heterogeneous cell 
population.13 Since FCs, after DGC, were still dispersed between large amounts of maternal 
cells, further enrichment was required. Numerous methods of cell separation have been 
developed and various FC markers have been used in the isolation of FCs from maternal 
blood. Most published studies described the use of fluorescent-activated cell sorting 
(FACS),14,15 magnetic-activated cell sorting (MACS),16,17 selective maternal cell lyses18, 
charge flow separation17 and lectin base method.19 
Over the past two decades, investigators have devised and pursued different 
strategies that depend on combinations of two or more successive steps of enrichments to 
provide efficient isolation of FCs from maternal blood. Although a number of reports 
describe successful enrichment of FCs, a preferred protocol has not been 
established.3,15,18,20,21 All of these multi-step procedures required many manipulations in 
which a considerable number of FCs could be lost. Comparison of these strategies has been 
the subject of several reviews but comparative analysis has been limited by the fact that the 
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samples were being processed across the entire protocol rather than determining the 
efficiency and impact of each single step alone.22-25 The numbers of FCs obtained were also 
too small to reflect the efficiency of an enrichment system and the initial number of target 
cells was never determined. Moreover, the application of enrichment protocols across 
varying gestational ages and the differences of the specificity of FC markers used in both 
enrichment and detection further complicates this analysis. It would have been more 
appropriate to evaluate each step alone to devise the most efficient protocol for the 
enrichment of FCs from maternal blood. 
The main objective of this study is to evaluate FC loss during the process of DGC as 
the most common initial step of enrichment used in the vast majority of designed protocols 
published to date.18-20,26-34 A technical obstacle, which had to be overcome, was how to 
know the exact number of FCs in a specific volume of maternal blood. Establishment of the 
total number of FCs in the maternal blood sample before and after enrichment is critical 
before optimising any procedure. Earlier estimates of the frequency of fetal to maternal cells 
have been based primarily on the DNA analysis of Y chromosome sequences using 
polymerase chain reaction (PCR) in male pregnancies.11,28 These experiments gave a wide 
estimated range but no absolute number had been determined. In our group, Krabchi et al.35-
37 implied a direct detection strategy, without prior enrichment, and have offered conclusive 
data of the absolute number of FCs per milliliter of maternal blood using a cumbersome 
manual scanning approach.  
We recently developed a robust detection algorithm for detection of rare cellular 
events using fluorescence-based automated microscopy and used the sequential spreading 
slide approach in the comparison of manual and automated scanning of 60 slides with pre-
defined number and location of rare male cells in a pure population of female cells using 
fluorescence in situ hybridization (XY-FISH)38,39. We validated the manual approach of 
Krabchi et al.35-37 and further refined its efficiency by automation. Consequently, we tested 
this method for the detection of FCs from the maternal blood of both normal pregnancies 
and Down syndrome aneuploid pregnancies.   
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In this study, we applied this methodology in evaluating the loss of FCs during 
enrichment by DGC and explored its etiology. We also presented a modified method of 
density gradient, which reduces FC loss to be considered in future prospective enrichment 
protocols. 
2. Materials and Methods 
2.1 Sample preparation 
Peripheral maternal blood samples (10 mL) were obtained in sodium-heparinized 
Vacutainers (Becton Dickinson VACUTAINER Systems, Franklin Lakes, NJ, USA) from 
12 pregnant women attending the High-Risk Pregnancy Clinic after obtaining written 
informed consent that had been approved by our institutional ethical research committee. In 
each case, the blood sample was divided into two portions of 1 mL and 5 ml for direct and 
indirect harvest respectively. White blood cells (WBCs) were counted by manual 
hemocytometer.  
2.2 Direct harvest 
For each case, 1 ml whole blood were dispensed into 250 µL aliquots in 4 tubes, 
washed with Hank’s balanced salt solution (HBSS) or phosphate-buffered saline solution 
(PBS), and harvested by standard cytogenetic techniques. The cell suspensions were pooled 
in one microtube (equivalent of 1 mL of maternal blood) as described in Krabchi et al.35-37 
2.3 Indirect harvest after density gradient  
For each case, 5 mL of blood was diluted 1:1 with PBS. Each 5 mL of diluted blood 
was layered over 3 ml of Histopaque 1.119 g/mL (Sigma Chemical Co., St Louis, MO, 
USA). One tube was centrifuged at 400 g for 30 min at room temperature (RT) to eliminate 
non-nucleated erythrocytes and all cells at the gradient interface were recovered. The 
remaining plasma was aspirated, centrifuged and any pellet obtained was added to the 
enriched fraction. The other tube was left undisturbed for 5-6 hours and then the enriched 
fraction at the gradient interface was recovered in exactly the same way. The enriched 
fraction recovered at the gradient interface and the pellet, if any, of each tube was washed as 
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described before and resuspended in 1 mL PBS. Cells were enumerated by hemocytometer, 
and then harvested by standard cytogenetic techniques. Each cell suspension was pooled in 
one microtube (equivalent of 2.5 mL of maternal blood). 
2.4 Spreading of MB 
For each case, three sets of slides were prepared as described before39 from the 
stored microtubes. One represented the direct harvest of 1 mL of maternal blood while the 
other two represented the cell yield obtained after density gradient of 2.5 mL maternal blood 
with and without centrifugation. The number of the slides per set ranged from 16 to 22 with 
an average number of 2.0x105 cell per slide as previously described.38,39 
2.5 FISH procedure 
Slides were first aged overnight at 37°C and, then, immersed in 2xSSC at 37°C for 
30 minutes. Slides were dehydrated through a series of ethanol baths (70%, 80%, 100%). 
Dual-color FISH was performed using probes specific for chromosomes X and Y (CEP X: 
spectrum orange alpha-satellite and CEP Y: spectrum green satellite-III; Vysis/ABBOTT 
Diagnostics, Downers Grove, Illinois, USA) diluted 1:100 and 1:300 respectively in 
cDenHyb-1 (Insitus Biotechnologies, Albuquerque, NM) as previously described.38,39 The 
slides and the probes were co-denatured at 75°C for 5 minutes before being sealed with 
rubber cement and placed in a humid chamber for hybridization at 37°C for 16 hours. 
Coverslips were then carefully removed and the slides were washed with a solution of 
0.4xSSC/0.3% NP-40 at 72°C for 2 minutes. A second wash was performed in a solution of 
2xSSC/0.1% NP-40 at room temperature for 3 minutes. After a final wash with distilled 
water, the slides were mounted in DAPI II (0,1 M Tris pH 8.0, 90% glycerol, 1 mg/mL p-
phenylenediamine, 0,01% 4,6-diamidino-2-phenylindole (DAPI). 
2.6 Automated microscopy and cell detection 
Automated scoring was performed as described before39 using our optimized 
custom-made classifier of MetaCyte software (Metafer3/Metafer4 scanning platform; 
MetaSystems, Altlussheim, Germany).  
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2.7 Re-hybridization and analysis 
A reverse-color FISH (re-FISH) was done for all slides with recovered cells as 
described in Krabchi et al.35-37 to verify the identity of detected cells. Briefly, coverslips 
were removed by dipping the slides in a pre-warmed 2xSSC bath at 37°C for 10 minutes. 
Stripping of FISH probes were performed by denaturing the slides with 70% 
formamide/2xSSC at 73°C for 2 min 30 sec. Slides were then dehydrated in ethanol and air-
dried. Finally, slides were processed through a second round of FISH procedure using the 
opposite fluorochrome labeling (X probe in green and Y probe in red). Slides were loaded 
and detected cells were relocated and examined under the microscope. Each cell is 
compared with its corresponding captured image for identification of true positive cells, 
which show reverse pattern of FISH signals. Target cells were imaged and registered as 
previously described.38,39 
2.8 Statistical analysis 
Multivariate ANNOVA using General Linear Model and Bonferroni correction of 
multiple comparisons using IPM statistical package of social science (IPM SPSS Statistics, 
version 20.0). 
3. Results  
Density gradient centrifugation (DGC) has been invaluable in the isolation of FCs 
from maternal peripheral blood. DGC is performed in order to collect the mononuclear cell 
layer potentially enriched with FCs while removing contaminating granulocytes and mature 
red blood cells, mostly of maternal origin. An understanding of the DGC step is essential for 
refining the procedure and for obtaining significant insight into devising an optimal protocol 
of enrichment that could provide sufficient number of FCs and lead to successful NIPD.  
The original purpose of this work was to evaluate the efficiency of DGC and to 
make a comparison between the different gradients. In preliminary experiments, we found 
that the yield of FCs in the enriched fraction was less than expected relative to the original 
number of FCs. These findings prompted us to evaluate the FCs in the rejected fractions of 
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few samples (samples 1-4 in Table 1). Surprisingly, the cumulative values of the two 
fractions were lower than the original number of FCs by an average of 16.6% (range: 0-
25%).  Therefore, the objective of the study was changed to explore the impact rather than 
the efficiency of DGC on FC loss during enrichment from maternal blood.  
To address this issue, we evaluated twelve cases of pregnancies involving male 
fetuses comprised of six cases with normal fetal karyotype and six with trisomy 21. The 
normal maternal blood samples were obtained from women attending prenatal care while 
the cases of trisomy 21 were taken from those referred for amniocentesis after genetic 
counseling for high-risk pregnancy due to abnormal marker screen or suspicious 
sonographic findings. For the cases of normal pregnancies, four cases were sampled at the 
end of the first trimester between 11th and 13th weeks while the other two were taken 
between 18th and 20th weeks of gestation before any invasive procedures. All of the cases 
of trisomy 21 were sampled between 16th and 20th week before confirmation of fetal 
karyotype by amniocentesis. Samples from the trisomy 21 pregnancies were collected two 
to four weeks after the amniocentesis and before any medications were given for 
termination of pregnancy. All blood samples were processed immediately after collection. 
We quantified FCs of maternal samples by automatic scanning using the Y-
chromosome as universal marker both before and after enrichment by density gradient using 
Histopaque 1.119 g/ml with and without centrifugation. FCs were considered positive if all 
of the following criteria were met: 1) the nuclei had two different fluorescent hybridization 
signals, through appropriate filters, representing X and Y chromosomes, 2) the nuclei had an 
intact nuclear border as indicated by DAPI staining (cells in direct contact were excluded), 
and 3) the recovered nuclei gave a reverse pattern of fluorescent signals by Re-FISH (Figure 
1).  
We also counted the total number of cells (TCs) by hemocytometer before and after 
enrichment by both methods. Table 1 displays all results obtained from six normal 
pregnancies in the 1st and 2nd trimester while Table 2 displays results of six aneuploid 
pregnancies with trisomy 21. All results were normalized to 10 mL maternal blood aliquots 
to permit comparative analysis.  
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Figure 1 – Fetal cells detected by FISH (images A, C and E) and confirmed by reverse 
color FISH (images B, D and F) respectively. 
Fetal cell detection was performed by FISH technique (Y probe in green and X probe in red) 
on DAPI stained nuclei with intact nuclear border as shown in images (A, C and E) and 
confirmed by reverse color FISH (Y probe in red and X probe in green) as shown in images 
(B, D and F) respectively. 
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Table 1 Results obtained from normal pregnancy cases (cases 1-6) normalized to 10 ml 
maternal blood.  
              
Case number  1 2 3 4 5 6 
Fetal karyotype 46,XY (Normal male pregnancy) 
Gestational age (weeks) 11w 12w 11w 13w 20w 19w 
Maternal peripheral blood:              
Total cells  (10 ml) x 106  45.4   54.2   67.6   44.8   64.2   72.4  
FCs confirmed (10ml) 40 30 60 50 40 50 
Histopaque 1.119 yield with 
centrifugation at 400 g for 30 min:             
Recovered cells (10 ml) x 106  20.5   28.7   30.0   20.5   28.4   30.9  
Cells Depletion factor 2.21 1.89 2.25 2.19 2.26 2.34 
Cell Loss (%) 54.8% 47.1% 55.6% 54.3% 55.8% 57.3% 
Recovered FCs (10ml) 10 10 20 10 10 20 
FCs depletion factor 4 3 3 5 4 2.5 
FCs Loss (%) 75.0% 66.7% 66.7% 80.0% 75.0% 60.0% 
FCs in rejected fraction (10 ml) 20 20 30 30 N/A N/A 
Histopaque 1.119 yield by gravity 
effect at 1 g for 5-6 hours:             
Recovered cells (10 ml) x 106  21.3   24.9   28.0   24.6   27.1   34.3  
Cells Depletion factor 2.13 2.18 2.41 1.82 2.37 2.11 
Cell Loss (%) 53.1% 54.1% 58.5% 45.1% 57.8% 52.6% 
Recovered FCs (10ml) 20 10 20 20 20 20 
FCs depletion factor 2 3 3 2.5 2 2.5 
FCs Loss (%) 50.0% 66.7% 66.7% 60.0% 50.0% 60.0% 
 
FCs: fetal cells. N/A: not acquired. Table shows the Gestational age by weeks, Total number 
of cells before and after enrichment by density gradient centrifugation with and without 
centrifugation, number of fetal cells recovered by scanning before and after enrichment by 
both methods and calculated fraction (percentage) and depletion factor of total and fetal cell 
loss by both methods in six cases of euploid pregnancies with normal fetal karyotype. All 
results were normalized to 10 ml aliquots of maternal blood to permit analysis 
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Table 2 Results obtained from aneuploid pregnancy cases (cases 7-12) normalized to 
10 ml maternal blood.  
              
Case number  7 8 9 10 11 12 
Fetal karyotype 47,XY, +21 (Down syndrome male pregnancy) 
Gestational age (weeks) 17w 20w 18w 19w 18w 17w 
Maternal peripheral blood:             
Total cells  (10 ml) x 106  53.8   75.4   62.4   48.6   80.2   42.6  
FCs confirmed (10ml) 190 140 130 150 170 210 
Histopaque 1.119 yield with 
centrifugation 400 g for 30 min:             
Recovered cells (10 ml) x 106  28.8   34.7   27.4   19.1   35.5   21.8  
Cells Depletion factor 1.87 2.17 2.28 2.55 2.26 1.95 
Cell Loss (%) 46.5% 53.9% 56.1% 60.8% 55.8% 48.7% 
Recovered FCs (10ml) 40 30 50 30 40 60 
FCs depletion factor  4.8   4.7   2.6   5.0   4.3   3.5  
FCs Loss (%) 78.9% 78.6% 61.5% 80.0% 76.5% 71.4% 
FCs in rejected fraction (10 ml) N/A N/A N/A N/A N/A N/A 
Histopaque 1.119 yield by gravity 
effect 1 g for 5-6 hours:             
Recovered cells (10 ml) x 106  26.6   32.2   25.9   21.8   31.8   24.5  
Cells Depletion factor 2.02 2.34 2.41 2.23 2.52 1.74 
Cell Loss (%) 50.5% 57.3% 58.5% 55.2% 60.3% 42.5% 
Recovered FCs (10ml) 60 50 60 50 50 90 
FCs depletion factor  3.2   2.8   2.2   3.0   3.4   2.3  
FCs Loss (%) 68.4% 64.3% 53.8% 66.7% 70.6% 57.1% 
 
FCs: fetal cells. N/A: not acquired. Table shows the Gestational age by weeks, Total number 
of cells before and after enrichment by density gradient with and without centrifugation, 
number of fetal cells recovered by scanning before and after enrichment by both methods 
and calculated fraction (percentage) and depletion factor of total and fetal cell loss by both 
methods in six cases of aneuploid pregnancies with trisomy 21. All results were normalized 
to 10 ml aliquots of maternal blood to permit analysis 
 
The recovered cells as well as the calculated fraction and depletion factor of TC and 
FC loss by both methods of density gradient were compared to their original values in the 
maternal blood. The mean number of TCs and FCs were 59.3 ±12.9 x 106 (range: 42.6-80.2) 
and 105 ±66.4 (30-210) in maternal blood samples. The recovered TCs and FCs were 27.2 
±5.5 x 106 (19.1-35.5) and 27.5 ±17.1 (10-60) after DGC at 400 g for 30 min, and 26.9 ±4.1 
x 106 (21.3-34.3) and 39.2 ±24.3 (10-90) after DGC at 1 g for 5-6 h, respectively. The 
number of TCs and FCs were reduced by a factor of 2.2 ±0.20 and 3.9 ±0.9 after DGC at 
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400 g, and 2.19 ±0.24 and 2.7 ±0.5 after DGC at 1 g, respectively. DGC at 400 g results in 
an average loss of 73 ±7% (ranges: 60-80%) of target FCs in comparison to 61 ±7% (50-
70%) using DGC at 1 g. 
The corresponding values of TCs and FCs were also obtained for each subgroup 
separately including 1st and 2nd trimester of normal pregnancies and 2nd trimester for cases 
of trisomy 21. ANOVA test was used in the analysis of multiple variants with Bonferroni 
correction. Both methods have insignificant reduction of TC loss (p=0.875) while extraction 
by DGC at 1 g resulted in a significant reduction of FC loss (p=0.002) with significant 
improvement of enrichment factor (p=0.005) as shown in Figure 2. 
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Figure 2 - Histogram comparing average and standard deviation (SD) of total and fetal 
cell loss. 
Statistical analysis showed significant reduction of FC loss at 1 g in comparison to 400 g 
(P=0.002) without significant difference at the level of TC loss (P=0.875) 
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4. Discussion  
DGC is used as a preliminary step of enrichment of FC from maternal blood in large 
number of papers published to date. The trend to use DGC in FC enrichment started in 1990 
using Histopaque 1.077 g/ml, in a model mixture of adult blood spiked with fetal cord 
blood.13 Three years later the same authors reported 25-fold enrichment with triple gradient. 
In fact, this represented the efficacy of the entire protocol including FACS rather than just 
the first enrichment step alone.15 Since then, many groups have used single, double or triple 
gradient as part of their protocols.19,31,32,34 Few comparative studies have been done. 
Although non-uniformity of the published protocols, there was general agreement that 
increased density resulted in improved FC recovery. It also resulted in an increased maternal 
cell contamination and subsequent sorting time.40-42  
The experiments performed during this study were not designed to determine the 
efficiency but rather to evaluate the impact of enrichment by DGC on FC loss. The very low 
number of FCs in maternal blood does indeed demand the greatest accuracy and rigorous 
attention to details. It might be worth pointing out that considerable amount of cell loss 
during an enrichment step might not be relevant when the cells of interest are abundant and 
a single enrichment method is used, but is quite dramatic when the target cells are present in 
minimal amounts and multi-step enrichment procedures are required.   
To address this issue, a proper understanding of the DGC procedure is required. 
When a heterogeneous cell population is centrifuged in a density gradient whose density at 
the bottom is greater than the density of the different cells present in the sample, the cells 
will float to a position in the gradient where the density of the solution is identical to that of 
the cells.43 The density and volume distribution profiles of different variety of peripheral 
blood and bone marrow cells are available in the literature but there is still controversy 
regarding that of FCs, presumably because of their extreme low frequency in maternal 
blood, which has prevented reliable density curves from being drawn.44 Therefore, the study 
of FCs densities has been guided by the aforementioned in-vitro model and by using adult 
blood mixed with cord blood to overcome this limitation.13  
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Most workers focus on nucleated red blood cells (NRBCs) and to a lesser extent on 
the trophoblasts as best candidates to be used in NIPD. The optimum gradient, which 
minimizes target cell loss but also limits contamination by maternal cells, is unclear 
although a general agreement was reached that the yield of FCs after DGC tends to be 
directly related to the used density but on the expense of the purity of the final sample.40-42  
The NRBCs probably have bimodal distribution in both the light and the heavy 
portion of the gradient.43 Furthermore, NRBCs are in a state of dynamic change and cells 
progressively become smaller with a lower cytoplasmic to nuclear ratio with maturation.45 
This variability causes them to sediment over a wide density range with more than 80% 
overlapping with maternal cells at a given density. Most NRBCs settled between 1.077 and 
1.110 g/mL,16,20 whereas the trophoblasts were found to settle mainly between 1.051 and 
1.064 g/mL.46,47 Narrowing the ‘density window’ was found to reduce the final yield but 
increase the cell purity.  
Since almost all nucleated cells present in human peripheral blood and bone marrow 
are lighter than 1.090 g/ml,44 the use of a very high density cut off, such as 1.119 g/ml, 
should allow the recovery of all FCs present in maternal blood, but without any 
enrichment.48 This is because all nucleated cells are equally retrieved.48 This is the rational 
behind using this density gradient for the design of experiments performed during this 
investigation to determine the impact of DGC on FCs.  
In this study, we provide evidence that the application of DGC for isolation of rare 
FCs from maternal blood is associated with a major loss of 60-80% of target FCs with an 
average of 73% in both normal and aneuploid pregnancies. Theoretically, loss of FCs at this 
high density cut off is usually due to entrapment of FCs between mature red blood cells that 
aggregate at the bottom of the tube when they come in contact with the gradient solution. 
Another possible explanation is that part of the cells could be lost as a consequence of the 
cytotoxicity of the density gradient medium. These latter findings are consistent with those 
of Choolani and his group45 who exclusively studied the buoyant densities of first-trimester 
fetal nucleated erythroblasts enriched from fetal blood samples. They observed that, even 
with the most commonly used gradients for FC enrichment from maternal samples such as 
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Ficoll 1.077 g/mL and 1.119 g/ml, 91.4% and 68.3% of NRBCs settle down, respectively, in 
the erythrocyte pellet at the first-step DGC process. Interestingly, they found also that the 
median recovery of fetal NRBCs from mixtures in maternal blood was superior with Percoll 
1.118 g/mL with 64.1% recovery as compared to 35.3% using Ficoll 1.119 g/mL which is 
probably due to a difference in the density medium cytotoxicity rather than to the gradient 
itself.45 
 We also hypothesized that a considerable number of FCs could be lost by 
aggressive manipulation during the DGC procedure. In order to explore this possibility with 
our samples and because centrifugation is not absolutely necessary so that most cells, given 
enough time, will eventually settle down by gravity at 1 g, we replicated each experiment on 
the same gradient by replacing vigorous centrifugation with 5-6 h of vertical incubation. 
Such a simple modification in the procedure significantly reduced the average FC loss by 
12% so that the final range was between 50-70% and without significant reduction of TC 
yield. We think that the process of DGC preferentially affects rare FCs more than the cells 
of maternal origin. Interestingly, it has been shown that a significant number of FCs undergo 
apoptosis and thus may become fragile and liable to rupture with time.49-51 We believe that 
not only time but also aggressive manipulations affect these rare cells. This could be a major 
drawback of many multi-step enrichment protocols employed in FC purification. It is worth 
pointing out that the low number of cells retrieved using a three-step enrichment protocol 
could be due to the application of an inappropriate step resulting in a major FC loss or due 
to too many steps being involved in the enrichment process. Besides, the enrichment 
procedures are time-consuming which has an additive effect on the loss of the fragile FCs.  
We also tested the hypothesis that the process of DGC preferentially affects the FCs 
of aneuploid pregnancies. We did not find a significant difference of the percentage of FC 
loss either between that of first and second trimester samples of normal pregnancies or 
between normal and aneuploid pregnancies. This argues for the fact that the FC loss is 
merely related to the enrichment procedure rather than to the status of the FCs. Additionally, 
it is possible that the bone marrow is stressed to produce more NRBCs in aneuploidies but 
these cells are physiologically the same as those found in a normal pregnancy.  
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5. Conclusion 
Results obtained in this study have many implications in the context of NIPD. 
Mechanical separation by DGC has received great attention in the purification of FCs from 
maternal blood, despite the fact that this procedure is associated with a significant loss of 
60-80% of rare FCs, which could probably complicate subsequent enrichment procedures. 
Since DGC is usually followed by other methods of enrichments, further loss would be 
expected and, thus, the eventual number of FCs available could be insufficient for genetic 
diagnosis.  
In addition, DGC results in only a slight enrichment of fetal NRBCs due to the broad 
density distribution profile of FCs. Putting all of this together, this raises questions about the 
appropriateness of DGC for the enrichment of rare events. On the other hand, the efficiency 
of the density gradient on FC enrichment could be improved by testing different gradients, 
densities and conditions. Alternatively, the elimination of this step or its replacement by an 
immune-sorting strategy would enhance recovery of rare FCs and cut down the number of 
enrichment steps and, consequently, reduce FC loss.  
Furthermore, automation and micromanipulation would be of great help, as purity in 
that case would not be of utmost importance for clinical applicability and contamination 
with maternal cells would not interfere with automatic scanning. However, such automated 
diagnostic techniques would need to be prospectively evaluated in proper clinical trials 
before being offered as a diagnostic service. 
In the light of results obtained in this study, our initial conception about the 
frequency of the FCs in maternal blood has been changed. We now believe that the real 
number of FCs is probably much higher than what has been published. The manipulations 
used in cytogenetic harvesting of cells are likely more aggressive than that of DGC. 
However, this does not affect the result of this study as the same type of manipulation is 
used to assess the frequency of the FCs before and after their enrichment by DGC. 
 
119 
 
  
ACKNOWLEDGEMENTS 
We are grateful to all the pregnant women for their participation in this study. We 
want to warmly thank Mr. Éric F. Bouchard for his help with the statistical analysis and Dr. 
Harry E. Peery for the English editing.  
120 
 
  
References 
1. Schmorl G. Pathologisch-anatomische Untersurchungen Über Publeraleklampsie. 
Vogel von FCW (ed.), Verlag, Leipzig 1893. 
2. Walknowska J CF, Grumback MM. Practical and theoretical implications of 
foetal/maternal lymphocyte transfer. Lancet 1969;1:1119–22. 
3. Simpson JL, Lewis DE, Bischoff FZ, et al. Isolating fetal nucleated red blood cells 
from maternal blood: the Baylor experience--1995. Prenat Diagn 1995;15:907-12. 
4. Lo YM, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal 
plasma and serum. Lancet 1997;350:485-7. 
5. Poon LL, Lo YM. Circulating fetal DNA in maternal plasma. Clin Chim Acta 
2001;313:151-5. 
6. Zimmermann B, Hill M, Gemelos G, et al. Noninvasive prenatal aneuploidy testing 
of chromosomes 13, 18, 21, X, and Y, using targeted sequencing of polymorphic loci. 
Prenat Diagn 2012;32:1233-41. 
7. Jensen TJ, Zwiefelhofer T, Tim RC, et al. High-throughput massively parallel 
sequencing for fetal aneuploidy detection from maternal plasma. PloS one 2013;8:e57381. 
8. Liang D, Lv W, Wang H, et al. Non-invasive prenatal testing of fetal whole 
chromosome aneuploidy by massively parallel sequencing. Prenat Diagn 2013;33:409-15. 
9. Nicolaides KH, Syngelaki A, Gil M, et al. Validation of targeted sequencing of 
single-nucleotide polymorphisms for non-invasive prenatal detection of aneuploidy of 
chromosomes 13, 18, 21, X, and Y. Prenat Diagn 2013;33:575-9. 
10. Hamada H, Arinami T, Kubo T, et al. Fetal nucleated cells in maternal peripheral 
blood: frequency and relationship to gestational age. Hum Genet 1993;91:427-32. 
121 
 
  
11. Bianchi DW, Williams JM, Sullivan LM, et al. PCR quantitation of fetal cells in 
maternal blood in normal and aneuploid pregnancies. Am J Hum Genet 1997;61:822-9. 
12. Sohda S, Arinami T, Hamada H, et al. The proportion of fetal nucleated red blood 
cells in maternal blood: estimation by FACS analysis. Prenat Diagn 1997;17:743-52. 
13. Bhat NM, Bieber MM, Teng NN. One step separation of human fetal lymphocytes 
from nucleated red blood cells. J Immunol Methods 1990;131:147-9. 
14. Wachtel S, Elias S, Price J, et al. Fetal cells in the maternal circulation: isolation by 
multiparameter flow cytometry and confirmation by polymerase chain reaction. Hum 
Reprod 1991;6:1466-9. 
15. Bhat NM, Bieber MM, Teng NN. One-step enrichment of nucleated red blood cells. 
A potential application in perinatal diagnosis. J Immunol Methods 1993;158:277-80. 
16. Ganshirt-Ahlert D, Burschyk M, Garritsen HS, et al. Magnetic cell sorting and the 
transferrin receptor as potential means of prenatal diagnosis from maternal blood. Am J 
Obstet Gynecol 1992;166:1350-5. 
17. Wachtel SS, Sammons D, Manley M, et al. Fetal cells in maternal blood: recovery 
by charge flow separation. Hum Genet 1996;98:162-6. 
18. de Graaf IM, Jakobs ME, Leschot NJ, et al. Enrichment, identification and analysis 
of fetal cells from maternal blood: evaluation of a prenatal diagnosis system. Prenat Diagn 
1999;19:648-52. 
19. Kitagawa M, Sugiura K, Omi H, et al. New technique using galactose-specific lectin 
for isolation of fetal cells from maternal blood. Prenat Diagn 2002;22:17-21. 
20. Ganshirt-Ahlert D, Borjesson-Stoll R, Burschyk M, et al. Detection of fetal trisomies 
21 and 18 from maternal blood using triple gradient and magnetic cell sorting. Am J Reprod 
Immunol 1993;30:194-201. 
122 
 
  
21. Zhao XX, Ozaki Y, Suzumori N, et al. An examination of different fetal specific 
antibodies and magnetic activated cell sorting for the enrichment of fetal erythroblasts from 
maternal blood. Congenit Anom (Kyoto) 2002;42:175-80. 
22. Wada S, Kitagawa M. Method of separation and concentration of fetal nucleated red 
blood cells in maternal blood and its application to fetal diagnosis. Congenit Anom (Kyoto) 
2004;44:72-8. 
23. Guetta E, Simchen MJ, Mammon-Daviko K, et al. Analysis of fetal blood cells in the 
maternal circulation: challenges, ongoing efforts, and potential solutions. Stem Cells Dev 
2004;13:93-9. 
24. Kavanagh DM, Kersaudy-Kerhoas M, Dhariwal RS, et al. Current and emerging 
techniques of fetal cell separation from maternal blood. J Chromatogr B Analyt Technol 
Biomed Life Sci 2010;878:1905-11. 
25. Purwosunu Y, Sekizawa A, Koide K, et al. Clinical potential for noninvasive 
prenatal diagnosis through detection of fetal cells in maternal blood. Taiwan J Obstet 
Gynecol 2006;45:10-20. 
26. Pezzolo A, Santi F, Pistoia V, et al. Prenatal diagnosis of triploidy using fetal cells in 
the maternal circulation. Prenat Diagn 1997;17:389. 
27. Ganshirt-Ahlert D, Smeets FW, Dohr A, et al. Enrichment of fetal nucleated red 
blood cells from the maternal circulation for prenatal diagnosis: experiences with triple 
density gradient and MACS based on more than 600 cases. Fetal Diagn Ther 1998;13:276-
86. 
28. Kuo PL. Frequencies of fetal nucleated red blood cells in maternal blood during 
different stages of gestation. Fetal Diagn Ther 1998;13:375-9. 
29. Oosterwijk JC, Mesker WE, Ouwerkerk-Van Velzen MC, et al. Prenatal diagnosis of 
trisomy 13 on fetal cells obtained from maternal blood after minor enrichment. Prenat Diagn 
1998;18:1082-5. 
123 
 
  
30. Al-Mufti R, Hambley H, Farzaneh F, et al. Investigation of maternal blood enriched 
for fetal cells: role in screening and diagnosis of fetal trisomies. Am J Med Genet 
1999;85:66-75. 
31. Parano E, Falcidia E, Grillo A, et al. Noninvasive prenatal diagnosis of chromosomal 
aneuploidies by isolation and analysis of fetal cells from maternal blood. Am J Med Genet 
2001;101:262-7. 
32. Rodriguez de Alba M, Palomino P, Gonzalez-Gonzalez C, et al. Prenatal diagnosis 
on fetal cells from maternal blood: practical comparative evaluation of the first and second 
trimesters. Prenat Diagn 2001;21:165-70. 
33. Vona G, Beroud C, Benachi A, et al. Enrichment, immunomorphological, and 
genetic characterization of fetal cells circulating in maternal blood. Am J Pathol 
2002;160:51-8. 
34. Al-Mufti R, Hambley H, Farzaneh F, et al. Distribution of fetal erythroblasts 
enriched from maternal blood in multifetal pregnancies. Hum Reprod 2003;18:1933-6. 
35. Krabchi K, Gros-Louis F, Yan J, et al. Quantification of all fetal nucleated cells in 
maternal blood between the 18th and 22nd weeks of pregnancy using molecular cytogenetic 
techniques. Clin Genet 2001;60:145-50. 
36. Krabchi K, Gadji M, Forest JC, et al. Quantification of all fetal nucleated cells in 
maternal blood in different cases of aneuploidies. Clin Genet 2006;69:145-54. 
37. Krabchi K, Gadji M, Samassekou O, et al. Quantification of fetal nucleated cells in 
maternal blood of pregnant women with a male trisomy 21 fetus using molecular 
cytogenetic techniques. Prenat Diagn 2006;26:28-34. 
38. Emad A, Ayub S, Samassekou O, et al. Efficiency of manual scanning in recovering 
rare cellular events identified by fluorescence in situ hybridization: simulation of the 
detection of fetal cells in maternal blood. J Biomed Biotechnol 2012;2012:610856. 
124 
 
  
39. Emad A, Bouchard EF, Lamoureux J, et al. Validation of automatic scanning of 
microscope slides in recovering rare cellular events: application for detection of fetal cells in 
maternal blood. Prenat Diagn 2014;34:in press. 
40. Sekizawa A, Farina A, Zhen DK, et al. Improvement of fetal cell recovery from 
maternal blood: suitable density gradient for FACS separation. Fetal Diagn Ther 
1999;14:229-33. 
41. Troeger C, Holzgreve W, Hahn S. A comparison of different density gradients and 
antibodies for enrichment of fetal erythroblasts by MACS. Prenat Diagn 1999;19:521-6. 
42. Samura O, Sekizawa A, Zhen DK, et al. Comparison of fetal cell recovery from 
maternal blood using a high density gradient for the initial separation step: 1.090 versus 
1.119 g/ml. Prenat Diagn 2000;20:281-6. 
43. Sitar G, Manenti L, Farina A, et al. Characterization of the biophysical properties of 
human erythroblasts as a preliminary step to the isolation of fetal erythroblasts from 
maternal peripheral blood for non invasive prenatal genetic investigation. Haematologica 
1997;82:5-10. 
44. Ellis WM, Georgiou GM, Roberton DM, et al. The use of discontinuous Percoll 
gradients to separate populations of cells from human bone marrow and peripheral blood. J 
Immunol Methods 1984;66:9-16. 
45. Choolani M, O'Donoghue K, Talbert D, et al. Characterization of first trimester fetal 
erythroblasts for non-invasive prenatal diagnosis. Mol Hum Reprod 2003;9:227-35. 
46. Karl PI, Alpy KL, Fisher SE. Serial enzymatic digestion method for isolation of 
human placental trophoblasts. Placenta 1992;13:385-7. 
47. Van Wijk IJ, van Vugt JM, Mulders MA, et al. Enrichment of fetal trophoblast cells 
from the maternal peripheral blood followed by detection of fetal deoxyribonucleic acid 
with a nested X/Y polymerase chain reaction. Am J Obstet Gynecol 1996;174:871-8. 
125 
 
  
48. Sitar G, Brambati B, Baldi M, et al. The use of non-physiological conditions to 
isolate fetal cells from maternal blood. Exp Cell Res 2005;302:153-61. 
49. Kolialexi A, Tsangaris GT, Antsaklis A, et al. Apoptosis in maternal peripheral 
blood during pregnancy. Fetal Diagn Ther 2001;16:32-7. 
50. Sekizawa A, Samura O, Zhen DK, et al. Apoptosis in fetal nucleated erythrocytes 
circulating in maternal blood. Prenat Diagn 2000;20:886-9. 
51. van Wijk IJ, de Hoon AC, Jurhawan R, et al. Detection of apoptotic fetal cells in 
plasma of pregnant women. Clin Chem 2000;46:729-31. 
 
126 
 
  
Chapter IV:  
The purpose of this study was to assess the feasibility of using single fetal 
cells to determine fetal sex and major chromosomal abnormalities by 
quantitative fluorescence-polymerase chain reaction (QF-PCR) as a proof 
of conception of the feasibility of fetal cells in non-invasive prenatal 
diagnosis. 
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Résumé 
OBJECTIF 
L’analyse d’évènements cellulaires rares peut apporter de nouvelles approches dans 
le diagnostic en oncologie et en diagnostic prénatal. La petite quantité d’ADN disponible 
dans des cellules qui sont rares comme les cellules fœtales circulant dans le sang maternel, 
est un facteur majeur limitant pour leur utilisation dans des applications cliniques. Les 
méthodes traditionnelles d’amplification du génome complet à partir d’un très petit nombre 
de cellules (SC-WGA) et leur analyse adéquate ont représenté un immense défi jusqu’à 
récemment. L’objectif de cette étude a été d’évaluer la faisabilité de la technique de PCR 
quantitatif en fluorescence (QF-PCR) à déterminer les anomalies chromosomiques à partir 
de seulement quelques cellules fœtales.  
MÉTHODOLOGIE 
Des cellules en culture provenant de 24 échantillons de liquide amniotique ont été 
utilisées pour une extraction standard d’ADN et à partir de cinq (5) cellules fœtales 
récupérées par microdissection. L’amplification du génome complet a été effectuée à partir 
de l’ADN extrait des cellules micro-disséquées. L’amplification par PCR des séquences 
courtes répétées en tandem spécifiques pour les chromosomes 13, 18, 21 ainsi que pour les 
chromosomes sexuels a été effectuée sur les échantillons amplifiés et extraits de façon 
standard. Le dosage des allèles et le sexage ont été analysés quantitativement après la 
séparation des fragments par électrophorèse capillaire. 
RÉSULTATS 
L’analyse des microsatellites amplifiés par QF-PCR a montré une forte corrélation 
du nombre de chromosomes entre les ADN extraits ou amplifiés quand cinq cellules et plus 
sont utilisées comme matériel de départ. Les résultats concordent avec les analyses 
cytogénétiques conventionnelles. 
CONCLUSION 
Il est possible d’obtenir une bonne couverture génomique à partir du SC-WGA, ce 
qui permet d’utiliser cette technique dans des applications où une quantité infime d’ADN est 
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disponible. Dans un contexte clinique, cette amplification associée à la technique QF-PCR 
peut représenter une méthode fiable, précise, rapide et peu coûteuse de détection des 
anomalies chromosomiques majeures chez le fœtus.  
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Abstract 
OBJECTIVE 
Analysis of DNA from small numbers of cells, such as fetal cells in maternal blood, 
is a major limiting factor for their use in clinical applications. Traditional methods of single-
cells whole genome amplification (SCs-WGA) and accurate analysis have been challenging 
to date. Our purpose was to assess the feasibility of using a few fetal cells to determine fetal 
sex and major chromosomal abnormalities by quantitative fluorescent-polymerase chain 
reaction (QF-PCR). 
METHODS 
Cultured cells from 26 amniotic fluid samples were used for standard DNA 
extraction and recovery of five fetal cells by laser-capture microdissection. SCs-WGA was 
performed using the DNA from microdissected cells. PCR amplification of short-tandem 
repeats specific for chromosomes 13, 18, 21, X and Y chromosomes was performed on 
extracted and amplified DNA. Allele dosage and sexing were quantitatively analyzed 
following separation by capillary electrophoresis. 
RESULTS 
Microsatellite QF-PCR analysis showed high concordance in chromosomal copy 
number between extracted and amplified DNA when 5 or more cells were used. Results 
were in concordance with that of conventional cytogenetic analysis. 
CONCLUSION 
Satisfactory genomic coverage can be obtained from SCs-WGA. Clinically, SCs-
WGA coupled with QF-PCR can provide a reliable, accurate, rapid and cost-effective 
method for detection of major fetal chromosome abnormalities. 
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1. Introduction 
The detection and molecular characterization of rare cellular events was first 
suggested more than one century ago [1], but has only recently become a clinical reality. It 
is now clear that these cells can provide novel approaches for cancer management, 
preimplantation genetic and non-invasive prenatal diagnosis (NIPD) [2-6].  
Current prenatal diagnosis depends on invasive procedures and is associated with 
small but finite risk of pregnancy loss. The use of circulating fetal cells in maternal blood as 
an alternative source of fetal genetic material can provide a non-invasive, risk-free 
opportunity for prenatal diagnosis [7-9].  
On a parallel context, occult shed tumor cells can travel through the blood to distant 
sites. Detection, monitoring, and molecular analysis of these cells will provide a powerful 
approach for detection and targeting of metastatic cells. It will also help in addressing 
relevant topics such as early detection of recurrence and minimal residual disease [10-12]. 
Molecular characterization of rare cellular events is also essential in pre-
implantation genetic diagnosis (PGD), which combines assisted reproductive technologies 
with genetic analysis of single cells, enabling the screening of embryos prior to their 
maternal transfer to avoid transfer of embryos affected with a specific genetic disease 
[3,13]. Furthermore, forensic medicine benefits from advanced single-cell technologies, as 
often only tiny amounts of material are available for analyses [14]. 
Many methods have been proposed for the detection of rare cellular events including 
flow cytometry and immunofluorescence microscopy [15-18]. Interphase fluorescent in situ 
hybridization (FISH) is a commonly used single-cell approach that allows visualization of 
chromosomal regions in the nucleus. This technology critically depends on the selection of 
probes and does not provide a screen of the entire genome within individual cells. In 
addition, the percentage of chromosomal anomalies correctly identified by FISH could be as 
low as 65% [19,20]. 
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As an alternative to FISH, molecular characterization can be done using single cell 
based amplification approach to obtain satisfactory genomic coverage followed by an 
appropriate molecular diagnostic technique. Single cells-based whole genome amplification 
(SCs-WGA) has the goal of generating enough quantities of genomic DNA from small 
amounts of starter material with minimal representational bias. The protocols usually 
include an optimized cell lysis protocol incorporated into the fragmentation step in addition 
to the universal primers for whole genome amplification. The term “single cells whole 
genome amplification” SCs-WGA is used for protocols developed for entire genome 
amplification from few numbers of cells and not necessary one single cell. Further 
downstream, this enables robust molecular characterization and detection of chromosomal 
abnormalities [21,22].  
Although different types of chromosomal abnormalities have been successfully 
identified by array-based comparative genomic hybridization (aCGH) following WGA of a 
small number of cells, the current aCGH protocol is a costly and time-consuming process 
that does not fit easily into all clinical schedules, particularly if specimens are required to be 
shipped to a reference laboratory [23-27]. Looking for an alternative approach that is 
clinically practical and has the potential to detect chromosomal abnormalities and single 
gene disorders, the present study focuses on evaluating the fidelity of WGA using DNA 
obtained from a small number of fetal cells for rapid and cost-effective prenatal diagnosis 
by multiplex QF-PCR [28]. This study, however, will not include characterization of single 
gene disorders although this is potentially possible.  
We recently developed a robust detection algorithm for rare cellular events using 
fluorescence-based automated microscopy [29] and validated its efficiency in the detection 
of rare fetal cells in maternal blood (unpublished data). In this study, we provide a proof-of-
concept of the feasibility of using a few fetal cells in NIPD. A small number of unfixed 
amniotic fetal cells obtained by laser microdissection were used for the detection of fetal sex 
and major fetal chromosomal aneuploidies using GenomePlex SCs-WGA technology 
(Sigma, Oakville, Ontario, Canada). This technology is based upon the generation of library 
molecules flanked by universal priming sites from non-enzymatic random fragmentation of 
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limited amounts of genomic DNA. This was followed by amplification using universal 
oligonucleotide primers through limited number of cycles to generate sufficient quantities of 
representative DNA suitable for varieties of downstream reactions. We then validated the 
DNA fidelity on QF-PCR using multiplex fragment analysis. The results were compared 
with that of extracted unamplified DNA and standard conventional cytogenetic analysis. 
2. Materials and Methods 
2.1 Sample preparation 
The Ethics Research Committee of the CHUS (Centre Hospitalier Universitaire de 
Sherbrooke) approved the protocol used in this study. The amniotic fluid was obtained after 
informed consent from 26 patients by amniocentesis in the second trimester between the 
16th to the 20th week of gestation. Immediately after sampling, the amniotic fluid samples 
were cultured then harvested by standard techniques to obtain the fetal karyotype. Cells 
derived from the initial culture were centrifuged at 700 g for 10 min at 20°C and washed 
three times in PBS before being transferred to a membrane-coated slide for microdissection. 
The spreading was done in a modified Thermotron environmental control chamber (CDS-5) 
(Thermotron, Amsterdam, the Netherlands) at 25°C and 40% humidity. Slides were dried 
within the Thermotron chamber, encoded and used immediately or stored at −20°C. In all 
cases, ordinary DNA extraction and cytogenetic analysis were done according to standard 
protocols. Slides were encoded and cells dissected blindly. 
2.2 Laser capturing microdissection 
Laser capture microdissection (LCM) was performed using a microscope equipped 
with a motorized scanning stage and a CCD camera. Membrane-coated slides were screened 
using a phase-contrast microscope for identifying cells of interest by morphology. The laser 
beam was adjusted to cut a circle in the membrane bearing the cell of interest with an 
adequate safety distance. The desired sample was collected using a LCM Eppendorf tube 
with a special collection cap covered with an adhesive layer. The dissected material was 
lifted directly into the cap and the tube was carefully removed and closed. The contents of 
the tube were used immediately or stored at −20°C. 
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2.3 Whole genome amplification 
For WGA, genomic DNA samples were amplified using the GenomePlex SCs-WGA 
kit (Sigma) according to the manufacturer’s protocol. After amplification, excess primers 
and dNTPs were removed using GenElute PCR Clean-Up Kit (Sigma) resulting in an 
average volume of 50 µl of DNA. Five µl of the PCR product could be checked on a 1.5% 
agarose gel. Reamplification was an optional step that could have been done if needed. The 
samples were stored at −20°C until further processing. 
2.4 QF-PCR analysis 
QF-PCR was carried out using a Multiplex PCR Master Mix (Qiagen, Toronto, 
Ontario, Canada) and a Primer Mix 10X designed for the identification of aneuploidy of 
chromosomes 13, 18, 21, X and Y (table 1). The standard Primer Mix contains 17 
polymorphic markers (four for chromosomes 13, 18 and 21; five for sex chromosomes 
including the SRY gene). Specific multiplexes for each chromosome (13, 18, 21 and X/Y) 
were also designed to confirm detection of aneuploidies in the samples (table 2). Forward 
primers were labeled with Well-Red D2, Well-Red D3 or Well-Red D4 (Beckman Coulter, 
Mississauga, Ontario, Canada). Amplified fragments were separated by capillary 
electrophoresis using the GenomeLab GeXP (Beckman Coulter) as described by the 
manufacturer. Results were finally analyzed using the GeneMarker software version 1.97 
(SoftGenetics, State College, PA). The ratio between the peak heights was calculated for 
each marker. We assigned ratios between 0.8 and 1.4 as a normal peaks and values greater 
than 1.8 or less than 0.65 as abnormal. Normal heterozygous subjects are expected to show 
two peaks (1:1 peak ratio) while trisomies are visualized either as three peaks with ratios 
between 0.8 and 1.4 (triallelic) or two peaks with a ratio greater than 1.8 or less than 0.65 
(2:1 peak ratio). A single homozygous peak as well as multiple small peaks were considered 
uninformative. A minimum of two informative markers is required for confident diagnosis. 
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Results obtained by QF-PCR of WGA-DNA from each specimen were analyzed, 
then decoded and compared with that obtained by standard DNA extraction as well as the 
fetal karyotype obtained by cytogenetic analysis of amniotic cells from the same sample. 
Table 1 Polymorphic markers used in the Primer Mix 10X 
Marker name Location Heterozygosity Allele 
size range 
(bp) 
Primer sequences  
(5->3; forward, reverse) 
AMXY Xp22.1-22.31  
Yp11.2 
- 106-112 D2-CCCTGGGCTCTGTAAAGAATAGTG 
ATCAGAGCTTAAACTGGGAAGCTG 
D13S252 13q12.2 0.64 280-308 D2-GCAGATGTACTGTTTTCCTACCAA 
AGATGGTATATTGTGGGACCTTGT 
D13S305 13q12.2-q14.1 0.75 430-465 D3-GCCTGTTTGAGGACCTGTCGTTA 
TGGTTATAGAGCAGTTAAGGCAC 
.D13S628 13q31.1 0.70 324-369 D4-TAACATTCATTGTCCCTTACAGAT 
GCAAGGCTATCTAACGATAATTCA 
D13S634 13q21.33 0.85 385-440 D4-GGCAGATTCAATAGGATAAATAGA 
GTAACCCCTCAGGTTCTCAAGTCT 
D18S1371 18q12.3 0.87 130-158 D3-CTCTCTTCATCCACCATTGG 
GCTGTCAGAGACCTGTGTTG 
D18S386 18q22.1 0.89 330-440 D2-TGAGTCAGGAGAATCACTTGGAAC 
CTCTTCCATGAAGTAGCTAAGCAG 
D18S391 18p11.31 0.75 182-220 D4-GGACTTACCACAGGCAATGTGACT 
TAGACTTCACTATTCCCATCTGAG 
D18S535 18q12.3 0.82 455-500 D4-CAGCAAACTTCATGTGACAAAAGC 
CAATGGTAACCTACTATTTACGTC 
D21S1411 21q22.3 0.93 256-340 D3-ATAGGTAGATACATAAATATGATGA 
TATTAATGTGTGTCCTTCCAGGC 
D21S1435 21q21.2 0.75 170-210 D2-CCCTCTCAATTGTTTGTCTACC 
ACAAAAGGAAAGCAAGAGATTTCA 
D21S1437 21q21.1 0.78 112-126 D4-ATGTACATGTGTCTGGGAAGG 
TTCTCTACATATTTACTGCCAACA 
D21S226 21q21.3 0.54 440-470 D2-GCAAATTTGTGGATGGGATTAACAG 
AAGCTAAATGTCTGTAGTTATTCT 
DXYS218 Xp22.32  
Yp11.3 
0.65 218-254 D2-TGTGTTTGGGTTTCCTCTGT 
CGAAACTCCGTCTCAAAATA 
HPRT Xq26.2 0.75 263-299 D4-ATGCCACAGATAATACACATCCCC 
CTCTCCAGAATAGTTAGATGTAGG 
SRY Yp11.2 - 470 D3-GAATATTCCCGCTCTCCGGA 
GCTGGTGCTCCATTCTTGAG 
X22 Xq28  
Yq 
0.91 194-238 D3-TCTGTTTAATGAGAGTTGGAAAGAAA 
ATTGTTGCTACTTGAGACTTGGTG 
 
The table shows the polymorphic markers used in the Primer Mix 10X by QF-PCR 
including: the marker name, location, degree of heterozygosity, allele size and primer 
sequence for each marker. 
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Table 2 - Polymorphic markers used in the chromosome-specific primer mix 
Marker name Location Heterozygosity Allele size 
range (bp) 
Primer sequences  
(5->3; forward, reverse) 
D13S258 13q21 0.89 230-267 D3-ACCTGCCAAATTTTACCAGG 
GACAGAGAGAGGGAATAAACC 
D13S317 13q22-13q31 0.79 157-201 D2-ACAGAAGTCTGGGATGTGGA 
GCCCAAAAAGACAGACAGAA 
D18S1002 18q11.2 0.80 340-370 D3-
GTTTGATGGGAGGAAGCTATCTAT 
GTGAAGTAGCGGAAGGCTGTAAT 
D18S847 18q21.1 0.76 208-229 D3-
TTAAATTTGACTCTGAGAGTTCTC
C 
CAGATGGCCTGTAGTGGAAC 
D18S499 18q21.32-
21.33 
0.72 260-300 D4-
AGATTACCCAGAAATGAGATCAG 
GCTCCATAAGCCAAATAGAGTCA
A 
D21S1270 21q22.11 0.87 285-340 D4-
CTATCCCACTGTATTATTCAGGGC 
TGAGTCTCCAGGTTGCAGGTGAC
A 
DXS981 Xq13.1 0.86 230-260 D3-
CTCCTTGTGGCCTTCCTTAAATG 
TTCTCTCCACTTTTCAGAGTCA 
DXS6803 Xq21.21 0.68 111-180 D2-GAAATGTGCTTTGACAGGAA 
CCTCAAAACAAAAAGGAACAT 
DXS6854 Xq25 0.73 90-125 D4-AGCACTTCTCCTACAACCCTC 
CAGCCTGGGCAGTAGAGA CT 
DYS448 Yq11.2 0.69 350-380 D2-
CAAGGATCCAAATAAAGAACAGA
GA 
GGTTATTTCTTGATTCCCTGTG 
 
The table shows the polymorphic markers used in the chromosome-specific primer mix by 
QF-PCR including: the marker name, location, degree of heterozygosity, allele size and 
primer sequence for each marker. 
 
3. Results 
We provide below a detailed protocol from cell preparation to single-cell isolation 
by laser microdissection and WGA to generate templates for QF-PCR analysis (figure 1). 
Initially, we tested WGA products from 1, 5, 10 and 20 cells and their diluted human 
genomic DNA-equivalent templates by agarose gel electrophoresis. All samples gave 
distinct patterns on an agarose gel (figure 2), which resulted in successful WGA in all 
titration experiments. The smears ranged from 100 to 1,500 bp with a mean size of 400 bp. 
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Negative controls did not produce any smear. Although we saw amplification on the agarose 
from a single cell, satisfactory genomic coverage by QF-PCR was only obtained in 33.3% 
of cases in contrast to more than 90% when five or more cells were used as templates on 
repeated trials. Indeed, lower amounts of DNA (<5 cells) will generate amplification 
products, but results obtained in downstream applications may not be faithful to the result 
that would have been obtained from non-amplified DNA. The DNA yield after WGA from 
5 cells obtained by laser-capture microdissection was in the range of 4 to 5 µg whereas the 
DNA yield after reamplification of a primary PCR product was in the range of about 6 to 8 
µg. The DNA yield increased exponentially with increased numbers of cells used as a 
template, reaching 11 to 12 µg when 20 cells or their equivalent diluted gDNA were used. 
These amplification products were also suitable for conventional and array CGH (data not 
shown). Although we obtained some satisfactory results using conventional CGH, 
especially when an amplified product was used as a reference, the process was very 
cumbersome and time consuming. The objective of this study was to develop a better – and 
clinically practical – approach to avoid the inherent inconveniences of array CGH.  
We tested the feasibility of using the multiplex QF-PCR and its compatibility with 
WGA products from controlled number of cultured amniotic fetal cells (5 cells) obtained by 
laser-capture microdissection (figure 3). Amniocytes were obtained after approximately 2-3 
weeks of culture with up to 3 passages and amount of viable cells >80%. In the current 
study, we used cultured amniocytes identified by morphology for the detection of fetal sex 
and major chromosomal abnormalities but there is no reason why this protocol would not 
work with uncultured cells or with cells identified by antibody staining or 
immunohistochemistry, although this was not done here. 
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Figure 1 Flow chart of the entire methodology.  
Protocol include cell preparation, single-cell isolation by laser microdissection, WGA to 
generate templates for QF-PCR analysis and comparison of results obtained by GenomePlex 
SCs-WGA and non-amplified DNA with conventional cytogenetic analysis. 
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Figure 2 Comparison of DNA yield obtained by whole genome amplification of serial 
numbers of single cells.  
Whole genome amplification was performed on 1, 5, 10 and 20 isolated cells in comparison 
with a negative control in duplicate experiments using the GenomePlex SCs-WGA. The 
obtained DNA fragments were separated by electrophoresis on 1.5% agarose, coloured with 
ethidium bromide, exposed to UV and photographed.  
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Figure 3. The process of Laser-capture microdissection of single cells on the slides.  
The figure shows the process of laser-capture microdissection: Selection of single cells (5 
cells) before microdissection (higher panel), laser microdissection (middle panel) and after 
the recuperation of microdissected cells (lower panel). 
 
The experimental design involved evaluation of 26 samples obtained for this study. 
Among these samples, only 2 failed to generate sufficient WGA DNA materials for 
subsequent QF-PCR analysis apparently due to the bad quality of the original cellular DNA 
on the slides on repeated trials. A second attempt of SCs-WGA has been needed for 5 cases 
to generate efficient DNA amplification and successful QF-PCR analysis. Chromosomal 
anomalies were detected in 8 out of 24 samples comprising six trisomies and two triploidies 
(table 3). 
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Table 3 Results obtained by QF-PCR of amplified and extracted DNA in comparison 
to standard chromosomal analysis of fetal Karyotype. 
Patient 
ID  
Fetal 
Sex 
Fetal 
Karyotype 
QF-PCR standard 
extracted DNA 
QF-PCR 
SCs-WGA 
1 Female T21 OK OK 
2 Male Normal OK OK 
3 Female Normal OK OK 
4 Female Normal OK OK 
5 Male Normal OK OK 
6 Male Normal OK OK 
7 Male Normal OK OK 
8 Male T21 OK OK 
9 Male T21 OK OK 
10 Female Normal OK OK 
11 Female Normal OK Failed 
12 Male Normal OK OK 
13 Female Normal OK OK 
14 Male Normal OK OK 
15 Male Normal OK OK 
16 Male T21 OK OK 
17 Female Normal OK OK 
18 Female Normal OK Failed 
19 Male T13 OK OK 
20 Male Normal OK OK 
21 Female Normal OK OK 
22 Female Normal OK OK 
23 Female Triploidy OK OK 
24 Female Triploidy OK OK 
25 Male Normal OK OK 
26 Male T21 OK OK 
 
The table shows comparison of the QF-PCR results obtained from whole genome 
amplification of 5 microdissected cells and that obtained by standard DNA extraction of 
fetal cells from amniotic fluid culture in comparison to the results of standard analysis of 
fetal karyotype for fetal sex and major chromosomal aneuploidies of the 26 patient samples. 
 
The normal cases consisted of 9 cases with a normal male karyotype (46,XY) and 9 
with a normal female karyotype (46,XX). The trisomies involve 5 cases of chromosome 21 
and one of chromosome 13. Four trisomy samples showed a male pattern with trisomy 21 
(figure 4) while one showed a female pattern with trisomy 21 and the other one showed a 
male pattern with trisomy 13. Two female samples showed a triploid pattern (figure 5).  
141 
 
  
 
  
Figure 4. The QF-PCR profile of a male trisomy 21 from amplified DNA from 5 
microdissected cells.  
The figure show the analysis of whole genome amplified DNA from 5 microdissected cells 
by QF-PCR of a case of male trisomy 21: D21S226 and D21S1411 markers show triallelic 
trisomic peaks, D21S1435 shows diallelic trisomic peaks whereas the D21S1437 marker 
shows a single peak. The fetal sex was confirmed by the presence of a peak for SRY gene.  
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Figure 5 The QF-PCR profile of a female triploidy case from amplified DNA from 5 
microdissected cells. 
The figure show the analysis of whole genome amplified DNA from 5 microdissected cells 
by QF-PCR of a case of triploid female fetus: D21S1435 and D12S1411 markers for 
chromosome 21 show triallelic peaks, D13S305 and D13S628 markers for chromosome 13 
present triallelic peaks whereas D13S252 shows a diallelic trisomic peak. For sexual 
chromosomes, absence of peak for SRY with triallelic peaks for X22 and diallelic trisomic 
peak for DXYS218 and HPRT confirm the female sex. 
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All but 2 samples were successfully diagnosed by QF-PCR and the results were 
available within 48 hours, and were in concordance with QF-PCR results of extracted 
unamplified DNA as well as the traditional karyotyping of cultured amniotic cells (table 4). 
Fetal sexing was correctly reported for all the female samples with absence of the unique 
sequence of SRY gene. In some samples with a lower DNA quality, the detection of a single 
sequence was difficult and therefore, 5 of normal male samples were further confirmed with 
the DYS448 which is a polymorphic marker with up to 20 repeats. Aneuploidies were 
confirmed by the replication of QF-PCR tests as well as by using back-up markers to 
increase the level of confidence. There were no reported sex chromosome aneuploidies or 
trisomy 18 within this panel. However, in the initial stage of validation of the STRs markers 
used in this study, we successfully confirmed the diagnosis of 2 sex chromosome 
aneuploidies (data not shown). 
Table 4 Cumulative results obtained from QF-PCR analysis of amplified DNA from 
single cells for determination of fetal sex and major chromosomal aneuploidies. 
Karyotype Sex Cases (n) Confirmed (n) Failed (n) 
Normal Female 9 7 2 
Normal Male 9 9 - 
T13 Male 1 1 - 
T21 Female 1 1 - 
T21 Male 4 4 - 
Triploidy Female 2 2 - 
 
The table shows the cumulative results obtained from whole genome amplification of 5 
microdissected cells by QF-PCR to correctly identify the fetal sex and major chromosomal 
aneuploidies for prenatal diagnosis 	  
4. Discussion  
Clinical practice is largely dependent on what has been made available by 
improvements in technology and by the availability of its delivery to large segments of the 
population. Although a variety of applications in research and clinical diagnostics critically 
depends on reliable and unbiased methodologies to amplify and analyse DNA from small 
numbers or even single cells; the scoop of this article will focus on their implications in the 
field of prenatal diagnosis. 
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Prenatal diagnosis is a well-established part of health care that enables timely 
interpretation of the fetal medical condition, thus giving the parents the choice to either 
continue or interrupt the pregnancy. Given the current state of medical technology, routine 
prenatal diagnosis requires the use of invasive obstetric techniques, with probes or needles 
being inserted into the uterus, for the collection of fetal cells and, therefore, involves a finite 
risk of the iatrogenic abortion [7,30]. In these cases, fetal cells obtained by amniocentesis or 
chorionic villus sampling are cultured and a full karyotype analysis is performed. This 
requires significant labor costs, considerable technical expertise, and, sets a limit to the 
number of analyses, which an experienced technician can safely handle. In addition, the 
time needed to culture fetal cells and complete the analysis ranges from 10 to 21 days, 
which is generally considered to be a psychological burden and results in late terminations 
after pathological diagnosis [31,32].  
In the early 1990s, FISH and, more recently, QF-PCR entered the field of prenatal 
diagnosis to allow rapid prenatal diagnosis within 24–48  h [33,34]. However, the results 
were – and still are – considered preliminary while awaiting the results of the gold standard, 
which is a full karyotype. QF-PCR has some advantages over FISH [35] in that QF-PCR 
can be done with fewer cells and, since the analysis can easily be automated, many samples 
can be processed at the same time with only 30  minutes of operator time. QF-PCR can also 
detect maternal cell contamination, which cannot be disclosed by FISH in cases of female 
fetuses. Based on these considerations, QF-PCR is increasingly being considered and 
proposed as a complementary investigation or even approved in some jurisdictions as an 
alternative to conventional cytogenetic analysis and considered as a stand-alone test in 
routine prenatal diagnosis as outlined in the Joint of the Society of Obstetricians and 
Gynaecologists of Canada and College of Medical Geneticists (SOGC-CCMG) Clinical 
Practice Guideline [36-38]. Although these techniques hasten the process of prenatal 
diagnosis, they did not overcome the risk associated with invasive sampling of fetal tissues, 
which limits offering prenatal diagnosis to all pregnant women and shorten its application to 
those at high risk, as estimated by increased maternal age, abnormal biochemical markers 
and ultrasonographic findings [39,40]. 
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NIPD is a long sought goal and could be the best alternative to overcome these 
limitations. It is now well known that fetal material (cells, nucleic acids) can be detected in 
blood of pregnant women. The presence of fetal cells in maternal blood has been well 
documented and consequently envisioned to enable NIPD [29,41-44]. In our group, Krabchi 
et al. [45] have offered conclusive data that fetal cells are present in the maternal blood of 
all pregnant women and their number ranges between 2 and 6 fetal cells per ml in normal 
pregnancies. Although the general agreement about the presence of fetal cells in the 
maternal blood, the scarce amount of DNA contained in these rare cells is a major problem 
that poses a challenge for their use in clinical practice.  
One of the most exciting developments in single cell analysis has been the evolution 
of protocols designed to amplify the entire genome from single cells. SCs-WGA provides a 
supply of sample DNA that can be further reassessed, allowing confirmation of diagnosis 
using different methods. Several PCR-based protocols for WGA have been established and 
their applications evaluated. These include: (1) primer extension pre-amplification (PEP), a 
Taq DNA polymerase PCR-based reaction that utilizes 15 base oligonucleotide primers of 
random sequence to initiate DNA synthesis [46-48]; (2) degenerate oligonucleotide-primed 
PCR (DOP-PCR) which depends on priming from short sequences specified by the 3′ end of 
the oligonucleotides during the initial low temperature cycles of the PCR reaction [49-51]; 
and, (3) multiple displacement amplification (MDA), an isothermal genome amplification 
using Phi29 DNA polymerase [52].  
A significant drawback of WGA techniques is that amplification of repetitive DNA 
sequences, such as STR, is error prone if performed on WGA products. In some studies over 
50% of amplified fragments differed from their expected size, presumably due to the 
uniformly low temperatures needed for WGA that could allow slippage of the DNA chain 
during product generation. In addition, these protocols have their limitations, including 
limited yield, strong biases and low genome coverage, defined as gene representation 
[22,53-57]. Conversely, GenomePlex WGA, described in this protocol, is a proprietary 
amplification technology based on non-enzymatic random fragmentation of genomic DNA. 
The protocol involves conversion of the genome into an in vitro molecular library of DNA 
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fragments, followed by incubation at various temperatures to add adaptor sequences with 
specific PCR priming sites to both ends of every fragment. This library is replicated using a 
linear, isothermal amplification in the initial stages, followed by a limited round of 
geometric amplification. The fragment library can then be amplified several thousand-fold 
to generate milligram quantities of DNA [58].  
In contrast to traditional WGA techniques, GenomePlex amplification technology is 
generally less affected by DNA quality and is more applicable to DNA extracted from 
various sources. The amplified DNA thus produced is suitable for a wide range of 
downstream genetic assays and therefore has the potential for use not only in academic 
research, but also in forensic and diagnostic laboratories [59-61]. QF-PCR of WGA 
products was able to successfully detect fetal sex and major chromosomal abnormalities in 
more than 92% of the tested samples. Only two cases failed to show the normal female 
pattern due to inadequate quality of the original DNA from cultured cells, which 
subsequently decreased the quality of results obtained in downstream application of QF-
PCR. We may hypothesize that results would have been better from fresh amniotic fluid 
samples, as previously reported with array CGH experiments from cultured and uncultured 
amniotic fluid due to difficult control of DNA quality of cultured cells [62,63]. In these 
cases, however, it is essential to use increased quantities of starting DNA to guarantee a 
satisfactory genomic coverage of final product.  
Although array CGH has been proposed as a genome-wide assessment approach of 
chromosomal abnormalities after WGA of few number of cells, array CGH traditionally 
requires DNA from larger number of cells in addition to the high cost and complicated 
equipment [64]. Furthermore, laser capture microdissected cells often yield limited 
quantities of genomic DNA, making array CGH analysis challenging. Another disadvantage 
of an array CGH system is the period required for DNA labeling, hybridization and analysis 
of results, especially with the many incidental findings of unknown clinical significance, 
which creates an ethical dilemma and raises the maternal anxiety [65]. Further research is 
required to shorten this time and to resolve these problems.  
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Cell-free fetal DNA is more and more used with massively parallel sequencing [66-
68] or targeted deep sequencing [69,70] to test for aneuploidy or single-gene disorders. 
Even if this test has very low false-positive and false-negative rates, it is still consider as a 
screening test and its application in clinics could be cumbersome and considerably 
expensive. In comparison with these techniques, QF-PCR is very simple, rapid and cost-
effective approach, and thus more suitable for integration in the clinical applications. It also 
has the advantage of providing a quick response, which relieves maternal anxiety. QF-PCR, 
being less expensive and almost entirely automated, enables more women to undergo 
prenatal diagnosis without a significant increase in health expenditure [37,38,71,72]. The 
use of innovative technology like automatic cellular scanning of slides for the detection of 
fetal cells from maternal peripheral blood, which we have recently optimized and used for 
detection and quantification of fetal cells in the maternal blood in euploid and aneuploid 
pregnancies will help to avoid the traditional cumbersome and time consuming manual 
detection of rare fetal cells from maternal blood [73]. 
This study shows that the utilization of 5 isolated cultured amnoicytes can provide 
an accurate and reliable NIPD. Satisfactory genome coverage can be obtained from WGA in 
more than 90% of cases. Our findings provide a proof for the feasibility of NIPD from very 
small numbers of fetal cells and suggest that detection, amplification and analysis of as few 
as 5 fetal cells that could be obtained from 2-3 ml of maternal peripheral blood [45] can be 
quite enough to provide an accurate NIPD. The few number of fetal cells required together 
with the use of automatic scanning for the detection of fetal cells [73] and SCs-WGA will 
help to overcome the problem of rarity of these cells in the maternal blood and make their 
use in NIPD much more easily achievable. Although this method is not a completely mature 
by now due to absence of perfect antigen that can recognize 100% of fetal cells, relentless 
efforts continue and should lead to the development of this antigen in the near future 
[74,75]. However, this protocol will be still feasible with the available markers that 
recognize specific types of fetal cells as the fetal trophoblasts or normoblasts but with likely 
larger amount of maternal blood as there is no general agreement about their exact 
frequencies per ml of maternal blood.  
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Limitations of our protocol are that single-cell isolation requires expensive 
equipment and precautions. As the handling of few cells will always remain a very delicate 
task, the application of this protocol will require some experience. 
5. Conclusion 
With multiplex QF-PCR, WGA from as few as five fetal cells can accurately and 
reliably used for detection of fetal sex and major chromosomal abnormalities and most 
likely single gene disorders as well. Our findings lay the groundwork for the use of very low 
levels of fetal cells in maternal blood for NIPD. 
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DISCUSSION 
Development of NIPD has the potential to reduce, or even eliminate, the risk of 
miscarriage associated with invasive diagnostic procedures like amniocentesis and CVS. 
Both procedures are also time consuming, costly and face problems of culture failure and 
culture artefact. Serious maternal complications such as abdominal cramps, vaginal bleeding 
and amniotic fluid leakage may occur in up to 3% of cases (Finegan et al., 1990). In 
addition, CVS may have a discrepancy between culture cytogenetic results and the actual 
fetal karyotype due to confined placental mosaicism (Slunga-Tallberg and Knuutila, 1995) 
or the phenomenon of trisomy rescue and natural selection against aneuploidy (Ledbetter 
and Engel, 1995). The frequency of procedure-related losses can be reduced by serum 
marker screening, which identify women with an increased risk of bearing abnormal fetuses. 
However, serum screening is a statistical method that identifies only 60-70% of fetuses with 
Down syndrome and has a 5% false positive rate (Phillips et al., 1992). 
The demonstration that FCs (Walknowska et al., 1969) and fetal DNA (Lo et al., 
1990) can be obtained from MB opened the possibility of obtaining fetal genetic material 
for prenatal diagnosis without the need for invasive testing. Fetal DNA can be retrieved 
from maternal plasma but is traditionally limited to the diagnosis of a few paternally 
inherited single gene differences in which the fetal genes mutations are genetically different 
from the corresponding sequences in the mother. In contrast, the analysis of intact FCs 
permits the diagnosis of any fetal aneuploidy or monogenic disorder (Zamerowski et al., 
2001). Currently, the research in this area not only focuses on the understanding of their 
biological role and effect on the mother but also how to isolate and use these nucleated FCs 
in NIPD. However, their rarity in MB has hindered the development of a non-invasive test. 
Their number can be still increased by various enrichment techniques. Therefore, NIPD 
using a cell-based strategy can be divided into three phases: (i) enrichment of FCs from MB; 
(ii) identification of enriched cells; and, (iii) making the genetic diagnosis. 
Through the last several decades, considerable efforts have been made to gain access 
to FCs from MB because this would prepare the ground for NIPD with virtually no risk to 
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the mother or the pregnancy. Yet, no conclusive progress has been made in this field of 
research in spite of decades of work. In order to implement FCs in clinical applications, a 
significant amount of work has to be devoted to the development of an accurate and reliable 
method of identification of FCs. Improvement of enrichment procedures which have to be 
more effective and not so labour-intensive as current ones, optimization of selection and 
analysis of FCs in order to provide unequivocal identification of chromosomal aneuploidies 
and single gene disorders from a small number of FCs. It will also be important to determine 
more precisely at what stage of pregnancy FCs can be reliably detected. 
In summary, a thorough assessment of the available protocols and introduction of 
innovative technologies are required before implementation of these rare FCs in NIPD. The 
data presented in this thesis summarize on one hand the information collected from 
literature that is relevant for a comprehension of the subject. In  addition to the results of our 
work in the assessment and development of accurate and reliable identification of FCs  
(Article I, Chapter I), quantification of the FCs in MB at the time of the pregnancy (Article 
I, Chapter II), comparison of the efficacy of different identification techniques, evaluation 
and improvement of enrichment procedures (Article I, Chapter III) and, finally, the 
optimization of genetic analysis for identification of fetal aneuploidies and major 
chromosomal abnormalities from single FCs (Article I, Chapter IV). The main objectives 
were to assess the current available techniques and development of future trends for NIPD 
using FCs in MB  
1. Development of a strategy for the evaluation of detection of rare cellular events 
Detection of rare cellular events is required for different applications. Cancer 
initially arises as an organ-confined lesion from which occult cells travel through the blood 
to anatomically distant sites to develop metastatic disease, which is a major cause of cancer-
related death in patients with solid tumors. Detection, monitoring, and molecular analysis of 
these cells can provide a powerful approach for cancer management such as in the detection 
of recurrence and minimal residual disease (Szatanek et al., 2008; Cristofanilli et al., 2007). 
At the same time, the detection of intact FCs in the MB at the time of pregnancy can provide 
an opportunity for collecting fetal genetic material for NIPD without the need for invasive 
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procedures. Interestingly, in both approaches, the disseminated cells are present in the 
circulation in extremely low concentrations, estimated to be in the range of one target cell in 
the background of 106–107 normal blood cells (Pantel and Otte, 2001; Hamada et al., 1993). 
Various protocols with either manual or, more recently, automatic scanning, can be 
used for retrieval of these rare cellular events from peripheral blood after molecular or 
immunological identification of specific genetic markers, exclusive of target cells, by 
various techniques (Ntouroupi et al., 2008; Johnson et al., 2007; Krabchi et al., 2006c; 
Krabchi et al., 2001). Evaluation of the efficacy of a particular protocol is mandatory before 
its clinical application. In general, assessment of the efficacy of detection of rare cellular 
events is always problematic, as is an accurate evaluation is difficult to obtain with currently 
available methodologies.  
Moreover, the establishment of the original number of rare events is critical for 
optimizing any enrichment procedure. Knowing the number of rare cells before and after 
enrichment is mandatory to measure the efficacy and to evaluate the number of cells lost or 
destroyed during enrichment. It is worth pointing out that increasing the efficacy of 
detection can even reduce the level of enrichment required, making NIPD much more easily 
achievable (Yan et al., 2000). 
In the context of detection of FCs from MB, optimisation of FC selection was made 
using model mixture experiments whereby adult non-pregnant blood was spiked with 
certain amounts of FCs (Yan et al., 2000; Bohmer et al., 1999). This dilution strategy is 
reliable within certain limits but it is almost impossible to obtain an accurate evaluation in 
cases of extreme rare events, such as FCs in MB, in which an average of 2 to 6 cells have 
been located by manual scanning of 20 to 30 slides with an average of 200,000 cells per 
slide (Krabchi et al., 2001). In such situations, the dilution strategy seems imprecise and 
could be just considered as an approximation of the real situation as it is not possible to tell 
for certain the exact original number of the FCs present in each slide. 
Other groups worked directly on maternal samples and compared the efficacy of 
automatic to manual scanning (Johnson et al., 2007; Kilpatrick et al., 2004; Kraeft et al., 
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2004). However, the accuracy of the manual scanning, which is taken as the gold standard 
in the detection of rare cellular events, has never been validated. Therefore, there was a 
pressing need to develop a strategy for the accurate evaluation of the detection of rare 
cellular events.  
We used sequential spreading approach to put a pre-determined number of rare 
cellular events (< 10 cells) of a particular type on the predefined areas on a slide in the first 
round of spreading. The target cells were then stained with Giemsa and photos of Giemsa-
stained cells were taken and registered with their coordinates on the slide. On the second 
round, we spread an average of 2.0 x 105 cells of different types on top of the whole 
spreading area of the slide, simulating the average concentration of cells on the slides 
prepared from MB. For instance, Giemsa-stained cells are those of uniform  differential 
karyotype such as male cells to which are added female cells that are not GIemsa-stained. 
The slides were then coded and blindly scanned (Article I, Chapter I). This strategy permits 
the precise evaluation rare cellular events detection. Furthermore, it allows the retrieval of 
the missed events as well as the evaluation of their hybridization signals after scanning to 
dissect the etiology of their missing and determine the impact of the identification technique 
used in their retrieval.  
This strategy could generally be applied in the evaluation of detection of rare cellular 
events and has many potential applications in different fields such as cancer and NIPD. In 
the context of detection of FCs from MB, we used a few XY-cells as rare events in a pure 
population of XX-cells; however, there is no reason why it should not work with any type of 
rare cellular events as long as there is a specific marker exclusive for the target cells of 
interest.  
In the context of NIPD, it can be used in the evaluation of manual and automatic 
scanning as well as in the comparison between the detection efficacy of different markers 
and identification techniques. Moreover, this strategy could be used in the optimization and 
comparison of different enrichment procedures. To our knowledge, this is the most precise 
approach available to date to evaluate the efficacy of the detection of rare cellular events. 
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2. Optimization and measuring the efficacy of manual scanning 
The number of FCs is very low compared to that of maternal cells. Accurate 
identification of circulating FCs is essential for their reliable use in prenatal diagnosis. The 
identification of these cells by targeting specific genetic markers exclusive for the FCs by 
molecular cytogenetic techniques like FISH and PRINS have been used before by many 
groups for estimating their number in the MB (Orsetti et al., 1998b; Goldberg, 1997; 
Hamada et al., 1993). Using this approach, our group previously established an estimate of 
the absolute number of FCs in normal and aneuploid pregnancies (Krabchi et al., 2006b; 
Krabchi et al., 2006c; Krabchi et al., 2001). Although these studies yielded important 
information concerning the number of circulating FCs in MB, the results are possibly 
skewed by the fact that the methodology of detection of these rare events by manual 
scanning with either of these techniques has never been evaluated.  
In the process of testing and optimizing the methodology to devise an efficient 
protocol for identification and selection of FCs from MB, the evaluation of the efficacy of 
manual scanning is mandatory. On one hand, the evaluation of the efficacy of any protocol 
is required before its clinical application. On the other hand, the evaluation of the efficacy of 
manual scanning will be a prerequisite for the validation of automatic scanning. Although 
manual scanning is very cumbersome and time consuming, the sensitivity of the technique 
in the detection of rare cellular events is far more important than any other consideration. In 
other words, automatic scanning should have a better or at least comparable sensitivity to 
manual scanning in the detection of rare events before switching to automation.    
We used the previously mentioned strategy to evaluate the efficacy of manual 
scanning in the detection of rare cellular events hybridized using FISH (Article I, Chapter I). 
The experimental design involved the assessment of 60 slides containing known number of 
XY cells (< 10 cells) in pre-defined areas among pure population of XX cells blindly by two 
independent observers. The protocol allowed for the evaluation of the efficacy of detection 
of manual scanning by knowing the exact number and coordinates of XY cells on the slides. 
For the first time, the protocol also allowed for the retrieval and evaluation of hybridization 
of missed events which, consequently, helps to determine the efficacy of FISH technique in 
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recovering rare cells and differentiate between cells missed due to defective hybridization 
from those missed by the process of manual scanning itself. 
In general, the accuracy of manual scanning for detection of rare events was quite good 
with an average of 84.5% (125/148) sensitivity. The FISH technique was responsible for 
missing 4% (6/148) either due to non-hybridization in 1.3% (2/148) or inadequate 
signalling in 2.7% (7/148) while 11.5% (14/148) of cells were missed as a lack in the 
process of the manual scanning itself (figure 1). However, the range of 74.5% to 90% in 
the detection efficacy and 2.2 to 2.6 hours in the average scanning time between two 
observers suggested a considerable range of inter-individual variations, meaning that 
laboratories with more senior personnel may provide more dependable results than those 
with less experienced staff (Article I, Chapter I). Interestingly, these limitations could be 
circumvented using automatic scanning 
 
 
Figure 1 Summary of the results of manual scanning using FISH technique for 
detection of rare cellular events. 
TP: true positive, FN: false negative. The figure shows the absolute number and percentage 
of detected and missed target cells on slides by manual scanning with evaluation of the 
hybridization efficiency of the missed events. 
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3. Optimization and measuring the efficiency of automatic scanning 
In the context of locating FCs from MB by manual scanning, one milliliter of 
maternal peripheral blood is concentrated in a cellular suspension of 300 µL. A spreading of 
15 µL/slide corresponds to an average of 20 slides per case (range: 16 to 24 slides) with an 
average number of 2.0 x 105 cells per slide as previously described  (Article I, Chapter I). 
The duration of the observation of each slide is approximately 150 minutes by manual 
scanning. An average of 4-6 cells/ml has been located by scanning an average of 20 slides in 
normal pregnancies (Emad et al., 2012; Krabchi et al., 2001). The analysis of all slides of 
one patient thus accounts for 6 to 7 days of fulltime work. Therefore, manual scanning is 
very cumbersome, time consuming and not suitable for clinical applications. There is, 
therefore, an urgent need for automation in the detection of FCs. Automated microscopy 
has the potential to make the procedure practical on a large scale because: (i) it reduces cost 
and relieves tedious human work; (ii) it can automatically determine statistically significant 
results; and, (iii) it can support expanded testing without requirements for additional 
personnel or space. Automation is not only required for the eventual clinical application of 
NIPD using FC in MB, but is also critical for research progress to be made in this field 
Therefore, many innovative technologies have been developed to alleviate the 
burden of scanning large numbers of cells and allow for rapid and precise detection of rare 
cellular events (Ntouroupi et al., 2008; Seppo et al., 2008; Johnson et al., 2007; Kilpatrick et 
al., 2004; Mehes et al., 2001). Automated approaches have transcended the investigational 
and developmental stage and systematic application of these approaches to the detection of 
FCs from MB is ongoing. Both flow and image cytometry can detect cells, but only image 
cytometry can provide re-location of detected cells using previously determined spatial 
locations on slides. This allows for re-examination and further manipulation of these cells. 
In image scanning devices, cells are located in one colour channel (e.g. blue for DAPI 
staining), and dots are counted in user-selected channels. A count of the number of dots of 
each colour in the nucleus provides chromosomal enumeration. For each slide, scanning 
results are reported as a distribution of `dots-per-cell' for each colour. Although they proved 
efficient for routine clinical tasks, their application in the detection of rare events is limited 
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due to difficult evaluation with currently available methodologies (Johnson et al., 2007; 
Kilpatrick et al., 2004). Accurate evaluation is required for both optimization of the 
selection criteria and the development of an efficacious algorithm for the identification of 
FCs from MB.  
3.1.Development of custom-made detection algorithm 
The software that controls the automated microscope generally includes functions 
for spatial and photometric calibration, automatic focusing, image scanning and digitization, 
background subtraction and colour compensation, nuclei segmentation, location and 
measurement, and FISH dot counting. Broadly, there are two types of operational systems in 
automatic scanning devices, the closed systems like Ikonisys (Ikonisys Inc., New Haven, 
Connecticut) and the opened systems like MetaSystems (MetaSystems Inc., Altlussheim, 
Germany).  In closed systems, the company optimizes the selection criteria for a specific 
purpose and users are only allowed to apply an integrated classifier for their application; 
whereas, in the open systems, users are allowed to develop their own detection algorithm 
and fine tune the selection criteria in a process called microscopy training to optimize their 
own classifier according to their specific application (Merchant and Castleman, 2002).  We 
tried both systems for the detection of FCs from MB but the open platform of MetaSystems 
was more accurate and reliable..  
Automatic scoring was performed using MetaSystems image cytometry platform 
(Altlussheim, Germany). Although Metafer/RC Detection mode integrated in the system 
software can be used for automatic detection of rare cellular events, a semi-automated 
approach using a custom-made detection algorithm was preferred. An automated 
classification algorithm was implemented to detect FCs by employing a series of relatively 
simple routine patterns of recognition as shown in figure 1 (Article I, Chapter II). We used 
our experience in manual scanning to devise a simple but efficacious protocol simulating the 
manual detection of FCs in MB. The scanning platform was used to find potential target 
cells with a final assessment being performed by an experienced operator. Cells’s location 
and primary selection was performed using spectrum green for the Y-signal at 20X 
magnification. Suspected events were verified at 40X magnification for the presence of X 
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chromosome signal on a DAPI-stained nucleus. Slides with pure XX cells and others spiked 
with defined number of XY-cells served as controls for optimization of microscope training 
process. Knowing beforehand the numbers and locations of positive cells allowed for better 
characterization and fine-tuning of selection criteria and required magnification for 
optimum detection (Article I, Chapter I).  
3.2.Measuring the efficacy of automatic scanning 
We used the previously mentioned strategy to evaluate the efficiency of automatic 
scanning in the detection of rare cellular events hybridized by FISH (Article I, Chapter I). 
The experimental design involved the assessment of 60 slides containing pre-defined XY 
cells (< 10 cells) among a pure population of XX cells blindly with an average of 2.0 x 105 
cells per slide. Selected events were imaged and recorded. The gallery was manually sorted 
to reject false events. Remaining cells were, then, visually assessed under the microscope 
for final selection of positive events. Selected events were compared with pictures and 
coordinates of real XY cells on the slides to evaluate the detection efficiency of automatic 
scanning. Missed events were retrieved and evaluated for hybridization using FISH 
technique to differentiate between cells missed due to defective hybridization from those 
missed as a drawback of automatic scanning. 
The sensitivity of automatic scanning in the detection of rare events was 87.9% 
(117/133) in comparison to 84.5% (125/148) with manual observation. Spearman’s 
correlation showed a high correlation coefficient (C.C= 0.96, P < 0.001, N=60) in 
comparison to correlation coefficient of 0.94 in manual scanning.  Index of Youden of 0.88 
confirmed the superiority of automatic scanning over manual detection with an index of 
0.85 in the detection of rare cellular events. Evaluation of FISH technique was very 
comparable to that obtained by manual scanning. FISH hybridization was responsible for 
missing of 4.5 % (6/1133) either due to non-hybridization in 1.5% (2/133) or inadequate 
signalling in 3% (4/133) while 7.5% (10/1133) of cells were missed as a drawback of the 
process of automatic scanning in which three cells were actually detected by scanning but 
rejected during observer revision (figure 2). Although automatic scanning requires longer 
time (an average of 239 minutes) the operator time was significantly reduced, with an 
167 
 
  
average of 15 minutes compared to 150 minutes per slide for manual scanning. Furthermore, 
automatic scanning is not operator dependent and consequently, more consistent than 
manual scoring. In addition it can be used all day long with the same efficacy (Article I, 
Chapter II). 
 
Figure 2 Summary of the results of automatic scanning using FISH for detection of 
rare cellular events. 
TP: true positive, FN: false negative. The figure shows the absolute number and percentage 
of detected and missed XY cells on slides by automatic scanning using FISH technique with 
evaluation of the hybridization efficacy of the missed events. 
 
The accuracy of prenatal diagnosis using FCs depends upon the specificity of their 
identification from MB. Validation of manual scanning for detection of rare cellular events 
paved the way for the automatic detection of FCs from MB. Automation not only helps in 
realization of NIPD, but is also essential for research progress in this field. We have applied 
automatic detection of FCs in the evaluation and comparison of different identification and 
enrichment approaches. 
4. Identification and quantification of fetal cells from maternal blood 
Accurate establishment of the frequency of FCs in the MB is a basic parameter to 
determine the feasibility of using FCs in NIPD and critical before optimising any 
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enrichment procedures. It is also known that gestational age influences FC trafficking and 
thus, affects frequency of FCs in MB; however, an ideal gestational age for FC sampling has 
not yet been established (Kuo, 1998; Hamada et al., 1993).  
In spite of many attempts to estimate their number and evaluate changes in their 
frequency with gestational age, there is still much controversy concerning these aspects. The 
numbers obtained vary widely, ranging from 1 to 150 FCs per ml of MB as well as the trend 
of change in their frequency with gestational age (explained in detail in the introduction 
section) (Lim et al., 2001; Rodriguez de Alba et al., 2001; Kuo, 1998; Shulman et al., 1998; 
Sohda et al., 1997; Hamada et al., 1993). This reflects variability in experimental conditions 
of detection, identification and isolation of FCs, timing of recovery, enrichment procedures 
and type of target cells.  
Studies which count specific types of FCs, based on staining or morphological 
criteria probably overestimated the total number of cells because no FC recognition system 
is completely specific (Lim et al., 2001; Troeger et al., 1999a; Wachtel et al., 1998; Sohda et 
al., 1997). On the other hand, less generous predictions but more precise values were given 
by studies which have been based on DNA analysis of the Y chromosome sequences as a 
universal marker that recognise all FCs using polymerase chain reaction (PCR) in male 
pregnancies (Kuo, 1998; Bianchi et al., 1997). However, PCR experiments gave a wide 
estimate range but no absolute number has been determined.  
Recent studies have indicated that FCs can be detected directly from the MB without 
prior enrichment to avoid losing fragile FCs. This was done using techniques such as FISH 
and PRINS. In our group, Krabchi et al (Krabchi et al., 2006b; Krabchi et al., 2006c; 
Krabchi et al., 2001) implied a direct detection strategy, without prior enrichment, and have 
offered conclusive data concerning the absolute number of FCs in one ml of MB in the 
second trimester using cumbersome manual scanning approach. Results were probably 
skewed by the efficacy of manual scanning in the detection of rare events. We validated the 
manual approach of Krabchi (Article I, Chapter I) and further refined its efficacy by 
automation. Consequently, we tested this classifier for the detection of FCs from MB on 
twelve cases of both euploid and aneuploid pregnancies with Down syndrome. Detected 
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events were evaluated by re-FISH to exclude false positive cells. True FCs confirmed by re-
FISH were tabulated whereas; extra-cells, which failed to give reverse signal pattern, were 
excluded (Figure 5, Chapter II). 
4.1.Comparison of fetal cells in the first and second trimester 
For cases of normal pregnancies, six cases were processed four cases have been 
sampled at the end of the first trimester while the other two have been taken between 18th 
and 20th week of gestation. Analysis of the number of confirmed FCs did not show a 
difference in the frequency of FCs between 1st and 2nd trimester of normal pregnancies. 
 Most groups found an increase in fetal NRBCs between the first and second 
trimesters (Rodriguez de Alba et al., 2001; Ganshirt et al., 1998; Ganshirt-Ahlert et al., 
1993) while there is a decreasing trend of the trophoblasts (Lim et al., 2001) from their peak 
at 9th  to 13th  weeks of gestation (Taniguchi R, 2001). As all our first trimester samples 
were obtained between 11th to 13th weeks and we used a universal marker for detection of 
both NRBCs and trophoblasts, the low number of NRBCs could have been compensated by 
a high number of trophoblasts. Although this should be confirmed on a larger series of 
samples, we think that this window period at the end of the 1st trimester may present an 
opportunity for an early NIPD. 
4.2. Comparison of fetal cells in normal and aneuploid pregnancy 
For cases of aneuploid pregnancies, six cases with trisomy 21, sampled in the second 
trimester, were processed. Analysis of the number of confirmed FCs did show a significant 
difference in the frequency of FCs between normal and aneuploid pregnancies (P< 0.001) 
(Figure 6, Chapter II).  
Interestingly, our findings matched with previous findings of Krabchi et al., and 
others using cumbersome manual scanning (Krabchi et al., 2006b; Krabchi et al., 2006c; 
Krabchi et al., 2001). However, their number of FCs seemed to be underestimated by at 
least 16%, apparently, due to the inherent false negative rate associated with manual 
detection (Article I, Chapter I).  
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5. Optimization and comparison of efficiencies of different techniques 
FCs could be identified by immunological and molecular techniques. Earlier studies 
used immunological approaches to target particular types of FCs, however, most detected 
cells were found to be of maternal origin (Lim et al., 2001; Troeger et al., 1999a; Wachtel et 
al., 1998; Sohda et al., 1997). Recent studies have employed molecular cytogenetic 
techniques for more precise identification of FCs, and, once located, the cells can be further 
identified by micromanipulation (Reading et al., 1995; Hamada et al., 1993).  
Accuracy in prenatal diagnosis using FCs depends upon the specificity of their 
identification. Therefore, one of the main objectives of our group was to develop and 
optimize methods of molecular cytogenetics in order to increase their sensitivities for the 
detection of rare events.  
Working on FISH and PRINS techniques for years in our laboratory enabled us to 
develop a great expertise in the use of these techniques to detect rare cells with a 
concentration lower than 0.01% (Yan et al., 2000) (Krabchi et al., 2006a; Yan et al., 2000). 
FISH technique is more popular and is used by many groups all over the world but is much 
more expensive than PRINS. Enthusiasm to extend molecular genetic diagnostic options, for 
techniques like PRINS, was mainly to reduce the cost of any potential diagnostic test using 
FCs, making NIPD more likely acceptable. Krabchi et al., have previously used both 
techniques in the identification of FCs from MB and stated that they have comparable 
efficacies (Krabchi et al., 2006b; Krabchi et al., 2006c; Krabchi et al., 2001).  
In this context, we committed ourselves to two main objectives: (i) reducing the cost 
of FISH technique without affecting its sensitivity for detection of rare events; and, (ii) 
evaluating and comparing the two techniques in the detection of rare cellular events. 
5.1. Validation of FISH probe dilution with commercial buffer 
The experimental design involved the evaluation of the hybridization efficiency of 
two FISH probes; CEP X: spectrum orange alpha-satellite and CEP Y: spectrum green 
satellite-III; (Vysis/ABBOTT Diagnostics, Downers Grove, Illinois, USA) on 3000 cells of 
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harvested blood samples of female and male donors, respectively, by two independent 
observers on three replicates of experiments (1000 cells per each experiment). The same 
experimental design was used to evaluate the hybridization efficacy of 5 serial dilutions of 
each probe (1/50, 1/100, 1/200, 1/300, 1/400) with a commercially available FISH 
hybridization buffer cDenHyb-1 (Insitus Biotechnologies, Albuquerque, NM). Exact “t” and 
ANOVA test showed statistically significant differences using dilutions of 1/200 and 1/400 
for CEP X and CEP Y probes respectively).  
Therefore, we used CEP X and CEP diluted 1:100 and 1:300 respectively in 
cDenHyb-1 buffer in the validation of detection of rare cellular evens by manual and 
automatic scanning as well as detection and quantification of FCs from MB. The same 
dilutions were also used in the comparison of the efficiency of FISH and PRINS techniques. 
This allowed for marked reduction of the cost of FISH technique without affecting the 
sensitivity of the probes in the detection of rare events. This would make NIPD using FCs 
more advantageous and cost-efficacious, in comparison even with the routine fetal 
karyotype of cultured FCs obtained by invasive methods in routine prenatal diagnosis.  
5.2. Evaluation and comparison of the efficacy of FISH and PRINS techniques 
We used the previously mentioned strategy to spread 90 slides with pre-defined XY 
cells as target cells, less than 10 cells per slide, among a pure population of XX cells with an 
average of 2.0 x 105 cells per slide. We compared the efficiency of automatic scanning in the 
detection of rare cellular events hybridized by FISH and PRINS technique. Automatic 
scanning with FISH was 10% greater in sensitivity than PRINS when detecting rare cellular 
events. The overall hybridization efficiency was 96.5% in PRINS when compared to 98.5% 
with FISH. Spearman’s correlation showed a lower correlation coefficient of 0.882 between 
detected cells and real numbers of XY cells on the slides in PRINS when compared to 0.96 
with FISH (Article I, Chapter II). Results indicated that FISH technique, even with the 
dilution buffer, is significantly superior to PRINS in detection of rare cellular events. Taking 
this valuable information into consideration in devising future protocols for the detection 
and isolation of FCs from MB will improve the efficiencies and reduce the cost of these 
protocols making NIPD more likely achievable.  
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6. Evaluation and improvement of enrichment protocols 
A prenatal test utilizing FCs from maternal circulation would necessitate the 
recovery of most FCs, while eliminating as many maternal cells as possible. Therefore, 
various purification and enrichment procedures have to be applied. However, the isolation 
of FCs from the maternal circulation presents considerable challenges, given their limited 
numbers, even with purification, thousands of cells have to be examined to locate one target 
cell. Numerous groups applied different multi-step protocols using combinations of two or 
more enrichment procedures to enrich FCs from MB, mostly without testing their efficacies 
in an in vitro model (Kitagawa et al., 2002; Zhao et al., 2002; de Graaf et al., 1999; 
Ganshirt-Ahlert et al., 1993). The in vivo enrichment efficacy reflects that of the entire 
protocol rather than single individual procedure and non-uniformity of the procedures used 
among different protocols. In addition the exact number of FCs circulating in MB cannot be 
known with certainty to evaluate each protocol. Knowing the number of FCs before and 
after enrichment is mandatory to measure the efficacy and to evaluate the number of cells 
lost or destroyed during enrichment. 
Furthermore, the studies also differed from each other in some ways, making direct 
comparisons unreliable, as for example: (i) application of enrichment protocols across 
varying gestational ages; (ii) usage of non-specific FC markers for enrichment and 
identification; (iii) absence of subsequent analysis with FISH to prove the fetal origin of 
detected cells; and, (iv) samples obtained either from two different groups of women or pre 
and post invasive procedure. Therefore, currently there is no accurate assessment of the 
efficacy of individual procedures and no standardized model is available to evaluate the in 
vivo efficacy of FC enrichment protocols  
It is worth to mention here also that the fragility of the FCs in MB limits attempts of 
FC enrichment. The least aggressive method of processing of the samples would be thus 
most adequate. In fact, it is proven that the FCs in MB are cellular elements not only rare, 
but also vulnerable. It was observed that some of FCs initiate apoptosis at the time of their 
passage to maternal circulation. The analysis by TUNNEL technique (Terminal dUTP Nick 
End Labelling) allowed for the detection of fragments of DNA of FCs origin (Sekizawa et 
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al., 2000) and showed that a significant number of FCs undergo apoptosis within short time, 
less than three hours, of their presence in MB. In fact, it is one of the proposed mechanisms 
by which FCs would be eliminated from MB (Kolialexi et al., 2004). This conception must 
be taken into consideration in the development of non-invasive prenatal diagnosis using FCs 
and maximum precautions should be taken to avoid aggressive manipulations in the 
recovery of FCs from MB. 
One of the objectives of our work was to develop an efficacious method that could 
be used to evaluate FC enrichment in vivo in a standardized fashion through knowing the 
exact number of FCs before and after enrichment. We applied this concept to the evaluation 
of the process density gradient centrifugation as the most common initial step in the vast 
majority of FC enrichment protocols published to date (Al-Mufti et al., 2003; Kitagawa et 
al., 2002; Vona et al., 2002; Parano et al., 2001; Rodriguez de Alba et al., 2001; de Graaf et 
al., 1999; Ganshirt et al., 1998; Kuo, 1998; Oosterwijk et al., 1998).  
The experimental design involved the quantification of total and FCs in twelve cases 
of normal and aneuploid pregnancies both before and after enrichment using Histopaque 
1.119. Considering the risks inherent to the brittleness of FCs and in order to avoid 
subjecting them to the further stress of a mechanical nature, we replicated the experiment 
with and without the routine 30 minute centrifugation. .  
We provided evidence that the application of density gradient centrifugation for 
isolation of rare FCs from MB is associated with a major loss of 60-80% of rare FCs, which 
would greatly limit the recovery efficacy of further purification steps and, thus, the eventual 
number of FCs available for analysis could be insufficient for making a genetic diagnosis. 
Furthermore, the elimination of aggressive centrifugation and allowing the cells to sediment 
by gravity reduced the average FC loss by 12%, probably due to fragility of FCs (Article I, 
Chapter III). Therefore, the elimination of this step or its replacement by the non-aggressive 
version of the procedure in future protocols would enhance the recovery of rare FCs and 
reduce the number of enrichment steps and consequently reduce FC loss. Furthermore, 
automation and micromanipulation would be of great help, as purity would not be of utmost 
importance and maternal contamination would not interfere with automatic scanning.  
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7. Optimization of genetic analysis from few fetal cells 
One of the main strategies that has emerged to exploit the FCs in NIPD was the 
genetic analysis of a few cells but, in fact, this strategy is mandatory for many different 
applications. The analysis of rare cellular events and their molecular characterization can 
provide novel approaches for cancer management, pre-implantation, genetic and forensic 
medicine (Maheswaran and Haber, 2010; Wei et al., 2007; Thornhill and Snow, 2002). 
Nevertheless, the scarce amount of DNA obtained from these rare cells poses a challenge 
for clinical applications. 
One of the most exciting developments in single cell analysis has been the evolution 
of protocols designed to amplify the entire genome from a single cell, which, could provide 
a supply of DNA sample that can be further reassessed, allowing confirmation of diagnosis 
using different methods (Dean et al., 2002; Xu et al., 1993; Telenius et al., 1992).  
Array-CGH has been proposed as a genome-wide assessment and was successfully 
used for molecular characterization of chromosomal abnormalities from single cells after 
whole genome amplification. However, the current protocol is costly, time-consuming and 
does not seem to fit into the clinical schedule (Fiegler et al., 2007; Hu et al., 2007). Novel 
strategies such as the use of short tandem repeats (Pertl et al., 2000) and differentially 
methylated sequences (Poon et al., 2002) have been explored but as yet seem unlikely to be 
applicable for NIPD of the common aneuploidies or monogenic disorders.  
Looking for an alternative approach that is clinically practical and has the potential 
to detect chromosomal abnormalities and single gene disorders, we focused on evaluating 
the fidelity of DNA from a few FCs in terms of detection of fetal sex and major 
chromosomal abnormalities using rapid and cost effective multiplex QF-PCR (Article I, 
Chapter IV). We provided a detailed protocol ranging from sample preparation, laser 
capture microdissection, and a few cell whole genome amplification, and then analysis of 
short tandem repeats using QF-PCR to detect fetal sex and major chromosomal 
aneuploidies.  
175 
 
  
The experimental design involved the evaluation of 26 cases of normal and 
aneuploid pregnancies from single FCs of amniotic fluid. High concordance, >90%, in 
chromosomal copy number between extracted and amplified DNA was obtained when five 
or more cells were used as templates. These results support the feasibility of using rare FCs 
in NIPD. 
Clinically, few cell-whole genome amplifications coupled with QF-PCR can provide 
a reliable, accurate and rapid method for prenatal diagnosis of major fetal aneuploidies. This 
protocol is advantageous in comparison to routine prenatal diagnosis with either analysis of 
fetal karyotype or even expresses FISH of FCs obtained by invasive methods. Routine fetal 
karyotype requires significant labor costs, considerable technical expertise, and,  in addition, 
the time needed to culture FCs and complete the analysis, which ranges from 10 to 21 days 
(Simoni et al., 1983; Niazi et al., 1981). Express FISH can reduce the time but is still costly 
with a low throughput and inapplicable for diagnosis of single gene disorders.  
QF-PCR analysis can easily be automated; many samples can be processed at the 
same run within 30  minutes. QF-PCR can also detect maternal cell contamination, which 
cannot be disclosed by FISH in cases of female fetuses (Langlois and Duncan, 2011; Leung 
et al., 2004; Leung et al., 2003). 
 On the other hand, this protocol is superior to other scenarios of NIPD using 
comparative genomic hybridization. When compared to genomic hybridization, QF-PCR is 
simple, rapid and cost-effective approach, and thus more suitable for integration in clinic. It 
also has the advantage of providing a quick response, which relieves maternal anxiety. QF-
PCR, being less expensive and almost entirely automated, permitting more women to 
undergo non-invasive prenatal diagnosis without a significant increase in health expenditure 
(Grimshaw et al., 2003; Wells et al., 1999). 
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8. Perspective 
Through the last two decades, considerable efforts have been made to gain access to 
the FCs in the MB. Most of the efforts were directed toward the development of strategies 
for identification, isolation, enrichment and analysis of FCs from MB. Evaluation and 
comparison of these strategies has been difficult in the absence of an appropriate in vitro 
model. At the same time, the in vivo efficacy only reflected that of the entire protocol rather 
than individual strategies within the protocol. Many fetal markers and techniques have been 
tested in absence of proper ways to evaluate them. The literature is burdened with tens of 
procedures and methods but no single optimal protocol using FCs has been approved for 
clinical practice. 
We believe that everything is possible but one has to find the right way of doing it. 
FC usage in NIPD depends to a great extent on the application of successive strategies of 
identification, enrichment and analysis of rare events. The development and optimization of 
these main strategies to devise an optimal protocol would likely lead to a successful NIPD. 
For the first time we have shown in our work an optimized and appropriate in vitro model 
for the accurate assessment of the detection of rare cellular events (Article I, Chapter I). We 
assumed at that time that this model could have several potential applications not only in the 
FC project but also in other applications in which detection and analysis of rare events is 
essential. We have already used this model in the evaluation and validation of manual and 
automatic scanning which is a comparison between different detection techniques (Article I, 
Chapter II) and in the evaluation of density gradient centrifugation, which is one of the most 
important and commonly used enrichment procedures (Article I, Chapter III). We have also 
demonstrated proof of concept for the feasibility of using rare FCs in NIPD through 
micromanipulation and whole genome amplification followed by multiplex QF-PCR 
analysis (Article I, Chapter IV). 
However, many interesting approaches and FC markers need to be properly 
evaluated. For example, the recognition of FCs by targeting different fetal cellular markers 
and their selection by fluorescent systems (FACS) or magnetic beads (MACS) were the 
subjects of many investigations. The techniques of cellular sorting seem very promising 
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since handling of only few FCs was already carried out successfully. However, the best 
approach to use still needs comparison and evaluation of different strategies (D'Souza et al., 
2007; Wada and Kitagawa, 2004; Zhao et al., 2002; Troeger et al., 1999b; DeMaria et al., 
1996; Johansen et al., 1995). 
Another very important question, which remains until now partially unanswered, is 
the exact frequencies of FCs at various stages of the pregnancy. It is important to determine 
the frequency of FCs at different stages of pregnancy to determine the optimal time for 
retrieving FCs from MB. Although considerable efforts have been done, no consensus has 
been reached (Lim et al., 2001; Rodriguez de Alba et al., 2001; Kuo, 1998; Shulman et al., 
1998; Sohda et al., 1997; Hamada et al., 1993). Our preliminary data indicated that there 
might be a brief window of time at the end of the 1st and the beginning of the 2nd trimester, 
which may present an opportunity not only for non-invasive but also for an early NIPD. 
However, these findings are very preliminary and should be verified using large series of 
samples. Ideally, the experimental design should involve periodic analysis of samples of the 
peripheral blood from a control group of women during their pregnancies using an interval 
of two to three weeks apart.  
Many fetal cellular markers have been identified. Testing, optimization, and 
comparison of different fetal markers would also be of utmost important to devise a sex- 
independent approach for the identification of FCs. Immunological and genetic markers can 
be broadly used to identify FCs. Many immunologic markers have been investigated but 
apparently no single one was entirely specific to FC (Lim et al., 2001; Troeger et al., 1999a; 
Wachtel et al., 1998; Sohda et al., 1997). Genetic markers are likely more sensitive and 
specific. We have already used Y chromosome in our studies and it was very specific. The 
Y chromosome is considered a universal marker for FCs in male pregnancies. There is no 
comparable universal marker for female pregnancies. To circumvent this problem of a 
universal sex marker, it is possible to target specific fetal genes that are expressed only in 
the fetal period by the trophoblastic or the erythroblastic cells. This would permit the 
detection of FCs regardless of fetal sex. PRINS technique can detect m-RNA in situ on 
intact FCs (Bains et al., 1993; Mogensen et al., 1991). Genes of interest would include 
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gamma Hb, HPL, HCG and HLA-G. The use of modern technology will also help in the 
identification of target genes by comparing the expression of fetal and maternal cells. 
Interestingly, Brinch et al., found five candidate genes whose protein are located on the 
outer surface of the cell membrane of FCs and not expressed by the maternal cells (Brinch 
et al., 2012). In a more recent work, the same Danish group proposed extravillous 
trophoblasts as a potential target for NIPD due to their unique expression of both 
mesodermal and ectodermal markers (Hatt et al., 2013).  
Although the identification of FCs is still not completely accomplished due to the 
absence of a perfect antigen that can recognize 100% of fetal cells, relentless efforts 
continue and should lead to the identification of this antigen in the near future. After the 
identification of FCs, suspected chromosomal aneuploidies could be tested by FISH 
technique or microdissected and analysed by QF-PCR as mentioned before.  Furthermore, 
determination of the source of FCs (either placental or haemopoietic) is also of considerable 
interest, as this may lead to the development of new tools permitting the efficacious 
isolation of FCs from MB samples. 
According to current protocol, it is necessary to prepare approximately 16-24 slides 
per one ml of MB to retrieve two to six FCs in normal pregnancies. One of the most exciting 
ideas is to optimize an enrichment method to allow concentrating the FCs contained in 5 ml 
of MB on one or two slides. Based on the number of fetal cells per ml of MB, there would 
be around 10-20 cells per slide. This will be very helpful to relieve the manual burden of 
preparing and scanning large numbers of slides on one hand, and in reducing significantly 
the cost of FISH probes on the other hand. Unrepentant progressive improvement of 
enrichment strategies, will certainly lead to a successful NIPD using FCs. 
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CONCLUSION 
Offering prenatal diagnosis to all pregnant women is limited by the risk of iatrogenic 
abortion associated with sampling of FCs by invasive methods (Finegan et al., 1990). The 
demonstration of the presence of FCs in maternal circulation during pregnancy offers NIPD 
opportunities. The risky invasive methods could then be replaced by non-invasive simple 
samples from peripheral venous blood without slightest risk for the ongoing pregnancy. 
There is no doubt that FCs do exist in MB and that they can be used for analysis of fetal 
aneuploidies and inherited Mendelian genetic disorders, but until now clinical application 
has not been established. Prenatal diagnosis using FCs from MB depends upon three main 
strategies ranging from identification, enrichment and genetic analysis of FCs. Devising of 
optimal protocols for these strategies will pave the way for the development of NIPD in 
clinical practice.  
Scientists agree that the presence of FCs in MB is a rare event, which makes their 
isolation difficult but not impossible (Bianchi et al., 2002; Ariga et al., 2001; Krabchi et al., 
2001). Their frequency can even be increased by various techniques of enrichment, which 
are still under development for the majority of protocols.. Even after enrichments, thousands 
of cells have to be examined to locate one FC. Most groups located FCs by a cumbersome 
time-consuming manual scanning approach and used techniques such as FISH or PRINS for 
the detection of these rare cells without evaluating the detection efficacy of either of these 
techniques in an appropriate in vitro model (Krabchi et al., 2006c; Krabchi et al., 2001; 
Orsetti et al., 1998b; Hamada et al., 1993). 
Furthermore, innovative technologies have been developed to relieve the burden of  
manual scanning but their validation for detection of rare events in clinical practice 
remained problematic (Johnson et al., 2007; Kilpatrick et al., 2004; Hennerbichler et al., 
2002). Accurate evaluation is not only required for validation but also for optimization of 
different procedures and strategies used for FC selection, isolation, identification and 
enrichment from MB in order to devise the optimal protocols which could lead to successful 
NIPD. 
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 In our work, considerable efforts have been made to design an appropriate in vitro 
model for accurate assessment of the detection of rare cellular events. This model has been 
used in the evaluation of manual scanning (Article I, Chapter I) as well as in the 
optimization and validation of automatic scanning (Article I, Chapter II). Not only does 
automation help in realization of NIPD, but it is also essential for research progress in this 
field. 
The same strategy has been also used in the evaluation and comparison of FISH and 
PRINS techniques after their optimization for the detection of rare cellular events. Results 
indicated that FISH technique, even when its probe mixed with the dilution buffer, is 
superior to PRINS technique. This permits a marked reduction of the cost of FISH technique 
without affecting its ability to detect rare cells (Article I, Chapter II). Automatic scanning 
has been used to quantify FCs in both euploid and aneuploid pregnancies. Establishment of 
the exact number of FCs in MB is essential in assessing the feasibility of FCs for NIPD and 
for the evaluation of FC enrichment procedures. Furthermore, automation and 
micromanipulation could reduce the level of required enrichment, since purity would not be 
of utmost importance and maternal contamination won’t interfere with automatic scanning. 
Interestingly, it has been shown that FCs can be detected in greater frequencies in aneuploid 
pregnancies. A considerable number of aneuploidies cases were studied in this work and 
these findings were confirmed.  
Automatic scanning has been also used in quantification of FCs before and after 
enrichment by density gradient centrifugation, which is the most common initial step of 
most enrichment protocols published to date (Article I, Chapter III). We provided evidence 
that application of this step is associated with a major loss (60-80%) of FCs, which would 
probably jeopardize subsequent steps of the enrichment protocol. Consequently, the 
eventual number of FCs available for final analysis may not be sufficient for NIPD. 
Furthermore, the elimination of aggressive centrifugation significantly reduced FC loss by 
about 12%. Therefore, elimination of this step or its replacement by the non-aggressive 
version of the procedure would enhance recovery and cut down the number of enrichment 
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steps and consequently reduce FC loss, thereby making NIPD using FCs more easily 
achievable. 
We also provided proof of concept of the feasibility of using rare FCs in NIPD 
through micromanipulation of single cells (Article I, Chapter IV). Satisfactory genomic 
coverage can be obtained from whole genome amplification of a few cells coupled with QF-
PCR analysis. Detection and utilization of as few as five FCs in MB can be quite enough to 
provide > 90% accuracy in detection of fetal sex and major chromosomal aneuploidies and 
potentially single gene disorders. Clinically, QF-PCR analysis of short tandem repeats can 
provide a viable alternative to array-comparative genomic hybridization in NIPD using FCs 
without a significant increase in health expenditure.  
The currently available results are sufficiently eloquent to indicate that FCs could be 
accessible from MB and could be used for analysis of fetal aneuploidies and inherited 
mendelian genetic disorders. Unrelenting progressive improvement of the sensitivity and 
specificity of strategies for detection and isolation of rare events combined with the 
development of fast and reproducible methods of enrichment, will certainly lead to 
optimization of a universal test of NIPD through the use of FCs. The possibility of 
diagnosing fetal genetic disorders, with virtually no risk either to the mother or to the 
pregnancy, would represent a considerable advance in fetal medicine. This approach would 
make it possible to offer a systematic prenatal diagnostic test for relatively common genetic 
aneuploidies such as that of Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), 
Turner syndrome (monosomy X) as well as single gene disorders to all pregnant women 
without having to select them according to risk criteria of age, values of the serum markers 
or echographic measures. At the end of our work, let us stress the fact that offering NIPD to 
all pregnant women will always be justifiable as it could prevent the birth of children with 
untreatable genetic disorders. However, it will remain for a long time indivisible from the 
concept of a medical interruption of pregnancy. 
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